data_1ibn_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ibn _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.195 0 N-CA-C 110.11 -1.196 . . . . 1.0 110.11 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp -46.1 -43.5 14.85 Favored 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 126.197 1.799 . . . . 1.0 113.686 -176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -51.09 -35.76 36.79 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.818 0.673 . . . . 1.0 112.818 178.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.57 -33.54 81.49 Favored Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.165 0.888 . . . . 1.0 112.135 174.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.54 -36.11 63.12 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 118.681 1.241 . . . . 1.0 111.889 174.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -57.91 -42.54 82.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 118.497 -0.763 . . . . 1.0 109.549 166.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.98 -35.89 82.62 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 119.34 0.973 . . . . 1.0 109.96 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -47.36 -59.56 5.76 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 118.53 -1.15 . . . . 1.0 111.487 163.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -59.27 -44.19 92.44 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 118.668 1.234 . . . . 1.0 112.143 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.7 mt -50.11 -24.89 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 125.671 1.588 . . . . 1.0 112.813 172.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.89 -1.16 17.94 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-N 119.468 1.031 . . . . 1.0 112.552 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -151.84 72.2 1.01 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.442 1.497 . . . . 1.0 108.524 -166.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 115.91 -5.03 20.53 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.538 -1.145 . . . . 1.0 113.761 173.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t90 -39.16 -41.99 0.9 Allowed 'General case' 0 C--N 1.343 0.297 0 C-N-CA 126.502 1.921 . . . . 1.0 113.044 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -50.81 -34.57 28.19 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.887 1.275 . . . . 1.0 112.438 -175.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.06 -18.7 67.15 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.675 -0.641 . . . . 1.0 113.725 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.43 -9.44 20.27 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.75 1.62 . . . . 1.0 113.038 169.098 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.9 mt -71.65 -43.14 71.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 166.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 44.4 t0 . . . . . 0 CA--C 1.542 0.644 0 C-N-CA 124.952 1.301 . . . . 1.0 111.588 172.583 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.32 -1.112 . . . . 1.0 110.32 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.5 tp -44.86 -43.69 8.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 C-N-CA 126.185 1.794 . . . . 1.0 113.51 -176.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -47.04 -35.51 6.87 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.83 1.252 . . . . 1.0 113.499 178.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.7 -42.88 86.52 Favored Glycine 0 CA--C 1.53 0.992 0 C-N-CA 123.913 0.768 . . . . 1.0 111.968 173.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.54 -30.17 70.42 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 118.356 1.078 . . . . 1.0 112.091 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.6 mt -54.57 -40.98 52.55 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-O 117.932 -1.033 . . . . 1.0 110.395 172.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.98 -29.31 70.16 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 120.416 1.462 . . . . 1.0 111.986 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.81 -47.84 64.71 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.885 -0.886 . . . . 1.0 110.885 169.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -60.27 -45.5 93.09 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.899 0.85 . . . . 1.0 112.653 177.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.2 mt -40.39 -50.25 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 C-N-CA 125.918 1.687 . . . . 1.0 110.937 168.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 mm-40 -79.87 -3.98 50.3 Favored 'General case' 0 CA--C 1.539 0.525 0 N-CA-C 113.037 0.754 . . . . 1.0 113.037 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -98.92 21.34 11.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 120.0 1.273 . . . . 1.0 110.583 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 24.77 47.54 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 118.849 -0.973 . . . . 1.0 112.015 -176.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -37.34 -49.91 1.01 Allowed 'General case' 0 C--N 1.347 0.477 0 C-N-CA 124.18 0.992 . . . . 1.0 112.615 173.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -59.08 -25.1 63.49 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.42 0.896 . . . . 1.0 113.42 -171.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.36 -43.59 6.93 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.529 -1.029 . . . . 1.0 110.529 171.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 5.7 ttt -63.58 -7.53 7.41 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.261 1.824 . . . . 1.0 114.057 177.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 66.3 mt -55.0 -30.37 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 C-N-CA 124.563 1.145 . . . . 1.0 110.649 162.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.7 t0 . . . . . 0 CA--C 1.537 0.451 0 CA-C-O 121.749 0.785 . . . . 1.0 111.111 178.358 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 109.995 -1.242 . . . . 1.0 109.995 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.8 tp -47.73 -43.7 27.27 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 125.647 1.579 . . . . 1.0 113.173 -176.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.91 -34.51 55.46 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.551 0.74 . . . . 1.0 112.582 179.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.89 -34.4 82.28 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 124.223 0.916 . . . . 1.0 112.041 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.7 -34.12 66.93 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 118.639 1.22 . . . . 1.0 111.806 172.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -59.15 -40.99 82.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 CA-C-N 119.313 0.96 . . . . 1.0 109.774 167.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.86 -39.89 94.26 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 119.767 1.167 . . . . 1.0 109.828 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.29 -49.49 31.35 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 119.163 -0.798 . . . . 1.0 112.023 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.3 t80 -64.68 -47.76 77.23 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.437 1.118 . . . . 1.0 111.686 177.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -47.99 -34.5 4.48 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.746 1.219 . . . . 1.0 111.735 172.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -91.46 -3.5 56.54 Favored 'General case' 0 CA--C 1.542 0.652 0 CA-C-O 117.867 -1.064 . . . . 1.0 113.318 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -145.11 -15.9 0.51 Allowed 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 115.956 1.836 . . . . 1.0 115.956 -166.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.44 0.55 0.39 Allowed Glycine 0 CA--C 1.529 0.925 0 CA-C-O 118.027 -1.429 . . . . 1.0 113.575 -174.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.3 t90 -38.41 -42.71 0.76 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.445 1.898 . . . . 1.0 113.519 -177.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -49.7 -34.78 19.72 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.967 1.307 . . . . 1.0 112.42 -177.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.69 -16.66 70.22 Favored Glycine 0 CA--C 1.533 1.184 0 CA-C-O 119.377 -0.679 . . . . 1.0 113.993 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.7 mtp -102.2 -8.19 21.54 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.328 1.451 . . . . 1.0 112.499 168.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mt -74.1 -54.65 14.42 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 107.136 -1.431 . . . . 1.0 107.136 165.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.3 t70 . . . . . 0 CA--C 1.543 0.697 0 C-N-CA 125.502 1.521 . . . . 1.0 110.712 -173.831 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.125 0 N-CA-C 110.27 -1.132 . . . . 1.0 110.27 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -45.59 -43.74 12.38 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 126.484 1.914 . . . . 1.0 113.89 -176.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.23 -35.3 49.23 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.301 0.572 . . . . 1.0 112.481 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -32.74 79.74 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.298 0.951 . . . . 1.0 112.078 174.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.32 -37.4 63.6 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.89 1.345 . . . . 1.0 111.658 173.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -58.36 -40.94 80.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-O 118.647 -0.692 . . . . 1.0 109.635 167.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.85 -35.89 81.94 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.421 1.01 . . . . 1.0 109.984 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.32 -56.43 10.79 Favored Glycine 0 CA--C 1.531 1.032 0 CA-C-O 118.862 -0.965 . . . . 1.0 111.359 164.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -60.74 -41.49 95.48 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.524 1.162 . . . . 1.0 112.396 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -51.52 -25.09 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 125.313 1.445 . . . . 1.0 112.56 170.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -105.32 -0.08 26.56 Favored 'General case' 0 CA--C 1.545 0.783 0 CA-C-N 119.459 1.027 . . . . 1.0 112.776 174.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -149.99 71.67 1.09 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 125.261 1.424 . . . . 1.0 108.767 -165.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 5.24 47.85 Favored Glycine 0 CA--C 1.528 0.904 0 CA-C-O 118.608 -1.107 . . . . 1.0 114.165 171.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -37.63 -44.78 0.72 Allowed 'General case' 0 C--N 1.343 0.294 0 C-N-CA 127.118 2.167 . . . . 1.0 113.737 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -48.06 -35.65 11.58 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.279 1.832 . . . . 1.0 112.219 -170.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.98 -27.83 65.25 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.598 -0.689 . . . . 1.0 113.484 178.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -95.19 -18.58 20.78 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.275 1.83 . . . . 1.0 111.963 176.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.9 mt -67.79 -50.03 63.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 168.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 30.1 t70 . . . . . 0 CA--C 1.533 0.325 0 C-N-CA 125.675 1.59 . . . . 1.0 110.793 170.367 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 110.086 -1.206 . . . . 1.0 110.086 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.8 tp -46.53 -43.72 17.19 Favored 'General case' 0 CA--C 1.513 -0.466 0 C-N-CA 126.113 1.765 . . . . 1.0 113.388 -177.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -51.74 -34.67 40.24 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.787 0.662 . . . . 1.0 112.787 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.21 -35.84 90.95 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.114 0.864 . . . . 1.0 112.243 173.116 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.95 -40.23 72.13 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.486 1.143 . . . . 1.0 111.264 173.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -56.7 -38.79 59.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-O 118.425 -0.798 . . . . 1.0 110.083 168.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -68.82 -26.14 65.03 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 119.703 1.138 . . . . 1.0 111.705 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.53 -55.42 27.44 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.48 -1.048 . . . . 1.0 110.48 163.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -55.16 -38.33 68.14 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 123.957 0.903 . . . . 1.0 112.146 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 mt -49.29 -26.54 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 126.298 1.839 . . . . 1.0 112.57 172.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -112.26 -4.92 14.23 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 119.931 1.241 . . . . 1.0 112.029 175.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -150.07 66.5 0.97 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 125.488 1.515 . . . . 1.0 108.11 -163.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.73 -20.9 4.05 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.957 -0.913 . . . . 1.0 112.405 178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.6 t90 -46.86 -42.86 18.04 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 124.441 1.097 . . . . 1.0 111.259 174.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -59.22 -26.96 65.31 Favored 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 123.889 0.876 . . . . 1.0 113.052 -177.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.54 -13.76 82.65 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 119.385 -0.675 . . . . 1.0 113.137 172.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.2 ttt -101.59 -19.91 15.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.189 1.796 . . . . 1.0 111.833 173.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.9 mt -65.67 -48.53 82.14 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 162.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.7 t0 . . . . . 0 N--CA 1.467 0.39 0 C-N-CA 126.298 1.839 . . . . 1.0 111.282 -174.03 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.104 0 N-CA-C 110.18 -1.168 . . . . 1.0 110.18 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -46.91 -43.77 19.19 Favored 'General case' 0 CA--C 1.515 -0.368 0 C-N-CA 126.115 1.766 . . . . 1.0 113.532 -176.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.54 -34.51 58.5 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 121.455 0.645 . . . . 1.0 112.431 179.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.74 -34.17 86.53 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.114 0.864 . . . . 1.0 112.006 173.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.01 -36.1 66.95 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 118.642 1.221 . . . . 1.0 111.692 173.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -58.09 -41.82 81.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 118.967 0.803 . . . . 1.0 109.628 166.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.54 -31.63 72.47 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.507 1.049 . . . . 1.0 110.61 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.97 -58.47 12.55 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 119.065 -0.853 . . . . 1.0 110.97 162.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -55.77 -42.66 75.84 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 118.67 1.235 . . . . 1.0 112.16 -178.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.1 mt -50.16 -23.97 1.84 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 C-N-CA 125.929 1.691 . . . . 1.0 113.236 171.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 -113.0 -1.81 14.39 Favored 'General case' 0 CA--C 1.543 0.711 0 CA-C-N 119.698 1.135 . . . . 1.0 111.914 173.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -146.95 65.9 1.16 Allowed 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.638 1.575 . . . . 1.0 108.335 -164.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 117.66 -3.42 17.57 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.394 -1.225 . . . . 1.0 114.069 175.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.8 t90 -38.56 -39.6 0.49 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 126.865 2.066 . . . . 1.0 113.166 176.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -50.36 -33.61 21.09 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.37 1.068 . . . . 1.0 112.419 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.93 -23.14 65.41 Favored Glycine 0 CA--C 1.534 1.25 0 O-C-N 121.353 -0.842 . . . . 1.0 113.594 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 23.8 mmt -102.0 -8.32 21.6 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.448 1.899 . . . . 1.0 112.478 172.497 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.8 mt -71.58 -23.97 23.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 N-CA-C 108.492 -0.929 . . . . 1.0 108.492 160.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t0 . . . . . 0 C--N 1.344 0.326 0 C-N-CA 128.169 2.588 . . . . 1.0 113.669 159.614 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.144 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.8 tp -48.43 -43.66 34.53 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 125.504 1.522 . . . . 1.0 113.273 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.11 -35.06 59.25 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.395 0.678 . . . . 1.0 112.376 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.31 -33.65 78.3 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 124.336 0.97 . . . . 1.0 112.156 173.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.59 -38.77 67.76 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 118.71 1.255 . . . . 1.0 111.48 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.77 -39.82 72.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 118.467 -0.778 . . . . 1.0 110.01 167.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.79 95.5 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.663 1.119 . . . . 1.0 109.683 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.33 -45.21 52.86 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.955 -0.914 . . . . 1.0 112.38 168.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 52.1 t80 -65.96 -50.71 63.4 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.755 1.278 . . . . 1.0 111.47 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mt -47.64 -31.74 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 C-N-CA 125.667 1.587 . . . . 1.0 112.347 170.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -91.02 -8.06 50.16 Favored 'General case' 0 CA--C 1.544 0.712 0 CA-C-O 117.696 -1.145 . . . . 1.0 113.628 178.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.04 -15.94 0.46 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 116.381 1.993 . . . . 1.0 116.381 -166.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.0 1.12 0.65 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 124.925 1.25 . . . . 1.0 113.32 -176.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.5 t90 -40.32 -43.14 1.68 Allowed 'General case' 0 C--N 1.343 0.302 0 C-N-CA 127.12 2.168 . . . . 1.0 113.809 -171.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -51.75 -33.62 35.7 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.802 1.241 . . . . 1.0 112.177 -169.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.99 -13.92 62.57 Favored Glycine 0 CA--C 1.537 1.451 0 CA-C-O 118.988 -0.895 . . . . 1.0 114.389 178.143 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 27.8 ttt -102.47 -13.35 17.28 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.284 1.834 . . . . 1.0 111.928 170.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.9 mt -75.34 -48.31 31.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 N-CA-C 107.254 -1.388 . . . . 1.0 107.254 170.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 . . . . . 0 CA--C 1.537 0.464 0 N-CA-C 109.554 -0.536 . . . . 1.0 109.554 162.746 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.143 0 N-CA-C 110.186 -1.166 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.3 tp -46.6 -43.76 17.6 Favored 'General case' 0 CA--C 1.515 -0.399 0 C-N-CA 126.231 1.812 . . . . 1.0 113.507 -176.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -53.48 -34.17 57.04 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 121.494 0.664 . . . . 1.0 112.462 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.43 -34.59 85.2 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.241 0.925 . . . . 1.0 112.046 173.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.13 -37.36 69.47 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 118.653 1.227 . . . . 1.0 111.538 173.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.21 -41.4 77.9 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-O 118.358 -0.83 . . . . 1.0 109.796 167.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.75 -33.7 76.48 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 119.832 1.196 . . . . 1.0 110.733 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.01 -54.65 30.15 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 118.927 -0.929 . . . . 1.0 111.416 164.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -59.8 -42.59 93.74 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.31 1.055 . . . . 1.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -50.27 -24.17 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 C-N-CA 125.856 1.663 . . . . 1.0 112.898 171.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -108.69 -1.67 19.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.58 1.152 . . . . 1.0 112.229 175.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -155.48 71.79 0.78 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.684 1.594 . . . . 1.0 108.709 -165.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 120.69 -9.49 10.64 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-O 118.949 -0.917 . . . . 1.0 113.531 174.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -37.13 -44.4 0.55 Allowed 'General case' 0 C--N 1.343 0.301 0 C-N-CA 126.88 2.072 . . . . 1.0 112.641 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.4 pm0 -53.75 -29.13 38.41 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 124.882 1.273 . . . . 1.0 112.68 -175.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.1 -15.51 74.45 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 118.932 0.787 . . . . 1.0 113.811 175.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.5 mmt -102.25 -8.08 21.57 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.215 1.806 . . . . 1.0 112.201 169.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.0 mt -77.5 -43.91 30.0 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.328 -1.36 . . . . 1.0 107.328 164.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 43.3 t0 . . . . . 0 CA--C 1.539 0.52 0 C-N-CA 123.645 0.778 . . . . 1.0 110.473 167.03 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp -46.38 -43.44 16.23 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.245 1.818 . . . . 1.0 113.586 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -51.38 -35.43 38.77 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.527 0.731 . . . . 1.0 112.836 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.65 -36.92 92.02 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 124.042 0.83 . . . . 1.0 111.713 173.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.03 -34.24 71.09 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 118.525 1.163 . . . . 1.0 111.872 174.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.2 mt -58.94 -42.06 84.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 119.306 0.957 . . . . 1.0 109.747 167.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.55 73.91 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.622 1.101 . . . . 1.0 110.505 177.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.16 -55.14 27.8 Favored Glycine 0 CA--C 1.532 1.15 0 CA-C-O 119.197 -0.779 . . . . 1.0 111.336 164.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -60.56 -39.75 89.11 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.93 1.292 . . . . 1.0 112.474 -179.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.4 mt -50.49 -24.04 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 125.694 1.598 . . . . 1.0 112.764 169.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.36 0.13 19.31 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.27 1.028 . . . . 1.0 112.369 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -150.51 70.83 1.03 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.693 1.597 . . . . 1.0 108.862 -166.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 107.19 2.89 35.94 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.67 -1.072 . . . . 1.0 114.202 172.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -35.9 -43.43 0.31 Allowed 'General case' 0 C--N 1.343 0.311 0 C-N-CA 127.966 2.506 . . . . 1.0 113.531 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -49.77 -33.64 16.99 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.422 1.489 . . . . 1.0 112.15 -174.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.29 -18.21 64.91 Favored Glycine 0 CA--C 1.537 1.453 0 CA-C-O 119.18 -0.789 . . . . 1.0 114.149 177.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.6 ttt -102.36 -10.69 19.25 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.251 1.82 . . . . 1.0 112.052 171.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mt -75.13 -40.67 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 167.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 . . . . . 0 CA--C 1.538 0.517 0 C-N-CA 123.783 0.833 . . . . 1.0 110.807 167.579 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.14 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -45.27 -43.48 10.57 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.431 1.892 . . . . 1.0 113.608 -176.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -50.4 -34.22 23.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.12 0.968 . . . . 1.0 112.951 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.93 -37.15 87.69 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.156 0.884 . . . . 1.0 112.213 173.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.13 -32.17 71.36 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.424 1.112 . . . . 1.0 111.527 173.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -58.08 -40.01 75.15 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 CA-C-O 118.072 -0.966 . . . . 1.0 109.907 170.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.71 -25.99 67.55 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 120.299 1.409 . . . . 1.0 111.82 176.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.79 -54.21 35.33 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.795 -0.922 . . . . 1.0 110.795 165.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -58.27 -34.11 70.15 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.604 1.162 . . . . 1.0 112.914 177.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 mt -53.1 -28.73 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.802 1.241 . . . . 1.0 111.726 172.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -102.6 -0.17 32.4 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.164 0.986 . . . . 1.0 111.912 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 -151.81 66.54 0.86 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.305 1.442 . . . . 1.0 108.857 -163.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.23 -2.37 14.3 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.247 -1.307 . . . . 1.0 114.455 176.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -45.15 -34.23 2.6 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.199 1.4 . . . . 1.0 114.169 174.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.0 tm-20 -54.38 -35.58 62.98 Favored 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 118.621 0.646 . . . . 1.0 111.197 175.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.23 -8.05 82.97 Favored Glycine 0 CA--C 1.531 1.091 0 C-N-CA 125.16 1.362 . . . . 1.0 113.959 176.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 10.1 ptm -102.21 -10.26 19.73 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 119.284 1.542 . . . . 1.0 112.541 164.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -75.57 -43.46 41.53 Favored 'Isoleucine or valine' 0 C--N 1.341 0.216 0 N-CA-C 107.073 -1.454 . . . . 1.0 107.073 163.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.0 t0 . . . . . 0 CA--C 1.537 0.446 0 C-N-CA 119.443 -0.903 . . . . 1.0 108.925 160.441 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.129 0 N-CA-C 110.062 -1.215 . . . . 1.0 110.062 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -47.86 -43.68 28.59 Favored 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 125.517 1.527 . . . . 1.0 113.401 -176.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -51.9 -35.42 45.33 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.775 0.657 . . . . 1.0 112.775 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.78 -34.64 87.92 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.022 0.82 . . . . 1.0 112.101 173.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.99 -36.8 67.13 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 118.477 1.139 . . . . 1.0 111.612 173.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.22 -39.76 74.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-O 118.237 -0.887 . . . . 1.0 109.7 167.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.24 -41.01 97.18 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 119.748 1.158 . . . . 1.0 109.766 175.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.08 -39.22 49.21 Favored Glycine 0 CA--C 1.535 1.32 0 CA-C-O 118.961 -0.911 . . . . 1.0 113.018 169.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.9 t80 -73.14 -47.8 40.98 Favored 'General case' 0 C--N 1.341 0.227 0 CA-C-N 118.819 1.31 . . . . 1.0 112.451 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -43.84 -51.78 1.42 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 C-N-CA 124.76 1.224 . . . . 1.0 110.13 169.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -77.03 -0.93 26.39 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.265 1.426 . . . . 1.0 112.033 -177.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -81.17 -0.43 40.31 Favored 'General case' 0 C--N 1.343 0.286 0 O-C-N 120.945 -1.097 . . . . 1.0 111.662 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.41 36.42 20.45 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.256 -1.302 . . . . 1.0 110.195 -160.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -35.44 -39.14 0.12 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 125.539 1.536 . . . . 1.0 113.926 171.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -52.46 -32.33 39.11 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.563 0.949 . . . . 1.0 113.563 178.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.28 -12.96 66.86 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 119.169 -0.795 . . . . 1.0 113.236 176.033 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.5 mpt? -102.28 -9.57 20.27 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.873 1.669 . . . . 1.0 111.976 171.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 53.4 mt -73.64 -49.74 33.93 Favored 'Isoleucine or valine' 0 C--N 1.341 0.218 0 N-CA-C 107.348 -1.353 . . . . 1.0 107.348 173.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.8 t0 . . . . . 0 CA--C 1.534 0.356 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 164.336 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.167 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.4 tp -48.48 -43.75 35.1 Favored 'General case' 0 CA--C 1.514 -0.406 0 C-N-CA 125.411 1.485 . . . . 1.0 113.421 -176.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -55.09 -34.17 63.41 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.46 0.648 . . . . 1.0 112.077 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.35 -31.02 73.64 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 124.341 0.972 . . . . 1.0 112.083 173.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.98 -36.11 62.04 Favored 'General case' 0 N--CA 1.456 -0.148 0 CA-C-N 118.998 1.399 . . . . 1.0 111.684 172.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 mt -59.37 -39.5 79.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-N 119.157 0.889 . . . . 1.0 109.757 167.351 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.24 -41.25 94.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 119.379 0.99 . . . . 1.0 109.53 175.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.15 -44.09 51.1 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.978 -0.901 . . . . 1.0 112.529 168.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -65.69 -51.58 58.26 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.79 1.295 . . . . 1.0 110.807 174.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.6 mt -47.89 -30.74 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 125.405 1.482 . . . . 1.0 112.502 171.172 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -91.38 -9.36 45.07 Favored 'General case' 0 CA--C 1.545 0.774 0 CA-C-O 117.723 -1.132 . . . . 1.0 113.602 178.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -145.49 -15.86 0.49 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 116.149 1.907 . . . . 1.0 116.149 -166.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.1 2.44 0.52 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 125.385 1.469 . . . . 1.0 113.487 -174.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.6 t90 -39.8 -41.34 1.11 Allowed 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 127.311 2.244 . . . . 1.0 113.727 -174.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -52.19 -31.27 31.0 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.845 1.258 . . . . 1.0 112.224 -169.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.77 -8.46 63.79 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-O 118.755 -1.025 . . . . 1.0 114.852 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.5 -12.5 17.76 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 126.162 1.785 . . . . 1.0 112.928 164.311 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.5 mt -79.24 -55.59 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.019 -1.845 . . . . 1.0 106.019 173.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.9 t0 . . . . . 0 CA--C 1.534 0.339 0 N-CA-C 108.381 -0.97 . . . . 1.0 108.381 158.798 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 . . . . . 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 . . . . . 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.217 0 N-CA-C 110.196 -1.162 . . . . 1.0 110.196 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.4 tp -45.83 -43.74 13.66 Favored 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 126.283 1.833 . . . . 1.0 113.469 -176.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -50.74 -35.05 29.53 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.54 0.736 . . . . 1.0 112.924 178.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.19 87.46 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.027 0.822 . . . . 1.0 112.122 173.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.89 -39.85 72.56 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.478 1.139 . . . . 1.0 111.349 173.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -56.72 -40.23 68.72 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-O 118.224 -0.893 . . . . 1.0 109.914 167.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.78 -31.85 72.75 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 120.136 1.335 . . . . 1.0 110.796 179.155 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.25 -55.3 31.11 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.915 -0.874 . . . . 1.0 110.915 164.503 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -55.85 -43.06 76.73 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 118.043 0.921 . . . . 1.0 111.977 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.8 mt -50.47 -26.65 3.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 125.431 1.493 . . . . 1.0 112.564 173.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -109.69 5.33 22.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.564 1.146 . . . . 1.0 112.164 178.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -138.06 -15.72 1.3 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 114.532 1.308 . . . . 1.0 114.532 -169.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -158.28 0.34 0.09 OUTLIER Glycine 0 CA--C 1.529 0.957 0 C-N-CA 125.146 1.355 . . . . 1.0 113.845 -174.13 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.1 t90 -44.79 -38.63 4.64 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 119.016 1.408 . . . . 1.0 113.074 176.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -57.05 -30.96 64.69 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 118.998 0.817 . . . . 1.0 112.145 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.18 -23.24 77.38 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 121.31 -0.869 . . . . 1.0 112.757 173.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 6.5 ptt? -92.67 -16.34 25.66 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.947 1.374 . . . . 1.0 112.5 173.752 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.7 mt -64.2 -56.71 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 106.562 -1.644 . . . . 1.0 106.562 160.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.2 t70 . . . . . 0 CA--C 1.534 0.351 0 C-N-CA 124.065 0.946 . . . . 1.0 111.08 176.255 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.201 0 N-CA-C 110.195 -1.162 . . . . 1.0 110.195 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -46.39 -43.61 16.39 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 126.123 1.769 . . . . 1.0 113.635 -176.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.9 -34.16 53.67 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.655 0.782 . . . . 1.0 112.684 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.15 -35.49 83.41 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 124.032 0.825 . . . . 1.0 111.959 172.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.77 -31.68 68.55 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 118.561 1.18 . . . . 1.0 111.825 173.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -59.77 -42.46 88.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 119.461 1.028 . . . . 1.0 109.578 167.446 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.59 -31.0 71.42 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 119.568 1.076 . . . . 1.0 110.738 177.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -56.1 25.81 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 111.073 -0.811 . . . . 1.0 111.073 164.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -58.25 -39.45 79.19 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.392 1.096 . . . . 1.0 112.396 -179.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.1 mt -51.2 -24.21 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 125.546 1.539 . . . . 1.0 112.862 170.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -109.96 0.2 18.46 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.719 1.145 . . . . 1.0 112.06 173.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -145.17 66.54 1.24 Allowed 'General case' 0 CA--C 1.535 0.372 0 O-C-N 120.297 -1.502 . . . . 1.0 108.709 -165.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 108.04 2.05 33.92 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 118.661 -1.077 . . . . 1.0 114.36 173.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -37.72 -43.97 0.68 Allowed 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 127.195 2.198 . . . . 1.0 113.662 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.33 -38.68 19.73 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.659 1.584 . . . . 1.0 111.951 -174.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -63.68 -22.04 65.69 Favored Glycine 0 CA--C 1.534 1.239 0 CA-C-O 119.235 -0.758 . . . . 1.0 113.543 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 mmt -102.18 -9.39 20.52 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.94 1.696 . . . . 1.0 113.042 172.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.7 mt -68.99 -48.37 70.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 106.646 -1.612 . . . . 1.0 106.646 162.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 8.3 t70 . . . . . 0 CA--C 1.534 0.346 0 C-N-CA 124.79 1.236 . . . . 1.0 110.472 169.552 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.163 0 N-CA-C 110.025 -1.23 . . . . 1.0 110.025 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -48.16 -43.67 31.68 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 125.588 1.555 . . . . 1.0 113.387 -177.087 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -52.16 -35.84 49.88 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.761 0.652 . . . . 1.0 112.761 178.207 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.83 -32.4 81.02 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 124.304 0.954 . . . . 1.0 112.103 174.067 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -38.91 58.06 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 118.783 1.292 . . . . 1.0 111.635 174.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.17 -39.45 73.25 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 CA-C-N 118.772 0.714 . . . . 1.0 109.861 167.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.74 -38.31 86.37 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 119.323 0.965 . . . . 1.0 109.677 176.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.13 -50.63 27.68 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 123.897 0.761 . . . . 1.0 111.747 165.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -62.46 -48.18 80.77 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.82 1.31 . . . . 1.0 111.211 175.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mt -49.83 -37.48 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-N 119.254 0.934 . . . . 1.0 111.942 172.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.9 mm-40 -87.29 -4.52 59.07 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.383 -0.823 . . . . 1.0 112.825 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -140.19 -15.93 0.97 Allowed 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 120.875 1.67 . . . . 1.0 114.656 -166.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.85 3.56 0.42 Allowed Glycine 0 CA--C 1.528 0.857 0 C-N-CA 126.298 1.904 . . . . 1.0 113.136 -172.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -46.0 -33.87 3.65 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 119.213 1.506 . . . . 1.0 113.454 174.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -55.91 -32.99 64.26 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 119.565 1.075 . . . . 1.0 111.538 177.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.56 -7.75 83.35 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.283 1.42 . . . . 1.0 114.151 174.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.2 ptm -102.63 -8.46 20.92 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.308 1.554 . . . . 1.0 113.189 163.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mt -72.42 -56.68 9.15 Favored 'Isoleucine or valine' 0 C--N 1.344 0.354 0 N-CA-C 106.029 -1.841 . . . . 1.0 106.029 161.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 . . . . . 0 CA--C 1.535 0.384 0 N-CA-C 109.16 -0.681 . . . . 1.0 109.16 165.745 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.174 0 N-CA-C 110.216 -1.154 . . . . 1.0 110.216 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.3 tp -45.85 -43.61 13.63 Favored 'General case' 0 CA--C 1.515 -0.377 0 C-N-CA 126.474 1.91 . . . . 1.0 113.591 -176.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -51.46 -35.16 38.64 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.535 0.734 . . . . 1.0 112.793 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.89 85.42 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.175 0.893 . . . . 1.0 112.056 173.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.12 -38.01 72.32 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 118.656 1.228 . . . . 1.0 111.293 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -57.84 -39.95 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 117.922 -1.037 . . . . 1.0 109.86 168.061 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.41 86.25 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 120.176 1.353 . . . . 1.0 110.175 177.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.4 -47.21 51.5 Favored Glycine 0 CA--C 1.533 1.17 0 CA-C-O 119.48 -0.622 . . . . 1.0 111.84 166.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -68.25 -43.46 77.8 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.388 1.094 . . . . 1.0 113.043 177.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -44.18 -52.81 1.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.693 1.197 . . . . 1.0 109.33 168.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -79.06 2.08 21.87 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.907 1.283 . . . . 1.0 112.582 -176.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -86.83 11.23 13.77 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.361 0.982 . . . . 1.0 110.154 171.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.92 38.37 23.34 Favored Glycine 0 C--N 1.338 0.685 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 -170.676 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.8 t90 -38.43 -44.8 0.96 Allowed 'General case' 0 C--N 1.349 0.586 0 C-N-CA 123.915 0.886 . . . . 1.0 112.703 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -60.66 -23.54 64.88 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 113.781 1.03 . . . . 1.0 113.781 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.35 -31.88 29.73 Favored Glycine 0 C--N 1.34 0.804 0 CA-C-N 118.857 0.753 . . . . 1.0 111.478 170.217 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 16.3 mmt -68.82 -11.98 61.03 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.519 1.128 . . . . 1.0 112.356 176.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mt -65.46 -29.07 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.23 1.012 . . . . 1.0 109.729 168.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.4 t0 . . . . . 0 CA--C 1.535 0.393 0 C-N-CA 129.206 3.002 . . . . 1.0 114.118 177.724 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.154 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -45.12 -43.55 9.83 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.29 1.836 . . . . 1.0 113.637 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -50.93 -34.28 27.97 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.984 0.914 . . . . 1.0 113.018 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.9 -36.56 86.83 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 123.981 0.8 . . . . 1.0 112.17 172.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.69 -36.07 73.11 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-N 118.316 1.058 . . . . 1.0 111.593 173.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mt -57.96 -39.64 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 118.016 -0.992 . . . . 1.0 110.067 168.023 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.68 91.3 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 120.072 1.306 . . . . 1.0 110.275 176.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.32 -48.66 59.15 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.692 -0.563 . . . . 1.0 111.692 167.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -63.23 -46.87 84.9 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 118.248 1.024 . . . . 1.0 112.157 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.5 mt -45.09 -45.2 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 125.295 1.438 . . . . 1.0 110.999 170.293 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -79.95 -8.05 59.12 Favored 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 112.791 0.663 . . . . 1.0 112.791 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -89.78 33.49 0.85 Allowed 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 120.408 1.458 . . . . 1.0 109.872 -174.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.3 22.93 73.15 Favored Glycine 0 CA--C 1.531 1.044 0 CA-C-O 118.17 -1.35 . . . . 1.0 112.504 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -41.42 -40.29 1.71 Allowed 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.039 1.336 . . . . 1.0 113.693 -179.007 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -51.31 -37.46 47.7 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.428 0.691 . . . . 1.0 111.996 -178.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.77 -9.56 75.17 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.754 -1.026 . . . . 1.0 113.836 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.6 ppp? -98.91 -8.23 25.94 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.76 1.28 . . . . 1.0 111.674 174.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.6 mt -66.39 -50.09 70.31 Favored 'Isoleucine or valine' 0 C--N 1.345 0.375 0 N-CA-C 108.878 -0.786 . . . . 1.0 108.878 176.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.5 t0 . . . . . 0 CA--C 1.54 0.58 0 C-N-CA 128.51 2.724 . . . . 1.0 113.831 177.127 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.132 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -47.24 -43.61 22.03 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 125.862 1.665 . . . . 1.0 113.371 -176.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -51.87 -35.22 44.2 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.306 0.643 . . . . 1.0 112.671 178.693 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -32.51 76.18 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.243 0.925 . . . . 1.0 112.329 173.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.64 -37.81 65.22 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 118.826 1.313 . . . . 1.0 111.482 172.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.1 mt -58.4 -39.43 74.59 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 CA-C-O 118.453 -0.784 . . . . 1.0 109.787 167.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -40.44 93.79 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.8 1.182 . . . . 1.0 109.659 176.17 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.8 -46.67 39.63 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 124.029 0.823 . . . . 1.0 112.255 167.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -65.52 -49.98 66.97 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.488 1.144 . . . . 1.0 111.483 175.418 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -48.66 -32.09 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 C-N-CA 125.098 1.359 . . . . 1.0 112.135 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -89.81 -8.26 52.48 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-O 117.718 -1.134 . . . . 1.0 113.338 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.25 -15.98 0.45 Allowed 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.315 1.968 . . . . 1.0 116.315 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -144.9 -1.11 0.85 Allowed Glycine 0 CA--C 1.53 0.999 0 C-N-CA 125.875 1.703 . . . . 1.0 113.388 -175.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.0 t90 -37.7 -41.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 127.461 2.304 . . . . 1.0 113.759 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tm-20 -49.27 -37.01 22.25 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.238 1.415 . . . . 1.0 112.371 -175.394 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.31 -17.62 70.51 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-O 119.348 -0.695 . . . . 1.0 113.783 178.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.6 mmt -102.51 -7.78 21.6 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.577 1.951 . . . . 1.0 112.808 169.145 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 57.1 mt -66.9 -50.73 62.24 Favored 'Isoleucine or valine' 0 C--N 1.342 0.267 0 N-CA-C 106.19 -1.782 . . . . 1.0 106.19 162.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.9 t0 . . . . . 0 CA--C 1.542 0.636 0 C-N-CA 124.216 1.007 . . . . 1.0 110.95 167.764 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.195 0 N-CA-C 110.11 -1.196 . . . . 1.0 110.11 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp -46.1 -43.5 14.85 Favored 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 126.197 1.799 . . . . 1.0 113.686 -176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -51.09 -35.76 36.79 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.818 0.673 . . . . 1.0 112.818 178.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.57 -33.54 81.49 Favored Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.165 0.888 . . . . 1.0 112.135 174.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.54 -36.11 63.12 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 118.681 1.241 . . . . 1.0 111.889 174.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -57.91 -42.54 82.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 118.497 -0.763 . . . . 1.0 109.549 166.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.98 -35.89 82.62 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 119.34 0.973 . . . . 1.0 109.96 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -47.36 -59.56 5.76 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 118.53 -1.15 . . . . 1.0 111.487 163.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -59.27 -44.19 92.44 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 118.668 1.234 . . . . 1.0 112.143 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.7 mt -50.11 -24.89 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 125.671 1.588 . . . . 1.0 112.813 172.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.89 -1.16 17.94 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-N 119.468 1.031 . . . . 1.0 112.552 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -151.84 72.2 1.01 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.442 1.497 . . . . 1.0 108.524 -166.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 115.91 -5.03 20.53 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.538 -1.145 . . . . 1.0 113.761 173.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t90 -39.16 -41.99 0.9 Allowed 'General case' 0 C--N 1.343 0.297 0 C-N-CA 126.502 1.921 . . . . 1.0 113.044 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -50.81 -34.57 28.19 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.887 1.275 . . . . 1.0 112.438 -175.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.06 -18.7 67.15 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.675 -0.641 . . . . 1.0 113.725 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.43 -9.44 20.27 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.75 1.62 . . . . 1.0 113.038 169.098 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.9 mt -71.65 -43.14 71.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 166.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -58.08 167.36 1.28 Allowed 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.952 1.301 . . . . 1.0 111.588 172.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.958 0 C-N-CA 125.575 1.56 . . . . 1.0 111.432 -173.707 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.32 -1.112 . . . . 1.0 110.32 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.5 tp -44.86 -43.69 8.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 C-N-CA 126.185 1.794 . . . . 1.0 113.51 -176.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -47.04 -35.51 6.87 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.83 1.252 . . . . 1.0 113.499 178.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.7 -42.88 86.52 Favored Glycine 0 CA--C 1.53 0.992 0 C-N-CA 123.913 0.768 . . . . 1.0 111.968 173.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.54 -30.17 70.42 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 118.356 1.078 . . . . 1.0 112.091 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.6 mt -54.57 -40.98 52.55 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-O 117.932 -1.033 . . . . 1.0 110.395 172.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.98 -29.31 70.16 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 120.416 1.462 . . . . 1.0 111.986 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.81 -47.84 64.71 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.885 -0.886 . . . . 1.0 110.885 169.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -60.27 -45.5 93.09 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.899 0.85 . . . . 1.0 112.653 177.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.2 mt -40.39 -50.25 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 C-N-CA 125.918 1.687 . . . . 1.0 110.937 168.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 mm-40 -79.87 -3.98 50.3 Favored 'General case' 0 CA--C 1.539 0.525 0 N-CA-C 113.037 0.754 . . . . 1.0 113.037 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -98.92 21.34 11.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 120.0 1.273 . . . . 1.0 110.583 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 24.77 47.54 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 118.849 -0.973 . . . . 1.0 112.015 -176.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -37.34 -49.91 1.01 Allowed 'General case' 0 C--N 1.347 0.477 0 C-N-CA 124.18 0.992 . . . . 1.0 112.615 173.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -59.08 -25.1 63.49 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.42 0.896 . . . . 1.0 113.42 -171.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.36 -43.59 6.93 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.529 -1.029 . . . . 1.0 110.529 171.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 5.7 ttt -63.58 -7.53 7.41 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.261 1.824 . . . . 1.0 114.057 177.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 66.3 mt -55.0 -30.37 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 C-N-CA 124.563 1.145 . . . . 1.0 110.649 162.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -58.54 150.69 22.2 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 121.749 0.785 . . . . 1.0 111.111 178.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.327 0 CA-C-O 118.66 -1.078 . . . . 1.0 112.379 -163.668 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 109.995 -1.242 . . . . 1.0 109.995 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.8 tp -47.73 -43.7 27.27 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 125.647 1.579 . . . . 1.0 113.173 -176.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.91 -34.51 55.46 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.551 0.74 . . . . 1.0 112.582 179.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.89 -34.4 82.28 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 124.223 0.916 . . . . 1.0 112.041 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.7 -34.12 66.93 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 118.639 1.22 . . . . 1.0 111.806 172.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -59.15 -40.99 82.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 CA-C-N 119.313 0.96 . . . . 1.0 109.774 167.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.86 -39.89 94.26 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 119.767 1.167 . . . . 1.0 109.828 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.29 -49.49 31.35 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 119.163 -0.798 . . . . 1.0 112.023 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.3 t80 -64.68 -47.76 77.23 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.437 1.118 . . . . 1.0 111.686 177.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -47.99 -34.5 4.48 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.746 1.219 . . . . 1.0 111.735 172.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -91.46 -3.5 56.54 Favored 'General case' 0 CA--C 1.542 0.652 0 CA-C-O 117.867 -1.064 . . . . 1.0 113.318 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -145.11 -15.9 0.51 Allowed 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 115.956 1.836 . . . . 1.0 115.956 -166.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.44 0.55 0.39 Allowed Glycine 0 CA--C 1.529 0.925 0 CA-C-O 118.027 -1.429 . . . . 1.0 113.575 -174.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.3 t90 -38.41 -42.71 0.76 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.445 1.898 . . . . 1.0 113.519 -177.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -49.7 -34.78 19.72 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.967 1.307 . . . . 1.0 112.42 -177.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.69 -16.66 70.22 Favored Glycine 0 CA--C 1.533 1.184 0 CA-C-O 119.377 -0.679 . . . . 1.0 113.993 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.7 mtp -102.2 -8.19 21.54 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.328 1.451 . . . . 1.0 112.499 168.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mt -74.1 -54.65 14.42 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 107.136 -1.431 . . . . 1.0 107.136 165.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.3 t70 43.2 -105.95 0.08 Allowed 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.502 1.521 . . . . 1.0 110.712 -173.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.135 0 CA-C-O 118.031 -1.427 . . . . 1.0 115.11 -178.721 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.125 0 N-CA-C 110.27 -1.132 . . . . 1.0 110.27 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -45.59 -43.74 12.38 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 126.484 1.914 . . . . 1.0 113.89 -176.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.23 -35.3 49.23 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.301 0.572 . . . . 1.0 112.481 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -32.74 79.74 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.298 0.951 . . . . 1.0 112.078 174.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.32 -37.4 63.6 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.89 1.345 . . . . 1.0 111.658 173.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -58.36 -40.94 80.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-O 118.647 -0.692 . . . . 1.0 109.635 167.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.85 -35.89 81.94 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.421 1.01 . . . . 1.0 109.984 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.32 -56.43 10.79 Favored Glycine 0 CA--C 1.531 1.032 0 CA-C-O 118.862 -0.965 . . . . 1.0 111.359 164.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -60.74 -41.49 95.48 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.524 1.162 . . . . 1.0 112.396 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -51.52 -25.09 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 125.313 1.445 . . . . 1.0 112.56 170.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -105.32 -0.08 26.56 Favored 'General case' 0 CA--C 1.545 0.783 0 CA-C-N 119.459 1.027 . . . . 1.0 112.776 174.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -149.99 71.67 1.09 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 125.261 1.424 . . . . 1.0 108.767 -165.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 5.24 47.85 Favored Glycine 0 CA--C 1.528 0.904 0 CA-C-O 118.608 -1.107 . . . . 1.0 114.165 171.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -37.63 -44.78 0.72 Allowed 'General case' 0 C--N 1.343 0.294 0 C-N-CA 127.118 2.167 . . . . 1.0 113.737 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -48.06 -35.65 11.58 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.279 1.832 . . . . 1.0 112.219 -170.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.98 -27.83 65.25 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.598 -0.689 . . . . 1.0 113.484 178.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -95.19 -18.58 20.78 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.275 1.83 . . . . 1.0 111.963 176.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.9 mt -67.79 -50.03 63.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 168.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -61.14 -56.07 25.0 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 125.675 1.59 . . . . 1.0 110.793 170.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.016 0 C-N-CA 124.953 1.263 . . . . 1.0 112.251 175.863 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 110.086 -1.206 . . . . 1.0 110.086 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.8 tp -46.53 -43.72 17.19 Favored 'General case' 0 CA--C 1.513 -0.466 0 C-N-CA 126.113 1.765 . . . . 1.0 113.388 -177.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -51.74 -34.67 40.24 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.787 0.662 . . . . 1.0 112.787 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.21 -35.84 90.95 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.114 0.864 . . . . 1.0 112.243 173.116 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.95 -40.23 72.13 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.486 1.143 . . . . 1.0 111.264 173.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -56.7 -38.79 59.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-O 118.425 -0.798 . . . . 1.0 110.083 168.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -68.82 -26.14 65.03 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 119.703 1.138 . . . . 1.0 111.705 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.53 -55.42 27.44 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.48 -1.048 . . . . 1.0 110.48 163.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -55.16 -38.33 68.14 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 123.957 0.903 . . . . 1.0 112.146 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 mt -49.29 -26.54 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 126.298 1.839 . . . . 1.0 112.57 172.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -112.26 -4.92 14.23 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 119.931 1.241 . . . . 1.0 112.029 175.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -150.07 66.5 0.97 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 125.488 1.515 . . . . 1.0 108.11 -163.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.73 -20.9 4.05 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.957 -0.913 . . . . 1.0 112.405 178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.6 t90 -46.86 -42.86 18.04 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 124.441 1.097 . . . . 1.0 111.259 174.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -59.22 -26.96 65.31 Favored 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 123.889 0.876 . . . . 1.0 113.052 -177.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.54 -13.76 82.65 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 119.385 -0.675 . . . . 1.0 113.137 172.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.2 ttt -101.59 -19.91 15.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.189 1.796 . . . . 1.0 111.833 173.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.9 mt -65.67 -48.53 82.14 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 162.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.7 t0 45.08 57.19 4.88 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 126.298 1.839 . . . . 1.0 111.282 -174.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.099 0 C-N-CA 124.559 1.076 . . . . 1.0 112.841 -176.105 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.104 0 N-CA-C 110.18 -1.168 . . . . 1.0 110.18 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -46.91 -43.77 19.19 Favored 'General case' 0 CA--C 1.515 -0.368 0 C-N-CA 126.115 1.766 . . . . 1.0 113.532 -176.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.54 -34.51 58.5 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 121.455 0.645 . . . . 1.0 112.431 179.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.74 -34.17 86.53 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.114 0.864 . . . . 1.0 112.006 173.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.01 -36.1 66.95 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 118.642 1.221 . . . . 1.0 111.692 173.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -58.09 -41.82 81.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 118.967 0.803 . . . . 1.0 109.628 166.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.54 -31.63 72.47 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.507 1.049 . . . . 1.0 110.61 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.97 -58.47 12.55 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 119.065 -0.853 . . . . 1.0 110.97 162.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -55.77 -42.66 75.84 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 118.67 1.235 . . . . 1.0 112.16 -178.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.1 mt -50.16 -23.97 1.84 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 C-N-CA 125.929 1.691 . . . . 1.0 113.236 171.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 -113.0 -1.81 14.39 Favored 'General case' 0 CA--C 1.543 0.711 0 CA-C-N 119.698 1.135 . . . . 1.0 111.914 173.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -146.95 65.9 1.16 Allowed 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.638 1.575 . . . . 1.0 108.335 -164.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 117.66 -3.42 17.57 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.394 -1.225 . . . . 1.0 114.069 175.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.8 t90 -38.56 -39.6 0.49 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 126.865 2.066 . . . . 1.0 113.166 176.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -50.36 -33.61 21.09 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.37 1.068 . . . . 1.0 112.419 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.93 -23.14 65.41 Favored Glycine 0 CA--C 1.534 1.25 0 O-C-N 121.353 -0.842 . . . . 1.0 113.594 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 23.8 mmt -102.0 -8.32 21.6 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.448 1.899 . . . . 1.0 112.478 172.497 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.8 mt -71.58 -23.97 23.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 N-CA-C 108.492 -0.929 . . . . 1.0 108.492 160.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t0 50.16 88.12 0.03 OUTLIER 'General case' 0 C--N 1.344 0.326 0 C-N-CA 128.169 2.588 . . . . 1.0 113.669 159.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.96 0 C-N-CA 124.698 1.142 . . . . 1.0 112.493 178.668 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.144 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.8 tp -48.43 -43.66 34.53 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 125.504 1.522 . . . . 1.0 113.273 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.11 -35.06 59.25 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.395 0.678 . . . . 1.0 112.376 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.31 -33.65 78.3 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 124.336 0.97 . . . . 1.0 112.156 173.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.59 -38.77 67.76 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 118.71 1.255 . . . . 1.0 111.48 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.77 -39.82 72.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 118.467 -0.778 . . . . 1.0 110.01 167.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.79 95.5 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.663 1.119 . . . . 1.0 109.683 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.33 -45.21 52.86 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.955 -0.914 . . . . 1.0 112.38 168.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 52.1 t80 -65.96 -50.71 63.4 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.755 1.278 . . . . 1.0 111.47 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mt -47.64 -31.74 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 C-N-CA 125.667 1.587 . . . . 1.0 112.347 170.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -91.02 -8.06 50.16 Favored 'General case' 0 CA--C 1.544 0.712 0 CA-C-O 117.696 -1.145 . . . . 1.0 113.628 178.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.04 -15.94 0.46 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 116.381 1.993 . . . . 1.0 116.381 -166.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.0 1.12 0.65 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 124.925 1.25 . . . . 1.0 113.32 -176.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.5 t90 -40.32 -43.14 1.68 Allowed 'General case' 0 C--N 1.343 0.302 0 C-N-CA 127.12 2.168 . . . . 1.0 113.809 -171.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -51.75 -33.62 35.7 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.802 1.241 . . . . 1.0 112.177 -169.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.99 -13.92 62.57 Favored Glycine 0 CA--C 1.537 1.451 0 CA-C-O 118.988 -0.895 . . . . 1.0 114.389 178.143 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 27.8 ttt -102.47 -13.35 17.28 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.284 1.834 . . . . 1.0 111.928 170.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.9 mt -75.34 -48.31 31.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 N-CA-C 107.254 -1.388 . . . . 1.0 107.254 170.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -65.39 157.75 28.48 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 109.554 -0.536 . . . . 1.0 109.554 162.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.011 0 C-N-CA 125.272 1.415 . . . . 1.0 111.799 -173.68 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.143 0 N-CA-C 110.186 -1.166 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.3 tp -46.6 -43.76 17.6 Favored 'General case' 0 CA--C 1.515 -0.399 0 C-N-CA 126.231 1.812 . . . . 1.0 113.507 -176.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -53.48 -34.17 57.04 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 121.494 0.664 . . . . 1.0 112.462 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.43 -34.59 85.2 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.241 0.925 . . . . 1.0 112.046 173.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.13 -37.36 69.47 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 118.653 1.227 . . . . 1.0 111.538 173.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.21 -41.4 77.9 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-O 118.358 -0.83 . . . . 1.0 109.796 167.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.75 -33.7 76.48 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 119.832 1.196 . . . . 1.0 110.733 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.01 -54.65 30.15 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 118.927 -0.929 . . . . 1.0 111.416 164.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -59.8 -42.59 93.74 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.31 1.055 . . . . 1.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -50.27 -24.17 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 C-N-CA 125.856 1.663 . . . . 1.0 112.898 171.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -108.69 -1.67 19.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.58 1.152 . . . . 1.0 112.229 175.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -155.48 71.79 0.78 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.684 1.594 . . . . 1.0 108.709 -165.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 120.69 -9.49 10.64 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-O 118.949 -0.917 . . . . 1.0 113.531 174.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -37.13 -44.4 0.55 Allowed 'General case' 0 C--N 1.343 0.301 0 C-N-CA 126.88 2.072 . . . . 1.0 112.641 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.4 pm0 -53.75 -29.13 38.41 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 124.882 1.273 . . . . 1.0 112.68 -175.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.1 -15.51 74.45 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 118.932 0.787 . . . . 1.0 113.811 175.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.5 mmt -102.25 -8.08 21.57 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.215 1.806 . . . . 1.0 112.201 169.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.0 mt -77.5 -43.91 30.0 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.328 -1.36 . . . . 1.0 107.328 164.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -57.08 157.66 5.75 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 123.645 0.778 . . . . 1.0 110.473 167.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.361 0 C-N-CA 124.58 1.086 . . . . 1.0 112.213 -162.456 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp -46.38 -43.44 16.23 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.245 1.818 . . . . 1.0 113.586 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -51.38 -35.43 38.77 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.527 0.731 . . . . 1.0 112.836 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.65 -36.92 92.02 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 124.042 0.83 . . . . 1.0 111.713 173.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.03 -34.24 71.09 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 118.525 1.163 . . . . 1.0 111.872 174.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.2 mt -58.94 -42.06 84.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 119.306 0.957 . . . . 1.0 109.747 167.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.55 73.91 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.622 1.101 . . . . 1.0 110.505 177.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.16 -55.14 27.8 Favored Glycine 0 CA--C 1.532 1.15 0 CA-C-O 119.197 -0.779 . . . . 1.0 111.336 164.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -60.56 -39.75 89.11 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.93 1.292 . . . . 1.0 112.474 -179.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.4 mt -50.49 -24.04 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 125.694 1.598 . . . . 1.0 112.764 169.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.36 0.13 19.31 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.27 1.028 . . . . 1.0 112.369 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -150.51 70.83 1.03 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.693 1.597 . . . . 1.0 108.862 -166.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 107.19 2.89 35.94 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.67 -1.072 . . . . 1.0 114.202 172.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -35.9 -43.43 0.31 Allowed 'General case' 0 C--N 1.343 0.311 0 C-N-CA 127.966 2.506 . . . . 1.0 113.531 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -49.77 -33.64 16.99 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.422 1.489 . . . . 1.0 112.15 -174.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.29 -18.21 64.91 Favored Glycine 0 CA--C 1.537 1.453 0 CA-C-O 119.18 -0.789 . . . . 1.0 114.149 177.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.6 ttt -102.36 -10.69 19.25 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.251 1.82 . . . . 1.0 112.052 171.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mt -75.13 -40.67 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 167.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -58.86 160.06 6.25 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 123.783 0.833 . . . . 1.0 110.807 167.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.157 0 C-N-CA 124.684 1.135 . . . . 1.0 111.272 -164.669 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.14 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -45.27 -43.48 10.57 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.431 1.892 . . . . 1.0 113.608 -176.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -50.4 -34.22 23.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.12 0.968 . . . . 1.0 112.951 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.93 -37.15 87.69 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.156 0.884 . . . . 1.0 112.213 173.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.13 -32.17 71.36 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.424 1.112 . . . . 1.0 111.527 173.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -58.08 -40.01 75.15 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 CA-C-O 118.072 -0.966 . . . . 1.0 109.907 170.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.71 -25.99 67.55 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 120.299 1.409 . . . . 1.0 111.82 176.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.79 -54.21 35.33 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.795 -0.922 . . . . 1.0 110.795 165.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -58.27 -34.11 70.15 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.604 1.162 . . . . 1.0 112.914 177.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 mt -53.1 -28.73 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.802 1.241 . . . . 1.0 111.726 172.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -102.6 -0.17 32.4 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.164 0.986 . . . . 1.0 111.912 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 -151.81 66.54 0.86 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.305 1.442 . . . . 1.0 108.857 -163.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.23 -2.37 14.3 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.247 -1.307 . . . . 1.0 114.455 176.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -45.15 -34.23 2.6 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.199 1.4 . . . . 1.0 114.169 174.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.0 tm-20 -54.38 -35.58 62.98 Favored 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 118.621 0.646 . . . . 1.0 111.197 175.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.23 -8.05 82.97 Favored Glycine 0 CA--C 1.531 1.091 0 C-N-CA 125.16 1.362 . . . . 1.0 113.959 176.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 10.1 ptm -102.21 -10.26 19.73 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 119.284 1.542 . . . . 1.0 112.541 164.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -75.57 -43.46 41.53 Favored 'Isoleucine or valine' 0 C--N 1.341 0.216 0 N-CA-C 107.073 -1.454 . . . . 1.0 107.073 163.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -55.46 138.87 45.34 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 119.443 -0.903 . . . . 1.0 108.925 160.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 1.669 0 C-N-CA 126.217 1.865 . . . . 1.0 116.798 -173.856 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.129 0 N-CA-C 110.062 -1.215 . . . . 1.0 110.062 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -47.86 -43.68 28.59 Favored 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 125.517 1.527 . . . . 1.0 113.401 -176.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -51.9 -35.42 45.33 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.775 0.657 . . . . 1.0 112.775 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.78 -34.64 87.92 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.022 0.82 . . . . 1.0 112.101 173.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.99 -36.8 67.13 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 118.477 1.139 . . . . 1.0 111.612 173.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.22 -39.76 74.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-O 118.237 -0.887 . . . . 1.0 109.7 167.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.24 -41.01 97.18 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 119.748 1.158 . . . . 1.0 109.766 175.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.08 -39.22 49.21 Favored Glycine 0 CA--C 1.535 1.32 0 CA-C-O 118.961 -0.911 . . . . 1.0 113.018 169.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.9 t80 -73.14 -47.8 40.98 Favored 'General case' 0 C--N 1.341 0.227 0 CA-C-N 118.819 1.31 . . . . 1.0 112.451 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -43.84 -51.78 1.42 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 C-N-CA 124.76 1.224 . . . . 1.0 110.13 169.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -77.03 -0.93 26.39 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.265 1.426 . . . . 1.0 112.033 -177.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -81.17 -0.43 40.31 Favored 'General case' 0 C--N 1.343 0.286 0 O-C-N 120.945 -1.097 . . . . 1.0 111.662 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.41 36.42 20.45 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.256 -1.302 . . . . 1.0 110.195 -160.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -35.44 -39.14 0.12 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 125.539 1.536 . . . . 1.0 113.926 171.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -52.46 -32.33 39.11 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.563 0.949 . . . . 1.0 113.563 178.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.28 -12.96 66.86 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 119.169 -0.795 . . . . 1.0 113.236 176.033 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.5 mpt? -102.28 -9.57 20.27 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.873 1.669 . . . . 1.0 111.976 171.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 53.4 mt -73.64 -49.74 33.93 Favored 'Isoleucine or valine' 0 C--N 1.341 0.218 0 N-CA-C 107.348 -1.353 . . . . 1.0 107.348 173.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.8 t0 -64.91 150.23 48.19 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 164.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.357 0 C-N-CA 126.254 1.883 . . . . 1.0 114.424 -175.65 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.167 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.4 tp -48.48 -43.75 35.1 Favored 'General case' 0 CA--C 1.514 -0.406 0 C-N-CA 125.411 1.485 . . . . 1.0 113.421 -176.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -55.09 -34.17 63.41 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.46 0.648 . . . . 1.0 112.077 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.35 -31.02 73.64 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 124.341 0.972 . . . . 1.0 112.083 173.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.98 -36.11 62.04 Favored 'General case' 0 N--CA 1.456 -0.148 0 CA-C-N 118.998 1.399 . . . . 1.0 111.684 172.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 mt -59.37 -39.5 79.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-N 119.157 0.889 . . . . 1.0 109.757 167.351 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.24 -41.25 94.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 119.379 0.99 . . . . 1.0 109.53 175.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.15 -44.09 51.1 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.978 -0.901 . . . . 1.0 112.529 168.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -65.69 -51.58 58.26 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.79 1.295 . . . . 1.0 110.807 174.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.6 mt -47.89 -30.74 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 125.405 1.482 . . . . 1.0 112.502 171.172 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -91.38 -9.36 45.07 Favored 'General case' 0 CA--C 1.545 0.774 0 CA-C-O 117.723 -1.132 . . . . 1.0 113.602 178.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -145.49 -15.86 0.49 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 116.149 1.907 . . . . 1.0 116.149 -166.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.1 2.44 0.52 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 125.385 1.469 . . . . 1.0 113.487 -174.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.6 t90 -39.8 -41.34 1.11 Allowed 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 127.311 2.244 . . . . 1.0 113.727 -174.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -52.19 -31.27 31.0 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.845 1.258 . . . . 1.0 112.224 -169.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.77 -8.46 63.79 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-O 118.755 -1.025 . . . . 1.0 114.852 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.5 -12.5 17.76 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 126.162 1.785 . . . . 1.0 112.928 164.311 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.5 mt -79.24 -55.59 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.019 -1.845 . . . . 1.0 106.019 173.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -66.64 155.71 37.17 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 108.381 -0.97 . . . . 1.0 108.381 158.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 1.516 0 O-C-N 121.638 -0.664 . . . . 1.0 113.717 -166.943 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -67.26 173.21 4.05 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.844 0 C-N-CA 126.096 1.808 . . . . 1.0 109.95 -175.922 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -67.26 173.21 4.05 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.844 0 C-N-CA 126.096 1.808 . . . . 1.0 109.95 -175.922 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.217 0 N-CA-C 110.196 -1.162 . . . . 1.0 110.196 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.4 tp -45.83 -43.74 13.66 Favored 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 126.283 1.833 . . . . 1.0 113.469 -176.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -50.74 -35.05 29.53 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.54 0.736 . . . . 1.0 112.924 178.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.19 87.46 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.027 0.822 . . . . 1.0 112.122 173.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.89 -39.85 72.56 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.478 1.139 . . . . 1.0 111.349 173.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -56.72 -40.23 68.72 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-O 118.224 -0.893 . . . . 1.0 109.914 167.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.78 -31.85 72.75 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 120.136 1.335 . . . . 1.0 110.796 179.155 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.25 -55.3 31.11 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.915 -0.874 . . . . 1.0 110.915 164.503 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -55.85 -43.06 76.73 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 118.043 0.921 . . . . 1.0 111.977 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.8 mt -50.47 -26.65 3.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 125.431 1.493 . . . . 1.0 112.564 173.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -109.69 5.33 22.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.564 1.146 . . . . 1.0 112.164 178.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -138.06 -15.72 1.3 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 114.532 1.308 . . . . 1.0 114.532 -169.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -158.28 0.34 0.09 OUTLIER Glycine 0 CA--C 1.529 0.957 0 C-N-CA 125.146 1.355 . . . . 1.0 113.845 -174.13 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.1 t90 -44.79 -38.63 4.64 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 119.016 1.408 . . . . 1.0 113.074 176.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -57.05 -30.96 64.69 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 118.998 0.817 . . . . 1.0 112.145 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.18 -23.24 77.38 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 121.31 -0.869 . . . . 1.0 112.757 173.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 6.5 ptt? -92.67 -16.34 25.66 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.947 1.374 . . . . 1.0 112.5 173.752 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.7 mt -64.2 -56.71 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 106.562 -1.644 . . . . 1.0 106.562 160.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -54.95 -44.94 74.79 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.065 0.946 . . . . 1.0 111.08 176.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.358 0 CA-C-O 118.338 -1.257 . . . . 1.0 115.107 173.837 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.201 0 N-CA-C 110.195 -1.162 . . . . 1.0 110.195 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -46.39 -43.61 16.39 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 126.123 1.769 . . . . 1.0 113.635 -176.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.9 -34.16 53.67 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.655 0.782 . . . . 1.0 112.684 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.15 -35.49 83.41 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 124.032 0.825 . . . . 1.0 111.959 172.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.77 -31.68 68.55 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 118.561 1.18 . . . . 1.0 111.825 173.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -59.77 -42.46 88.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 119.461 1.028 . . . . 1.0 109.578 167.446 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.59 -31.0 71.42 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 119.568 1.076 . . . . 1.0 110.738 177.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -56.1 25.81 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 111.073 -0.811 . . . . 1.0 111.073 164.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -58.25 -39.45 79.19 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.392 1.096 . . . . 1.0 112.396 -179.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.1 mt -51.2 -24.21 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 125.546 1.539 . . . . 1.0 112.862 170.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -109.96 0.2 18.46 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.719 1.145 . . . . 1.0 112.06 173.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -145.17 66.54 1.24 Allowed 'General case' 0 CA--C 1.535 0.372 0 O-C-N 120.297 -1.502 . . . . 1.0 108.709 -165.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 108.04 2.05 33.92 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 118.661 -1.077 . . . . 1.0 114.36 173.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -37.72 -43.97 0.68 Allowed 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 127.195 2.198 . . . . 1.0 113.662 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.33 -38.68 19.73 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.659 1.584 . . . . 1.0 111.951 -174.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -63.68 -22.04 65.69 Favored Glycine 0 CA--C 1.534 1.239 0 CA-C-O 119.235 -0.758 . . . . 1.0 113.543 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 mmt -102.18 -9.39 20.52 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.94 1.696 . . . . 1.0 113.042 172.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.7 mt -68.99 -48.37 70.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 106.646 -1.612 . . . . 1.0 106.646 162.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -63.77 -62.65 1.51 Allowed 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.79 1.236 . . . . 1.0 110.472 169.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.115 0 C-N-CA 125.368 1.461 . . . . 1.0 114.766 177.083 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.163 0 N-CA-C 110.025 -1.23 . . . . 1.0 110.025 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -48.16 -43.67 31.68 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 125.588 1.555 . . . . 1.0 113.387 -177.087 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -52.16 -35.84 49.88 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.761 0.652 . . . . 1.0 112.761 178.207 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.83 -32.4 81.02 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 124.304 0.954 . . . . 1.0 112.103 174.067 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -38.91 58.06 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 118.783 1.292 . . . . 1.0 111.635 174.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.17 -39.45 73.25 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 CA-C-N 118.772 0.714 . . . . 1.0 109.861 167.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.74 -38.31 86.37 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 119.323 0.965 . . . . 1.0 109.677 176.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.13 -50.63 27.68 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 123.897 0.761 . . . . 1.0 111.747 165.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -62.46 -48.18 80.77 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.82 1.31 . . . . 1.0 111.211 175.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mt -49.83 -37.48 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-N 119.254 0.934 . . . . 1.0 111.942 172.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.9 mm-40 -87.29 -4.52 59.07 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.383 -0.823 . . . . 1.0 112.825 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -140.19 -15.93 0.97 Allowed 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 120.875 1.67 . . . . 1.0 114.656 -166.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.85 3.56 0.42 Allowed Glycine 0 CA--C 1.528 0.857 0 C-N-CA 126.298 1.904 . . . . 1.0 113.136 -172.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -46.0 -33.87 3.65 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 119.213 1.506 . . . . 1.0 113.454 174.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -55.91 -32.99 64.26 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 119.565 1.075 . . . . 1.0 111.538 177.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.56 -7.75 83.35 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.283 1.42 . . . . 1.0 114.151 174.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.2 ptm -102.63 -8.46 20.92 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.308 1.554 . . . . 1.0 113.189 163.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mt -72.42 -56.68 9.15 Favored 'Isoleucine or valine' 0 C--N 1.344 0.354 0 N-CA-C 106.029 -1.841 . . . . 1.0 106.029 161.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -60.16 151.63 26.55 Favored 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 109.16 -0.681 . . . . 1.0 109.16 165.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.534 0 C-N-CA 124.899 1.238 . . . . 1.0 114.662 -168.661 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.174 0 N-CA-C 110.216 -1.154 . . . . 1.0 110.216 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.3 tp -45.85 -43.61 13.63 Favored 'General case' 0 CA--C 1.515 -0.377 0 C-N-CA 126.474 1.91 . . . . 1.0 113.591 -176.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -51.46 -35.16 38.64 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.535 0.734 . . . . 1.0 112.793 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.89 85.42 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.175 0.893 . . . . 1.0 112.056 173.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.12 -38.01 72.32 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 118.656 1.228 . . . . 1.0 111.293 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -57.84 -39.95 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 117.922 -1.037 . . . . 1.0 109.86 168.061 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.41 86.25 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 120.176 1.353 . . . . 1.0 110.175 177.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.4 -47.21 51.5 Favored Glycine 0 CA--C 1.533 1.17 0 CA-C-O 119.48 -0.622 . . . . 1.0 111.84 166.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -68.25 -43.46 77.8 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.388 1.094 . . . . 1.0 113.043 177.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -44.18 -52.81 1.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.693 1.197 . . . . 1.0 109.33 168.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -79.06 2.08 21.87 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.907 1.283 . . . . 1.0 112.582 -176.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -86.83 11.23 13.77 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.361 0.982 . . . . 1.0 110.154 171.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.92 38.37 23.34 Favored Glycine 0 C--N 1.338 0.685 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 -170.676 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.8 t90 -38.43 -44.8 0.96 Allowed 'General case' 0 C--N 1.349 0.586 0 C-N-CA 123.915 0.886 . . . . 1.0 112.703 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -60.66 -23.54 64.88 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 113.781 1.03 . . . . 1.0 113.781 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.35 -31.88 29.73 Favored Glycine 0 C--N 1.34 0.804 0 CA-C-N 118.857 0.753 . . . . 1.0 111.478 170.217 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 16.3 mmt -68.82 -11.98 61.03 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.519 1.128 . . . . 1.0 112.356 176.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mt -65.46 -29.07 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.23 1.012 . . . . 1.0 109.729 168.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.4 t0 30.91 75.54 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 129.206 3.002 . . . . 1.0 114.118 177.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.932 0 CA-C-N 115.328 -0.851 . . . . 1.0 112.607 177.215 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.154 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -45.12 -43.55 9.83 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.29 1.836 . . . . 1.0 113.637 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -50.93 -34.28 27.97 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.984 0.914 . . . . 1.0 113.018 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.9 -36.56 86.83 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 123.981 0.8 . . . . 1.0 112.17 172.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.69 -36.07 73.11 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-N 118.316 1.058 . . . . 1.0 111.593 173.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mt -57.96 -39.64 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 118.016 -0.992 . . . . 1.0 110.067 168.023 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.68 91.3 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 120.072 1.306 . . . . 1.0 110.275 176.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.32 -48.66 59.15 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.692 -0.563 . . . . 1.0 111.692 167.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -63.23 -46.87 84.9 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 118.248 1.024 . . . . 1.0 112.157 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.5 mt -45.09 -45.2 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 125.295 1.438 . . . . 1.0 110.999 170.293 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -79.95 -8.05 59.12 Favored 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 112.791 0.663 . . . . 1.0 112.791 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -89.78 33.49 0.85 Allowed 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 120.408 1.458 . . . . 1.0 109.872 -174.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.3 22.93 73.15 Favored Glycine 0 CA--C 1.531 1.044 0 CA-C-O 118.17 -1.35 . . . . 1.0 112.504 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -41.42 -40.29 1.71 Allowed 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.039 1.336 . . . . 1.0 113.693 -179.007 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -51.31 -37.46 47.7 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.428 0.691 . . . . 1.0 111.996 -178.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.77 -9.56 75.17 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.754 -1.026 . . . . 1.0 113.836 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.6 ppp? -98.91 -8.23 25.94 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.76 1.28 . . . . 1.0 111.674 174.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.6 mt -66.39 -50.09 70.31 Favored 'Isoleucine or valine' 0 C--N 1.345 0.375 0 N-CA-C 108.878 -0.786 . . . . 1.0 108.878 176.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.5 t0 35.17 54.69 0.77 Allowed 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 128.51 2.724 . . . . 1.0 113.831 177.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.744 0 N-CA-C 109.772 -1.331 . . . . 1.0 109.772 -176.318 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.132 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -47.24 -43.61 22.03 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 125.862 1.665 . . . . 1.0 113.371 -176.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -51.87 -35.22 44.2 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.306 0.643 . . . . 1.0 112.671 178.693 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -32.51 76.18 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.243 0.925 . . . . 1.0 112.329 173.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.64 -37.81 65.22 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 118.826 1.313 . . . . 1.0 111.482 172.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.1 mt -58.4 -39.43 74.59 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 CA-C-O 118.453 -0.784 . . . . 1.0 109.787 167.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -40.44 93.79 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.8 1.182 . . . . 1.0 109.659 176.17 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.8 -46.67 39.63 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 124.029 0.823 . . . . 1.0 112.255 167.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -65.52 -49.98 66.97 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.488 1.144 . . . . 1.0 111.483 175.418 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -48.66 -32.09 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 C-N-CA 125.098 1.359 . . . . 1.0 112.135 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -89.81 -8.26 52.48 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-O 117.718 -1.134 . . . . 1.0 113.338 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.25 -15.98 0.45 Allowed 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.315 1.968 . . . . 1.0 116.315 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -144.9 -1.11 0.85 Allowed Glycine 0 CA--C 1.53 0.999 0 C-N-CA 125.875 1.703 . . . . 1.0 113.388 -175.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.0 t90 -37.7 -41.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 127.461 2.304 . . . . 1.0 113.759 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tm-20 -49.27 -37.01 22.25 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.238 1.415 . . . . 1.0 112.371 -175.394 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.31 -17.62 70.51 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-O 119.348 -0.695 . . . . 1.0 113.783 178.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.6 mmt -102.51 -7.78 21.6 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.577 1.951 . . . . 1.0 112.808 169.145 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 57.1 mt -66.9 -50.73 62.24 Favored 'Isoleucine or valine' 0 C--N 1.342 0.267 0 N-CA-C 106.19 -1.782 . . . . 1.0 106.19 162.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -64.16 168.05 5.88 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.216 1.007 . . . . 1.0 110.95 167.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.265 0 C-N-CA 124.305 0.955 . . . . 1.0 112.363 -170.281 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.195 0 N-CA-C 110.11 -1.196 . . . . 1.0 110.11 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp -46.1 -43.5 14.85 Favored 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 126.197 1.799 . . . . 1.0 113.686 -176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -51.09 -35.76 36.79 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.818 0.673 . . . . 1.0 112.818 178.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.57 -33.54 81.49 Favored Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.165 0.888 . . . . 1.0 112.135 174.038 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.54 -36.11 63.12 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 118.681 1.241 . . . . 1.0 111.889 174.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -57.91 -42.54 82.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 118.497 -0.763 . . . . 1.0 109.549 166.414 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.98 -35.89 82.62 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 119.34 0.973 . . . . 1.0 109.96 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -47.36 -59.56 5.76 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 118.53 -1.15 . . . . 1.0 111.487 163.308 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -59.27 -44.19 92.44 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 118.668 1.234 . . . . 1.0 112.143 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.7 mt -50.11 -24.89 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 125.671 1.588 . . . . 1.0 112.813 172.092 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.89 -1.16 17.94 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-N 119.468 1.031 . . . . 1.0 112.552 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -151.84 72.2 1.01 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.442 1.497 . . . . 1.0 108.524 -166.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 115.91 -5.03 20.53 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.538 -1.145 . . . . 1.0 113.761 173.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t90 -39.16 -41.99 0.9 Allowed 'General case' 0 C--N 1.343 0.297 0 C-N-CA 126.502 1.921 . . . . 1.0 113.044 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -50.81 -34.57 28.19 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.887 1.275 . . . . 1.0 112.438 -175.383 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.06 -18.7 67.15 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.675 -0.641 . . . . 1.0 113.725 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.43 -9.44 20.27 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.75 1.62 . . . . 1.0 113.038 169.098 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.9 mt -71.65 -43.14 71.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 166.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 44.4 t0 . . . . . 0 CA--C 1.542 0.644 0 C-N-CA 124.952 1.301 . . . . 1.0 111.588 172.583 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.32 -1.112 . . . . 1.0 110.32 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.5 tp -44.86 -43.69 8.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 C-N-CA 126.185 1.794 . . . . 1.0 113.51 -176.394 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -47.04 -35.51 6.87 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.83 1.252 . . . . 1.0 113.499 178.344 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.7 -42.88 86.52 Favored Glycine 0 CA--C 1.53 0.992 0 C-N-CA 123.913 0.768 . . . . 1.0 111.968 173.189 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.54 -30.17 70.42 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 118.356 1.078 . . . . 1.0 112.091 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.6 mt -54.57 -40.98 52.55 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-O 117.932 -1.033 . . . . 1.0 110.395 172.117 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.98 -29.31 70.16 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 120.416 1.462 . . . . 1.0 111.986 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.81 -47.84 64.71 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.885 -0.886 . . . . 1.0 110.885 169.616 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -60.27 -45.5 93.09 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.899 0.85 . . . . 1.0 112.653 177.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.2 mt -40.39 -50.25 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 C-N-CA 125.918 1.687 . . . . 1.0 110.937 168.272 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 mm-40 -79.87 -3.98 50.3 Favored 'General case' 0 CA--C 1.539 0.525 0 N-CA-C 113.037 0.754 . . . . 1.0 113.037 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -98.92 21.34 11.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 120.0 1.273 . . . . 1.0 110.583 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 24.77 47.54 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 118.849 -0.973 . . . . 1.0 112.015 -176.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -37.34 -49.91 1.01 Allowed 'General case' 0 C--N 1.347 0.477 0 C-N-CA 124.18 0.992 . . . . 1.0 112.615 173.321 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -59.08 -25.1 63.49 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.42 0.896 . . . . 1.0 113.42 -171.526 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.36 -43.59 6.93 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.529 -1.029 . . . . 1.0 110.529 171.464 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 5.7 ttt -63.58 -7.53 7.41 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.261 1.824 . . . . 1.0 114.057 177.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 66.3 mt -55.0 -30.37 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 C-N-CA 124.563 1.145 . . . . 1.0 110.649 162.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.7 t0 . . . . . 0 CA--C 1.537 0.451 0 CA-C-O 121.749 0.785 . . . . 1.0 111.111 178.358 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 109.995 -1.242 . . . . 1.0 109.995 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.8 tp -47.73 -43.7 27.27 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 125.647 1.579 . . . . 1.0 113.173 -176.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.91 -34.51 55.46 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.551 0.74 . . . . 1.0 112.582 179.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.89 -34.4 82.28 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 124.223 0.916 . . . . 1.0 112.041 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.7 -34.12 66.93 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 118.639 1.22 . . . . 1.0 111.806 172.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -59.15 -40.99 82.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 CA-C-N 119.313 0.96 . . . . 1.0 109.774 167.36 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.86 -39.89 94.26 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 119.767 1.167 . . . . 1.0 109.828 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.29 -49.49 31.35 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 119.163 -0.798 . . . . 1.0 112.023 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.3 t80 -64.68 -47.76 77.23 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.437 1.118 . . . . 1.0 111.686 177.011 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -47.99 -34.5 4.48 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.746 1.219 . . . . 1.0 111.735 172.017 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -91.46 -3.5 56.54 Favored 'General case' 0 CA--C 1.542 0.652 0 CA-C-O 117.867 -1.064 . . . . 1.0 113.318 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -145.11 -15.9 0.51 Allowed 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 115.956 1.836 . . . . 1.0 115.956 -166.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.44 0.55 0.39 Allowed Glycine 0 CA--C 1.529 0.925 0 CA-C-O 118.027 -1.429 . . . . 1.0 113.575 -174.141 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.3 t90 -38.41 -42.71 0.76 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.445 1.898 . . . . 1.0 113.519 -177.257 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -49.7 -34.78 19.72 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.967 1.307 . . . . 1.0 112.42 -177.486 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.69 -16.66 70.22 Favored Glycine 0 CA--C 1.533 1.184 0 CA-C-O 119.377 -0.679 . . . . 1.0 113.993 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.7 mtp -102.2 -8.19 21.54 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.328 1.451 . . . . 1.0 112.499 168.237 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mt -74.1 -54.65 14.42 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 107.136 -1.431 . . . . 1.0 107.136 165.339 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.3 t70 . . . . . 0 CA--C 1.543 0.697 0 C-N-CA 125.502 1.521 . . . . 1.0 110.712 -173.831 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.125 0 N-CA-C 110.27 -1.132 . . . . 1.0 110.27 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -45.59 -43.74 12.38 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 126.484 1.914 . . . . 1.0 113.89 -176.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.23 -35.3 49.23 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.301 0.572 . . . . 1.0 112.481 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -32.74 79.74 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.298 0.951 . . . . 1.0 112.078 174.051 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.32 -37.4 63.6 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.89 1.345 . . . . 1.0 111.658 173.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -58.36 -40.94 80.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-O 118.647 -0.692 . . . . 1.0 109.635 167.144 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.85 -35.89 81.94 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.421 1.01 . . . . 1.0 109.984 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.32 -56.43 10.79 Favored Glycine 0 CA--C 1.531 1.032 0 CA-C-O 118.862 -0.965 . . . . 1.0 111.359 164.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -60.74 -41.49 95.48 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.524 1.162 . . . . 1.0 112.396 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -51.52 -25.09 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 125.313 1.445 . . . . 1.0 112.56 170.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -105.32 -0.08 26.56 Favored 'General case' 0 CA--C 1.545 0.783 0 CA-C-N 119.459 1.027 . . . . 1.0 112.776 174.228 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -149.99 71.67 1.09 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 125.261 1.424 . . . . 1.0 108.767 -165.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 5.24 47.85 Favored Glycine 0 CA--C 1.528 0.904 0 CA-C-O 118.608 -1.107 . . . . 1.0 114.165 171.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -37.63 -44.78 0.72 Allowed 'General case' 0 C--N 1.343 0.294 0 C-N-CA 127.118 2.167 . . . . 1.0 113.737 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -48.06 -35.65 11.58 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.279 1.832 . . . . 1.0 112.219 -170.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.98 -27.83 65.25 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.598 -0.689 . . . . 1.0 113.484 178.191 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -95.19 -18.58 20.78 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.275 1.83 . . . . 1.0 111.963 176.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.9 mt -67.79 -50.03 63.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 168.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 30.1 t70 . . . . . 0 CA--C 1.533 0.325 0 C-N-CA 125.675 1.59 . . . . 1.0 110.793 170.367 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 110.086 -1.206 . . . . 1.0 110.086 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.8 tp -46.53 -43.72 17.19 Favored 'General case' 0 CA--C 1.513 -0.466 0 C-N-CA 126.113 1.765 . . . . 1.0 113.388 -177.045 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -51.74 -34.67 40.24 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.787 0.662 . . . . 1.0 112.787 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.21 -35.84 90.95 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.114 0.864 . . . . 1.0 112.243 173.116 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.95 -40.23 72.13 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.486 1.143 . . . . 1.0 111.264 173.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -56.7 -38.79 59.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-O 118.425 -0.798 . . . . 1.0 110.083 168.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -68.82 -26.14 65.03 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 119.703 1.138 . . . . 1.0 111.705 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.53 -55.42 27.44 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.48 -1.048 . . . . 1.0 110.48 163.107 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -55.16 -38.33 68.14 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 123.957 0.903 . . . . 1.0 112.146 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 mt -49.29 -26.54 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 126.298 1.839 . . . . 1.0 112.57 172.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -112.26 -4.92 14.23 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 119.931 1.241 . . . . 1.0 112.029 175.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -150.07 66.5 0.97 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 125.488 1.515 . . . . 1.0 108.11 -163.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.73 -20.9 4.05 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.957 -0.913 . . . . 1.0 112.405 178.267 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.6 t90 -46.86 -42.86 18.04 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 124.441 1.097 . . . . 1.0 111.259 174.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -59.22 -26.96 65.31 Favored 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 123.889 0.876 . . . . 1.0 113.052 -177.581 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.54 -13.76 82.65 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 119.385 -0.675 . . . . 1.0 113.137 172.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.2 ttt -101.59 -19.91 15.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.189 1.796 . . . . 1.0 111.833 173.098 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.9 mt -65.67 -48.53 82.14 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 162.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.7 t0 . . . . . 0 N--CA 1.467 0.39 0 C-N-CA 126.298 1.839 . . . . 1.0 111.282 -174.03 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.104 0 N-CA-C 110.18 -1.168 . . . . 1.0 110.18 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -46.91 -43.77 19.19 Favored 'General case' 0 CA--C 1.515 -0.368 0 C-N-CA 126.115 1.766 . . . . 1.0 113.532 -176.541 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.54 -34.51 58.5 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 121.455 0.645 . . . . 1.0 112.431 179.314 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.74 -34.17 86.53 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.114 0.864 . . . . 1.0 112.006 173.101 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.01 -36.1 66.95 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 118.642 1.221 . . . . 1.0 111.692 173.662 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -58.09 -41.82 81.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 118.967 0.803 . . . . 1.0 109.628 166.609 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.54 -31.63 72.47 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.507 1.049 . . . . 1.0 110.61 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.97 -58.47 12.55 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 119.065 -0.853 . . . . 1.0 110.97 162.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -55.77 -42.66 75.84 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 118.67 1.235 . . . . 1.0 112.16 -178.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.1 mt -50.16 -23.97 1.84 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 C-N-CA 125.929 1.691 . . . . 1.0 113.236 171.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 -113.0 -1.81 14.39 Favored 'General case' 0 CA--C 1.543 0.711 0 CA-C-N 119.698 1.135 . . . . 1.0 111.914 173.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -146.95 65.9 1.16 Allowed 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.638 1.575 . . . . 1.0 108.335 -164.196 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 117.66 -3.42 17.57 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.394 -1.225 . . . . 1.0 114.069 175.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.8 t90 -38.56 -39.6 0.49 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 126.865 2.066 . . . . 1.0 113.166 176.03 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -50.36 -33.61 21.09 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.37 1.068 . . . . 1.0 112.419 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.93 -23.14 65.41 Favored Glycine 0 CA--C 1.534 1.25 0 O-C-N 121.353 -0.842 . . . . 1.0 113.594 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 23.8 mmt -102.0 -8.32 21.6 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.448 1.899 . . . . 1.0 112.478 172.497 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.8 mt -71.58 -23.97 23.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 N-CA-C 108.492 -0.929 . . . . 1.0 108.492 160.217 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t0 . . . . . 0 C--N 1.344 0.326 0 C-N-CA 128.169 2.588 . . . . 1.0 113.669 159.614 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.144 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.8 tp -48.43 -43.66 34.53 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 125.504 1.522 . . . . 1.0 113.273 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.11 -35.06 59.25 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.395 0.678 . . . . 1.0 112.376 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.31 -33.65 78.3 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 124.336 0.97 . . . . 1.0 112.156 173.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.59 -38.77 67.76 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 118.71 1.255 . . . . 1.0 111.48 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.77 -39.82 72.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 118.467 -0.778 . . . . 1.0 110.01 167.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.79 95.5 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.663 1.119 . . . . 1.0 109.683 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.33 -45.21 52.86 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.955 -0.914 . . . . 1.0 112.38 168.51 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 52.1 t80 -65.96 -50.71 63.4 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.755 1.278 . . . . 1.0 111.47 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mt -47.64 -31.74 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 C-N-CA 125.667 1.587 . . . . 1.0 112.347 170.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -91.02 -8.06 50.16 Favored 'General case' 0 CA--C 1.544 0.712 0 CA-C-O 117.696 -1.145 . . . . 1.0 113.628 178.358 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.04 -15.94 0.46 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 116.381 1.993 . . . . 1.0 116.381 -166.003 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.0 1.12 0.65 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 124.925 1.25 . . . . 1.0 113.32 -176.058 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.5 t90 -40.32 -43.14 1.68 Allowed 'General case' 0 C--N 1.343 0.302 0 C-N-CA 127.12 2.168 . . . . 1.0 113.809 -171.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -51.75 -33.62 35.7 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.802 1.241 . . . . 1.0 112.177 -169.447 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.99 -13.92 62.57 Favored Glycine 0 CA--C 1.537 1.451 0 CA-C-O 118.988 -0.895 . . . . 1.0 114.389 178.143 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 27.8 ttt -102.47 -13.35 17.28 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.284 1.834 . . . . 1.0 111.928 170.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.9 mt -75.34 -48.31 31.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 N-CA-C 107.254 -1.388 . . . . 1.0 107.254 170.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 . . . . . 0 CA--C 1.537 0.464 0 N-CA-C 109.554 -0.536 . . . . 1.0 109.554 162.746 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.143 0 N-CA-C 110.186 -1.166 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.3 tp -46.6 -43.76 17.6 Favored 'General case' 0 CA--C 1.515 -0.399 0 C-N-CA 126.231 1.812 . . . . 1.0 113.507 -176.657 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -53.48 -34.17 57.04 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 121.494 0.664 . . . . 1.0 112.462 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.43 -34.59 85.2 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.241 0.925 . . . . 1.0 112.046 173.058 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.13 -37.36 69.47 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 118.653 1.227 . . . . 1.0 111.538 173.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.21 -41.4 77.9 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-O 118.358 -0.83 . . . . 1.0 109.796 167.015 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.75 -33.7 76.48 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 119.832 1.196 . . . . 1.0 110.733 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.01 -54.65 30.15 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 118.927 -0.929 . . . . 1.0 111.416 164.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -59.8 -42.59 93.74 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.31 1.055 . . . . 1.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -50.27 -24.17 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 C-N-CA 125.856 1.663 . . . . 1.0 112.898 171.055 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -108.69 -1.67 19.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.58 1.152 . . . . 1.0 112.229 175.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -155.48 71.79 0.78 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.684 1.594 . . . . 1.0 108.709 -165.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 120.69 -9.49 10.64 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-O 118.949 -0.917 . . . . 1.0 113.531 174.245 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -37.13 -44.4 0.55 Allowed 'General case' 0 C--N 1.343 0.301 0 C-N-CA 126.88 2.072 . . . . 1.0 112.641 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.4 pm0 -53.75 -29.13 38.41 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 124.882 1.273 . . . . 1.0 112.68 -175.512 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.1 -15.51 74.45 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 118.932 0.787 . . . . 1.0 113.811 175.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.5 mmt -102.25 -8.08 21.57 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.215 1.806 . . . . 1.0 112.201 169.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.0 mt -77.5 -43.91 30.0 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.328 -1.36 . . . . 1.0 107.328 164.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 43.3 t0 . . . . . 0 CA--C 1.539 0.52 0 C-N-CA 123.645 0.778 . . . . 1.0 110.473 167.03 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp -46.38 -43.44 16.23 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.245 1.818 . . . . 1.0 113.586 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -51.38 -35.43 38.77 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.527 0.731 . . . . 1.0 112.836 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.65 -36.92 92.02 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 124.042 0.83 . . . . 1.0 111.713 173.46 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.03 -34.24 71.09 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 118.525 1.163 . . . . 1.0 111.872 174.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.2 mt -58.94 -42.06 84.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 119.306 0.957 . . . . 1.0 109.747 167.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.55 73.91 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.622 1.101 . . . . 1.0 110.505 177.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.16 -55.14 27.8 Favored Glycine 0 CA--C 1.532 1.15 0 CA-C-O 119.197 -0.779 . . . . 1.0 111.336 164.469 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -60.56 -39.75 89.11 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.93 1.292 . . . . 1.0 112.474 -179.175 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.4 mt -50.49 -24.04 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 125.694 1.598 . . . . 1.0 112.764 169.419 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.36 0.13 19.31 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.27 1.028 . . . . 1.0 112.369 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -150.51 70.83 1.03 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.693 1.597 . . . . 1.0 108.862 -166.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 107.19 2.89 35.94 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.67 -1.072 . . . . 1.0 114.202 172.613 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -35.9 -43.43 0.31 Allowed 'General case' 0 C--N 1.343 0.311 0 C-N-CA 127.966 2.506 . . . . 1.0 113.531 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -49.77 -33.64 16.99 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.422 1.489 . . . . 1.0 112.15 -174.13 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.29 -18.21 64.91 Favored Glycine 0 CA--C 1.537 1.453 0 CA-C-O 119.18 -0.789 . . . . 1.0 114.149 177.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.6 ttt -102.36 -10.69 19.25 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.251 1.82 . . . . 1.0 112.052 171.169 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mt -75.13 -40.67 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 167.072 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 . . . . . 0 CA--C 1.538 0.517 0 C-N-CA 123.783 0.833 . . . . 1.0 110.807 167.579 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.14 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -45.27 -43.48 10.57 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.431 1.892 . . . . 1.0 113.608 -176.475 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -50.4 -34.22 23.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.12 0.968 . . . . 1.0 112.951 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.93 -37.15 87.69 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.156 0.884 . . . . 1.0 112.213 173.014 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.13 -32.17 71.36 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.424 1.112 . . . . 1.0 111.527 173.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -58.08 -40.01 75.15 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 CA-C-O 118.072 -0.966 . . . . 1.0 109.907 170.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.71 -25.99 67.55 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 120.299 1.409 . . . . 1.0 111.82 176.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.79 -54.21 35.33 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.795 -0.922 . . . . 1.0 110.795 165.261 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -58.27 -34.11 70.15 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.604 1.162 . . . . 1.0 112.914 177.173 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.418 ' HA ' ' HB2' ' A' ' 14' ' ' TRP . 1.2 mt -53.1 -28.73 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.802 1.241 . . . . 1.0 111.726 172.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -102.6 -0.17 32.4 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.164 0.986 . . . . 1.0 111.912 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 -151.81 66.54 0.86 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.305 1.442 . . . . 1.0 108.857 -163.461 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.23 -2.37 14.3 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.247 -1.307 . . . . 1.0 114.455 176.189 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.418 ' HB2' ' HA ' ' A' ' 10' ' ' ILE . 2.6 t90 -45.15 -34.23 2.6 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.199 1.4 . . . . 1.0 114.169 174.101 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.0 tm-20 -54.38 -35.58 62.98 Favored 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 118.621 0.646 . . . . 1.0 111.197 175.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.23 -8.05 82.97 Favored Glycine 0 CA--C 1.531 1.091 0 C-N-CA 125.16 1.362 . . . . 1.0 113.959 176.217 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 10.1 ptm -102.21 -10.26 19.73 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 119.284 1.542 . . . . 1.0 112.541 164.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -75.57 -43.46 41.53 Favored 'Isoleucine or valine' 0 C--N 1.341 0.216 0 N-CA-C 107.073 -1.454 . . . . 1.0 107.073 163.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.0 t0 . . . . . 0 CA--C 1.537 0.446 0 C-N-CA 119.443 -0.903 . . . . 1.0 108.925 160.441 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.129 0 N-CA-C 110.062 -1.215 . . . . 1.0 110.062 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -47.86 -43.68 28.59 Favored 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 125.517 1.527 . . . . 1.0 113.401 -176.764 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -51.9 -35.42 45.33 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.775 0.657 . . . . 1.0 112.775 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.78 -34.64 87.92 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.022 0.82 . . . . 1.0 112.101 173.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.99 -36.8 67.13 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 118.477 1.139 . . . . 1.0 111.612 173.455 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.22 -39.76 74.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-O 118.237 -0.887 . . . . 1.0 109.7 167.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.24 -41.01 97.18 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 119.748 1.158 . . . . 1.0 109.766 175.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.08 -39.22 49.21 Favored Glycine 0 CA--C 1.535 1.32 0 CA-C-O 118.961 -0.911 . . . . 1.0 113.018 169.001 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.9 t80 -73.14 -47.8 40.98 Favored 'General case' 0 C--N 1.341 0.227 0 CA-C-N 118.819 1.31 . . . . 1.0 112.451 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -43.84 -51.78 1.42 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 C-N-CA 124.76 1.224 . . . . 1.0 110.13 169.738 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -77.03 -0.93 26.39 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.265 1.426 . . . . 1.0 112.033 -177.548 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -81.17 -0.43 40.31 Favored 'General case' 0 C--N 1.343 0.286 0 O-C-N 120.945 -1.097 . . . . 1.0 111.662 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.41 36.42 20.45 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.256 -1.302 . . . . 1.0 110.195 -160.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -35.44 -39.14 0.12 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 125.539 1.536 . . . . 1.0 113.926 171.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -52.46 -32.33 39.11 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.563 0.949 . . . . 1.0 113.563 178.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.28 -12.96 66.86 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 119.169 -0.795 . . . . 1.0 113.236 176.033 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.5 mpt? -102.28 -9.57 20.27 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.873 1.669 . . . . 1.0 111.976 171.665 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 53.4 mt -73.64 -49.74 33.93 Favored 'Isoleucine or valine' 0 C--N 1.341 0.218 0 N-CA-C 107.348 -1.353 . . . . 1.0 107.348 173.329 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.8 t0 . . . . . 0 CA--C 1.534 0.356 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 164.336 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.167 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.4 tp -48.48 -43.75 35.1 Favored 'General case' 0 CA--C 1.514 -0.406 0 C-N-CA 125.411 1.485 . . . . 1.0 113.421 -176.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -55.09 -34.17 63.41 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.46 0.648 . . . . 1.0 112.077 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.35 -31.02 73.64 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 124.341 0.972 . . . . 1.0 112.083 173.461 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.98 -36.11 62.04 Favored 'General case' 0 N--CA 1.456 -0.148 0 CA-C-N 118.998 1.399 . . . . 1.0 111.684 172.334 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 mt -59.37 -39.5 79.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-N 119.157 0.889 . . . . 1.0 109.757 167.351 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.24 -41.25 94.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 119.379 0.99 . . . . 1.0 109.53 175.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.15 -44.09 51.1 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.978 -0.901 . . . . 1.0 112.529 168.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -65.69 -51.58 58.26 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.79 1.295 . . . . 1.0 110.807 174.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.6 mt -47.89 -30.74 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 125.405 1.482 . . . . 1.0 112.502 171.172 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -91.38 -9.36 45.07 Favored 'General case' 0 CA--C 1.545 0.774 0 CA-C-O 117.723 -1.132 . . . . 1.0 113.602 178.537 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -145.49 -15.86 0.49 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 116.149 1.907 . . . . 1.0 116.149 -166.204 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.1 2.44 0.52 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 125.385 1.469 . . . . 1.0 113.487 -174.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.6 t90 -39.8 -41.34 1.11 Allowed 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 127.311 2.244 . . . . 1.0 113.727 -174.082 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -52.19 -31.27 31.0 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.845 1.258 . . . . 1.0 112.224 -169.244 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.77 -8.46 63.79 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-O 118.755 -1.025 . . . . 1.0 114.852 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.5 -12.5 17.76 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 126.162 1.785 . . . . 1.0 112.928 164.311 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.5 mt -79.24 -55.59 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.019 -1.845 . . . . 1.0 106.019 173.66 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.9 t0 . . . . . 0 CA--C 1.534 0.339 0 N-CA-C 108.381 -0.97 . . . . 1.0 108.381 158.798 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 . . . . . 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 . . . . . 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.217 0 N-CA-C 110.196 -1.162 . . . . 1.0 110.196 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.4 tp -45.83 -43.74 13.66 Favored 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 126.283 1.833 . . . . 1.0 113.469 -176.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -50.74 -35.05 29.53 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.54 0.736 . . . . 1.0 112.924 178.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.19 87.46 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.027 0.822 . . . . 1.0 112.122 173.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.89 -39.85 72.56 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.478 1.139 . . . . 1.0 111.349 173.86 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -56.72 -40.23 68.72 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-O 118.224 -0.893 . . . . 1.0 109.914 167.645 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.78 -31.85 72.75 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 120.136 1.335 . . . . 1.0 110.796 179.155 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.25 -55.3 31.11 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.915 -0.874 . . . . 1.0 110.915 164.503 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -55.85 -43.06 76.73 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 118.043 0.921 . . . . 1.0 111.977 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.8 mt -50.47 -26.65 3.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 125.431 1.493 . . . . 1.0 112.564 173.677 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -109.69 5.33 22.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.564 1.146 . . . . 1.0 112.164 178.316 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -138.06 -15.72 1.3 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 114.532 1.308 . . . . 1.0 114.532 -169.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -158.28 0.34 0.09 OUTLIER Glycine 0 CA--C 1.529 0.957 0 C-N-CA 125.146 1.355 . . . . 1.0 113.845 -174.13 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.1 t90 -44.79 -38.63 4.64 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 119.016 1.408 . . . . 1.0 113.074 176.454 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -57.05 -30.96 64.69 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 118.998 0.817 . . . . 1.0 112.145 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.18 -23.24 77.38 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 121.31 -0.869 . . . . 1.0 112.757 173.591 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 6.5 ptt? -92.67 -16.34 25.66 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.947 1.374 . . . . 1.0 112.5 173.752 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.7 mt -64.2 -56.71 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 106.562 -1.644 . . . . 1.0 106.562 160.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.2 t70 . . . . . 0 CA--C 1.534 0.351 0 C-N-CA 124.065 0.946 . . . . 1.0 111.08 176.255 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.201 0 N-CA-C 110.195 -1.162 . . . . 1.0 110.195 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -46.39 -43.61 16.39 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 126.123 1.769 . . . . 1.0 113.635 -176.376 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.9 -34.16 53.67 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.655 0.782 . . . . 1.0 112.684 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.15 -35.49 83.41 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 124.032 0.825 . . . . 1.0 111.959 172.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.77 -31.68 68.55 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 118.561 1.18 . . . . 1.0 111.825 173.69 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -59.77 -42.46 88.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 119.461 1.028 . . . . 1.0 109.578 167.446 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.59 -31.0 71.42 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 119.568 1.076 . . . . 1.0 110.738 177.53 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -56.1 25.81 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 111.073 -0.811 . . . . 1.0 111.073 164.051 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -58.25 -39.45 79.19 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.392 1.096 . . . . 1.0 112.396 -179.509 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.1 mt -51.2 -24.21 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 125.546 1.539 . . . . 1.0 112.862 170.03 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -109.96 0.2 18.46 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.719 1.145 . . . . 1.0 112.06 173.091 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -145.17 66.54 1.24 Allowed 'General case' 0 CA--C 1.535 0.372 0 O-C-N 120.297 -1.502 . . . . 1.0 108.709 -165.329 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 108.04 2.05 33.92 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 118.661 -1.077 . . . . 1.0 114.36 173.404 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -37.72 -43.97 0.68 Allowed 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 127.195 2.198 . . . . 1.0 113.662 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.33 -38.68 19.73 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.659 1.584 . . . . 1.0 111.951 -174.075 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -63.68 -22.04 65.69 Favored Glycine 0 CA--C 1.534 1.239 0 CA-C-O 119.235 -0.758 . . . . 1.0 113.543 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 mmt -102.18 -9.39 20.52 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.94 1.696 . . . . 1.0 113.042 172.61 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.7 mt -68.99 -48.37 70.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 106.646 -1.612 . . . . 1.0 106.646 162.751 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 8.3 t70 . . . . . 0 CA--C 1.534 0.346 0 C-N-CA 124.79 1.236 . . . . 1.0 110.472 169.552 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.163 0 N-CA-C 110.025 -1.23 . . . . 1.0 110.025 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -48.16 -43.67 31.68 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 125.588 1.555 . . . . 1.0 113.387 -177.087 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -52.16 -35.84 49.88 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.761 0.652 . . . . 1.0 112.761 178.207 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.83 -32.4 81.02 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 124.304 0.954 . . . . 1.0 112.103 174.067 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -38.91 58.06 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 118.783 1.292 . . . . 1.0 111.635 174.188 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.17 -39.45 73.25 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 CA-C-N 118.772 0.714 . . . . 1.0 109.861 167.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.74 -38.31 86.37 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 119.323 0.965 . . . . 1.0 109.677 176.163 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.13 -50.63 27.68 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 123.897 0.761 . . . . 1.0 111.747 165.582 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -62.46 -48.18 80.77 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.82 1.31 . . . . 1.0 111.211 175.781 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mt -49.83 -37.48 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-N 119.254 0.934 . . . . 1.0 111.942 172.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.9 mm-40 -87.29 -4.52 59.07 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.383 -0.823 . . . . 1.0 112.825 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -140.19 -15.93 0.97 Allowed 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 120.875 1.67 . . . . 1.0 114.656 -166.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.85 3.56 0.42 Allowed Glycine 0 CA--C 1.528 0.857 0 C-N-CA 126.298 1.904 . . . . 1.0 113.136 -172.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -46.0 -33.87 3.65 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 119.213 1.506 . . . . 1.0 113.454 174.092 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -55.91 -32.99 64.26 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 119.565 1.075 . . . . 1.0 111.538 177.01 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.56 -7.75 83.35 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.283 1.42 . . . . 1.0 114.151 174.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.2 ptm -102.63 -8.46 20.92 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.308 1.554 . . . . 1.0 113.189 163.408 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mt -72.42 -56.68 9.15 Favored 'Isoleucine or valine' 0 C--N 1.344 0.354 0 N-CA-C 106.029 -1.841 . . . . 1.0 106.029 161.68 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 . . . . . 0 CA--C 1.535 0.384 0 N-CA-C 109.16 -0.681 . . . . 1.0 109.16 165.745 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.174 0 N-CA-C 110.216 -1.154 . . . . 1.0 110.216 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.3 tp -45.85 -43.61 13.63 Favored 'General case' 0 CA--C 1.515 -0.377 0 C-N-CA 126.474 1.91 . . . . 1.0 113.591 -176.667 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -51.46 -35.16 38.64 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.535 0.734 . . . . 1.0 112.793 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.89 85.42 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.175 0.893 . . . . 1.0 112.056 173.686 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.12 -38.01 72.32 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 118.656 1.228 . . . . 1.0 111.293 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -57.84 -39.95 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 117.922 -1.037 . . . . 1.0 109.86 168.061 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.41 86.25 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 120.176 1.353 . . . . 1.0 110.175 177.167 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.4 -47.21 51.5 Favored Glycine 0 CA--C 1.533 1.17 0 CA-C-O 119.48 -0.622 . . . . 1.0 111.84 166.736 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -68.25 -43.46 77.8 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.388 1.094 . . . . 1.0 113.043 177.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -44.18 -52.81 1.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.693 1.197 . . . . 1.0 109.33 168.268 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -79.06 2.08 21.87 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.907 1.283 . . . . 1.0 112.582 -176.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -86.83 11.23 13.77 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.361 0.982 . . . . 1.0 110.154 171.647 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.92 38.37 23.34 Favored Glycine 0 C--N 1.338 0.685 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 -170.676 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.8 t90 -38.43 -44.8 0.96 Allowed 'General case' 0 C--N 1.349 0.586 0 C-N-CA 123.915 0.886 . . . . 1.0 112.703 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -60.66 -23.54 64.88 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 113.781 1.03 . . . . 1.0 113.781 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.35 -31.88 29.73 Favored Glycine 0 C--N 1.34 0.804 0 CA-C-N 118.857 0.753 . . . . 1.0 111.478 170.217 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 16.3 mmt -68.82 -11.98 61.03 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.519 1.128 . . . . 1.0 112.356 176.353 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mt -65.46 -29.07 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.23 1.012 . . . . 1.0 109.729 168.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.4 t0 . . . . . 0 CA--C 1.535 0.393 0 C-N-CA 129.206 3.002 . . . . 1.0 114.118 177.724 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.154 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -45.12 -43.55 9.83 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.29 1.836 . . . . 1.0 113.637 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -50.93 -34.28 27.97 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.984 0.914 . . . . 1.0 113.018 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.9 -36.56 86.83 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 123.981 0.8 . . . . 1.0 112.17 172.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.69 -36.07 73.11 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-N 118.316 1.058 . . . . 1.0 111.593 173.033 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mt -57.96 -39.64 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 118.016 -0.992 . . . . 1.0 110.067 168.023 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.68 91.3 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 120.072 1.306 . . . . 1.0 110.275 176.634 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.32 -48.66 59.15 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.692 -0.563 . . . . 1.0 111.692 167.769 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -63.23 -46.87 84.9 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 118.248 1.024 . . . . 1.0 112.157 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.5 mt -45.09 -45.2 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 125.295 1.438 . . . . 1.0 110.999 170.293 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -79.95 -8.05 59.12 Favored 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 112.791 0.663 . . . . 1.0 112.791 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -89.78 33.49 0.85 Allowed 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 120.408 1.458 . . . . 1.0 109.872 -174.265 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.3 22.93 73.15 Favored Glycine 0 CA--C 1.531 1.044 0 CA-C-O 118.17 -1.35 . . . . 1.0 112.504 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -41.42 -40.29 1.71 Allowed 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.039 1.336 . . . . 1.0 113.693 -179.007 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -51.31 -37.46 47.7 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.428 0.691 . . . . 1.0 111.996 -178.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.77 -9.56 75.17 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.754 -1.026 . . . . 1.0 113.836 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.6 ppp? -98.91 -8.23 25.94 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.76 1.28 . . . . 1.0 111.674 174.286 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.6 mt -66.39 -50.09 70.31 Favored 'Isoleucine or valine' 0 C--N 1.345 0.375 0 N-CA-C 108.878 -0.786 . . . . 1.0 108.878 176.648 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.5 t0 . . . . . 0 CA--C 1.54 0.58 0 C-N-CA 128.51 2.724 . . . . 1.0 113.831 177.127 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.132 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -47.24 -43.61 22.03 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 125.862 1.665 . . . . 1.0 113.371 -176.787 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -51.87 -35.22 44.2 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.306 0.643 . . . . 1.0 112.671 178.693 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -32.51 76.18 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.243 0.925 . . . . 1.0 112.329 173.755 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.64 -37.81 65.22 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 118.826 1.313 . . . . 1.0 111.482 172.744 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.1 mt -58.4 -39.43 74.59 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 CA-C-O 118.453 -0.784 . . . . 1.0 109.787 167.31 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -40.44 93.79 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.8 1.182 . . . . 1.0 109.659 176.17 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.8 -46.67 39.63 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 124.029 0.823 . . . . 1.0 112.255 167.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -65.52 -49.98 66.97 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.488 1.144 . . . . 1.0 111.483 175.418 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -48.66 -32.09 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 C-N-CA 125.098 1.359 . . . . 1.0 112.135 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -89.81 -8.26 52.48 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-O 117.718 -1.134 . . . . 1.0 113.338 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.25 -15.98 0.45 Allowed 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.315 1.968 . . . . 1.0 116.315 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -144.9 -1.11 0.85 Allowed Glycine 0 CA--C 1.53 0.999 0 C-N-CA 125.875 1.703 . . . . 1.0 113.388 -175.335 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.0 t90 -37.7 -41.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 127.461 2.304 . . . . 1.0 113.759 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tm-20 -49.27 -37.01 22.25 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.238 1.415 . . . . 1.0 112.371 -175.394 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.31 -17.62 70.51 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-O 119.348 -0.695 . . . . 1.0 113.783 178.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.6 mmt -102.51 -7.78 21.6 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.577 1.951 . . . . 1.0 112.808 169.145 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 57.1 mt -66.9 -50.73 62.24 Favored 'Isoleucine or valine' 0 C--N 1.342 0.267 0 N-CA-C 106.19 -1.782 . . . . 1.0 106.19 162.681 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.9 t0 . . . . . 0 CA--C 1.542 0.636 0 C-N-CA 124.216 1.007 . . . . 1.0 110.95 167.764 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.195 0 N-CA-C 110.11 -1.196 . . . . 1.0 110.11 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp -46.1 -43.5 14.85 Favored 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 126.197 1.799 . . . . 1.0 113.686 -176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -51.09 -35.76 36.79 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.818 0.673 . . . . 1.0 112.818 178.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.57 -33.54 81.49 Favored Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.165 0.888 . . . . 1.0 112.135 174.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.54 -36.11 63.12 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 118.681 1.241 . . . . 1.0 111.889 174.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -57.91 -42.54 82.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 118.497 -0.763 . . . . 1.0 109.549 166.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.98 -35.89 82.62 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 119.34 0.973 . . . . 1.0 109.96 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -47.36 -59.56 5.76 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 118.53 -1.15 . . . . 1.0 111.487 163.308 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -59.27 -44.19 92.44 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 118.668 1.234 . . . . 1.0 112.143 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.7 mt -50.11 -24.89 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 125.671 1.588 . . . . 1.0 112.813 172.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.89 -1.16 17.94 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-N 119.468 1.031 . . . . 1.0 112.552 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -151.84 72.2 1.01 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.442 1.497 . . . . 1.0 108.524 -166.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 115.91 -5.03 20.53 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.538 -1.145 . . . . 1.0 113.761 173.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t90 -39.16 -41.99 0.9 Allowed 'General case' 0 C--N 1.343 0.297 0 C-N-CA 126.502 1.921 . . . . 1.0 113.044 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -50.81 -34.57 28.19 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.887 1.275 . . . . 1.0 112.438 -175.383 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.06 -18.7 67.15 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.675 -0.641 . . . . 1.0 113.725 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.43 -9.44 20.27 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.75 1.62 . . . . 1.0 113.038 169.098 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.9 mt -71.65 -43.14 71.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 166.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -58.08 167.36 1.28 Allowed 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.952 1.301 . . . . 1.0 111.588 172.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.958 0 C-N-CA 125.575 1.56 . . . . 1.0 111.432 -173.707 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.32 -1.112 . . . . 1.0 110.32 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.5 tp -44.86 -43.69 8.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 C-N-CA 126.185 1.794 . . . . 1.0 113.51 -176.394 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -47.04 -35.51 6.87 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.83 1.252 . . . . 1.0 113.499 178.344 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.7 -42.88 86.52 Favored Glycine 0 CA--C 1.53 0.992 0 C-N-CA 123.913 0.768 . . . . 1.0 111.968 173.189 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.54 -30.17 70.42 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 118.356 1.078 . . . . 1.0 112.091 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.6 mt -54.57 -40.98 52.55 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-O 117.932 -1.033 . . . . 1.0 110.395 172.117 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.98 -29.31 70.16 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 120.416 1.462 . . . . 1.0 111.986 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.81 -47.84 64.71 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.885 -0.886 . . . . 1.0 110.885 169.616 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -60.27 -45.5 93.09 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.899 0.85 . . . . 1.0 112.653 177.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.2 mt -40.39 -50.25 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 C-N-CA 125.918 1.687 . . . . 1.0 110.937 168.272 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 mm-40 -79.87 -3.98 50.3 Favored 'General case' 0 CA--C 1.539 0.525 0 N-CA-C 113.037 0.754 . . . . 1.0 113.037 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -98.92 21.34 11.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 120.0 1.273 . . . . 1.0 110.583 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 24.77 47.54 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 118.849 -0.973 . . . . 1.0 112.015 -176.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -37.34 -49.91 1.01 Allowed 'General case' 0 C--N 1.347 0.477 0 C-N-CA 124.18 0.992 . . . . 1.0 112.615 173.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -59.08 -25.1 63.49 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.42 0.896 . . . . 1.0 113.42 -171.526 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.36 -43.59 6.93 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.529 -1.029 . . . . 1.0 110.529 171.464 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 5.7 ttt -63.58 -7.53 7.41 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.261 1.824 . . . . 1.0 114.057 177.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 66.3 mt -55.0 -30.37 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 C-N-CA 124.563 1.145 . . . . 1.0 110.649 162.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -58.54 150.69 22.2 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 121.749 0.785 . . . . 1.0 111.111 178.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.327 0 CA-C-O 118.66 -1.078 . . . . 1.0 112.379 -163.668 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 109.995 -1.242 . . . . 1.0 109.995 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.8 tp -47.73 -43.7 27.27 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 125.647 1.579 . . . . 1.0 113.173 -176.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.91 -34.51 55.46 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.551 0.74 . . . . 1.0 112.582 179.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.89 -34.4 82.28 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 124.223 0.916 . . . . 1.0 112.041 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.7 -34.12 66.93 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 118.639 1.22 . . . . 1.0 111.806 172.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -59.15 -40.99 82.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 CA-C-N 119.313 0.96 . . . . 1.0 109.774 167.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.86 -39.89 94.26 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 119.767 1.167 . . . . 1.0 109.828 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.29 -49.49 31.35 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 119.163 -0.798 . . . . 1.0 112.023 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.3 t80 -64.68 -47.76 77.23 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.437 1.118 . . . . 1.0 111.686 177.011 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -47.99 -34.5 4.48 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.746 1.219 . . . . 1.0 111.735 172.017 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -91.46 -3.5 56.54 Favored 'General case' 0 CA--C 1.542 0.652 0 CA-C-O 117.867 -1.064 . . . . 1.0 113.318 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -145.11 -15.9 0.51 Allowed 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 115.956 1.836 . . . . 1.0 115.956 -166.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.44 0.55 0.39 Allowed Glycine 0 CA--C 1.529 0.925 0 CA-C-O 118.027 -1.429 . . . . 1.0 113.575 -174.141 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.3 t90 -38.41 -42.71 0.76 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.445 1.898 . . . . 1.0 113.519 -177.257 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -49.7 -34.78 19.72 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.967 1.307 . . . . 1.0 112.42 -177.486 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.69 -16.66 70.22 Favored Glycine 0 CA--C 1.533 1.184 0 CA-C-O 119.377 -0.679 . . . . 1.0 113.993 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.7 mtp -102.2 -8.19 21.54 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.328 1.451 . . . . 1.0 112.499 168.237 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mt -74.1 -54.65 14.42 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 107.136 -1.431 . . . . 1.0 107.136 165.339 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.3 t70 43.2 -105.95 0.08 Allowed 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.502 1.521 . . . . 1.0 110.712 -173.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.135 0 CA-C-O 118.031 -1.427 . . . . 1.0 115.11 -178.721 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.125 0 N-CA-C 110.27 -1.132 . . . . 1.0 110.27 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -45.59 -43.74 12.38 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 126.484 1.914 . . . . 1.0 113.89 -176.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.23 -35.3 49.23 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.301 0.572 . . . . 1.0 112.481 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -32.74 79.74 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.298 0.951 . . . . 1.0 112.078 174.051 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.32 -37.4 63.6 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.89 1.345 . . . . 1.0 111.658 173.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -58.36 -40.94 80.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-O 118.647 -0.692 . . . . 1.0 109.635 167.144 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.85 -35.89 81.94 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.421 1.01 . . . . 1.0 109.984 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.32 -56.43 10.79 Favored Glycine 0 CA--C 1.531 1.032 0 CA-C-O 118.862 -0.965 . . . . 1.0 111.359 164.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -60.74 -41.49 95.48 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.524 1.162 . . . . 1.0 112.396 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -51.52 -25.09 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 125.313 1.445 . . . . 1.0 112.56 170.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -105.32 -0.08 26.56 Favored 'General case' 0 CA--C 1.545 0.783 0 CA-C-N 119.459 1.027 . . . . 1.0 112.776 174.228 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -149.99 71.67 1.09 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 125.261 1.424 . . . . 1.0 108.767 -165.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 5.24 47.85 Favored Glycine 0 CA--C 1.528 0.904 0 CA-C-O 118.608 -1.107 . . . . 1.0 114.165 171.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -37.63 -44.78 0.72 Allowed 'General case' 0 C--N 1.343 0.294 0 C-N-CA 127.118 2.167 . . . . 1.0 113.737 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -48.06 -35.65 11.58 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.279 1.832 . . . . 1.0 112.219 -170.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.98 -27.83 65.25 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.598 -0.689 . . . . 1.0 113.484 178.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -95.19 -18.58 20.78 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.275 1.83 . . . . 1.0 111.963 176.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.9 mt -67.79 -50.03 63.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 168.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -61.14 -56.07 25.0 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 125.675 1.59 . . . . 1.0 110.793 170.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.016 0 C-N-CA 124.953 1.263 . . . . 1.0 112.251 175.863 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 110.086 -1.206 . . . . 1.0 110.086 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.8 tp -46.53 -43.72 17.19 Favored 'General case' 0 CA--C 1.513 -0.466 0 C-N-CA 126.113 1.765 . . . . 1.0 113.388 -177.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -51.74 -34.67 40.24 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.787 0.662 . . . . 1.0 112.787 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.21 -35.84 90.95 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.114 0.864 . . . . 1.0 112.243 173.116 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.95 -40.23 72.13 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.486 1.143 . . . . 1.0 111.264 173.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -56.7 -38.79 59.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-O 118.425 -0.798 . . . . 1.0 110.083 168.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -68.82 -26.14 65.03 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 119.703 1.138 . . . . 1.0 111.705 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.53 -55.42 27.44 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.48 -1.048 . . . . 1.0 110.48 163.107 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -55.16 -38.33 68.14 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 123.957 0.903 . . . . 1.0 112.146 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 mt -49.29 -26.54 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 126.298 1.839 . . . . 1.0 112.57 172.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -112.26 -4.92 14.23 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 119.931 1.241 . . . . 1.0 112.029 175.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -150.07 66.5 0.97 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 125.488 1.515 . . . . 1.0 108.11 -163.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.73 -20.9 4.05 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.957 -0.913 . . . . 1.0 112.405 178.267 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.6 t90 -46.86 -42.86 18.04 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 124.441 1.097 . . . . 1.0 111.259 174.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -59.22 -26.96 65.31 Favored 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 123.889 0.876 . . . . 1.0 113.052 -177.581 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.54 -13.76 82.65 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 119.385 -0.675 . . . . 1.0 113.137 172.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.2 ttt -101.59 -19.91 15.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.189 1.796 . . . . 1.0 111.833 173.098 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.9 mt -65.67 -48.53 82.14 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 162.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.7 t0 45.08 57.19 4.88 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 126.298 1.839 . . . . 1.0 111.282 -174.03 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.099 0 C-N-CA 124.559 1.076 . . . . 1.0 112.841 -176.105 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.104 0 N-CA-C 110.18 -1.168 . . . . 1.0 110.18 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -46.91 -43.77 19.19 Favored 'General case' 0 CA--C 1.515 -0.368 0 C-N-CA 126.115 1.766 . . . . 1.0 113.532 -176.541 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.54 -34.51 58.5 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 121.455 0.645 . . . . 1.0 112.431 179.314 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.74 -34.17 86.53 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.114 0.864 . . . . 1.0 112.006 173.101 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.01 -36.1 66.95 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 118.642 1.221 . . . . 1.0 111.692 173.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -58.09 -41.82 81.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 118.967 0.803 . . . . 1.0 109.628 166.609 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.54 -31.63 72.47 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.507 1.049 . . . . 1.0 110.61 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.97 -58.47 12.55 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 119.065 -0.853 . . . . 1.0 110.97 162.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -55.77 -42.66 75.84 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 118.67 1.235 . . . . 1.0 112.16 -178.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.1 mt -50.16 -23.97 1.84 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 C-N-CA 125.929 1.691 . . . . 1.0 113.236 171.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 -113.0 -1.81 14.39 Favored 'General case' 0 CA--C 1.543 0.711 0 CA-C-N 119.698 1.135 . . . . 1.0 111.914 173.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -146.95 65.9 1.16 Allowed 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.638 1.575 . . . . 1.0 108.335 -164.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 117.66 -3.42 17.57 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.394 -1.225 . . . . 1.0 114.069 175.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.8 t90 -38.56 -39.6 0.49 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 126.865 2.066 . . . . 1.0 113.166 176.03 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -50.36 -33.61 21.09 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.37 1.068 . . . . 1.0 112.419 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.93 -23.14 65.41 Favored Glycine 0 CA--C 1.534 1.25 0 O-C-N 121.353 -0.842 . . . . 1.0 113.594 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 23.8 mmt -102.0 -8.32 21.6 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.448 1.899 . . . . 1.0 112.478 172.497 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.8 mt -71.58 -23.97 23.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 N-CA-C 108.492 -0.929 . . . . 1.0 108.492 160.217 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t0 50.16 88.12 0.03 OUTLIER 'General case' 0 C--N 1.344 0.326 0 C-N-CA 128.169 2.588 . . . . 1.0 113.669 159.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.96 0 C-N-CA 124.698 1.142 . . . . 1.0 112.493 178.668 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.144 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.8 tp -48.43 -43.66 34.53 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 125.504 1.522 . . . . 1.0 113.273 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.11 -35.06 59.25 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.395 0.678 . . . . 1.0 112.376 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.31 -33.65 78.3 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 124.336 0.97 . . . . 1.0 112.156 173.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.59 -38.77 67.76 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 118.71 1.255 . . . . 1.0 111.48 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.77 -39.82 72.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 118.467 -0.778 . . . . 1.0 110.01 167.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.79 95.5 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.663 1.119 . . . . 1.0 109.683 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.33 -45.21 52.86 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.955 -0.914 . . . . 1.0 112.38 168.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 52.1 t80 -65.96 -50.71 63.4 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.755 1.278 . . . . 1.0 111.47 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mt -47.64 -31.74 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 C-N-CA 125.667 1.587 . . . . 1.0 112.347 170.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -91.02 -8.06 50.16 Favored 'General case' 0 CA--C 1.544 0.712 0 CA-C-O 117.696 -1.145 . . . . 1.0 113.628 178.358 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.04 -15.94 0.46 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 116.381 1.993 . . . . 1.0 116.381 -166.003 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.0 1.12 0.65 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 124.925 1.25 . . . . 1.0 113.32 -176.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.5 t90 -40.32 -43.14 1.68 Allowed 'General case' 0 C--N 1.343 0.302 0 C-N-CA 127.12 2.168 . . . . 1.0 113.809 -171.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -51.75 -33.62 35.7 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.802 1.241 . . . . 1.0 112.177 -169.447 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.99 -13.92 62.57 Favored Glycine 0 CA--C 1.537 1.451 0 CA-C-O 118.988 -0.895 . . . . 1.0 114.389 178.143 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 27.8 ttt -102.47 -13.35 17.28 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.284 1.834 . . . . 1.0 111.928 170.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.9 mt -75.34 -48.31 31.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 N-CA-C 107.254 -1.388 . . . . 1.0 107.254 170.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -65.39 157.75 28.48 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 109.554 -0.536 . . . . 1.0 109.554 162.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.011 0 C-N-CA 125.272 1.415 . . . . 1.0 111.799 -173.68 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.143 0 N-CA-C 110.186 -1.166 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.3 tp -46.6 -43.76 17.6 Favored 'General case' 0 CA--C 1.515 -0.399 0 C-N-CA 126.231 1.812 . . . . 1.0 113.507 -176.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -53.48 -34.17 57.04 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 121.494 0.664 . . . . 1.0 112.462 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.43 -34.59 85.2 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.241 0.925 . . . . 1.0 112.046 173.058 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.13 -37.36 69.47 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 118.653 1.227 . . . . 1.0 111.538 173.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.21 -41.4 77.9 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-O 118.358 -0.83 . . . . 1.0 109.796 167.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.75 -33.7 76.48 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 119.832 1.196 . . . . 1.0 110.733 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.01 -54.65 30.15 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 118.927 -0.929 . . . . 1.0 111.416 164.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -59.8 -42.59 93.74 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.31 1.055 . . . . 1.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -50.27 -24.17 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 C-N-CA 125.856 1.663 . . . . 1.0 112.898 171.055 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -108.69 -1.67 19.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.58 1.152 . . . . 1.0 112.229 175.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -155.48 71.79 0.78 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.684 1.594 . . . . 1.0 108.709 -165.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 120.69 -9.49 10.64 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-O 118.949 -0.917 . . . . 1.0 113.531 174.245 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -37.13 -44.4 0.55 Allowed 'General case' 0 C--N 1.343 0.301 0 C-N-CA 126.88 2.072 . . . . 1.0 112.641 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.4 pm0 -53.75 -29.13 38.41 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 124.882 1.273 . . . . 1.0 112.68 -175.512 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.1 -15.51 74.45 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 118.932 0.787 . . . . 1.0 113.811 175.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.5 mmt -102.25 -8.08 21.57 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.215 1.806 . . . . 1.0 112.201 169.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.0 mt -77.5 -43.91 30.0 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.328 -1.36 . . . . 1.0 107.328 164.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -57.08 157.66 5.75 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 123.645 0.778 . . . . 1.0 110.473 167.03 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.361 0 C-N-CA 124.58 1.086 . . . . 1.0 112.213 -162.456 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp -46.38 -43.44 16.23 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.245 1.818 . . . . 1.0 113.586 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -51.38 -35.43 38.77 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.527 0.731 . . . . 1.0 112.836 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.65 -36.92 92.02 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 124.042 0.83 . . . . 1.0 111.713 173.46 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.03 -34.24 71.09 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 118.525 1.163 . . . . 1.0 111.872 174.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.2 mt -58.94 -42.06 84.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 119.306 0.957 . . . . 1.0 109.747 167.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.55 73.91 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.622 1.101 . . . . 1.0 110.505 177.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.16 -55.14 27.8 Favored Glycine 0 CA--C 1.532 1.15 0 CA-C-O 119.197 -0.779 . . . . 1.0 111.336 164.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -60.56 -39.75 89.11 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.93 1.292 . . . . 1.0 112.474 -179.175 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.4 mt -50.49 -24.04 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 125.694 1.598 . . . . 1.0 112.764 169.419 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.36 0.13 19.31 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.27 1.028 . . . . 1.0 112.369 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -150.51 70.83 1.03 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.693 1.597 . . . . 1.0 108.862 -166.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 107.19 2.89 35.94 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.67 -1.072 . . . . 1.0 114.202 172.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -35.9 -43.43 0.31 Allowed 'General case' 0 C--N 1.343 0.311 0 C-N-CA 127.966 2.506 . . . . 1.0 113.531 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -49.77 -33.64 16.99 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.422 1.489 . . . . 1.0 112.15 -174.13 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.29 -18.21 64.91 Favored Glycine 0 CA--C 1.537 1.453 0 CA-C-O 119.18 -0.789 . . . . 1.0 114.149 177.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.6 ttt -102.36 -10.69 19.25 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.251 1.82 . . . . 1.0 112.052 171.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mt -75.13 -40.67 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 167.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -58.86 160.06 6.25 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 123.783 0.833 . . . . 1.0 110.807 167.579 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.157 0 C-N-CA 124.684 1.135 . . . . 1.0 111.272 -164.669 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.14 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -45.27 -43.48 10.57 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.431 1.892 . . . . 1.0 113.608 -176.475 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -50.4 -34.22 23.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.12 0.968 . . . . 1.0 112.951 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.93 -37.15 87.69 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.156 0.884 . . . . 1.0 112.213 173.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.13 -32.17 71.36 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.424 1.112 . . . . 1.0 111.527 173.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -58.08 -40.01 75.15 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 CA-C-O 118.072 -0.966 . . . . 1.0 109.907 170.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.71 -25.99 67.55 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 120.299 1.409 . . . . 1.0 111.82 176.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.79 -54.21 35.33 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.795 -0.922 . . . . 1.0 110.795 165.261 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -58.27 -34.11 70.15 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.604 1.162 . . . . 1.0 112.914 177.173 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.418 ' HA ' ' HB2' ' A' ' 14' ' ' TRP . 1.2 mt -53.1 -28.73 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.802 1.241 . . . . 1.0 111.726 172.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -102.6 -0.17 32.4 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.164 0.986 . . . . 1.0 111.912 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 -151.81 66.54 0.86 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.305 1.442 . . . . 1.0 108.857 -163.461 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.23 -2.37 14.3 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.247 -1.307 . . . . 1.0 114.455 176.189 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.418 ' HB2' ' HA ' ' A' ' 10' ' ' ILE . 2.6 t90 -45.15 -34.23 2.6 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.199 1.4 . . . . 1.0 114.169 174.101 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.0 tm-20 -54.38 -35.58 62.98 Favored 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 118.621 0.646 . . . . 1.0 111.197 175.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.23 -8.05 82.97 Favored Glycine 0 CA--C 1.531 1.091 0 C-N-CA 125.16 1.362 . . . . 1.0 113.959 176.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 10.1 ptm -102.21 -10.26 19.73 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 119.284 1.542 . . . . 1.0 112.541 164.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -75.57 -43.46 41.53 Favored 'Isoleucine or valine' 0 C--N 1.341 0.216 0 N-CA-C 107.073 -1.454 . . . . 1.0 107.073 163.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -55.46 138.87 45.34 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 119.443 -0.903 . . . . 1.0 108.925 160.441 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 1.669 0 C-N-CA 126.217 1.865 . . . . 1.0 116.798 -173.856 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.129 0 N-CA-C 110.062 -1.215 . . . . 1.0 110.062 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -47.86 -43.68 28.59 Favored 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 125.517 1.527 . . . . 1.0 113.401 -176.764 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -51.9 -35.42 45.33 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.775 0.657 . . . . 1.0 112.775 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.78 -34.64 87.92 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.022 0.82 . . . . 1.0 112.101 173.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.99 -36.8 67.13 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 118.477 1.139 . . . . 1.0 111.612 173.455 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.22 -39.76 74.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-O 118.237 -0.887 . . . . 1.0 109.7 167.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.24 -41.01 97.18 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 119.748 1.158 . . . . 1.0 109.766 175.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.08 -39.22 49.21 Favored Glycine 0 CA--C 1.535 1.32 0 CA-C-O 118.961 -0.911 . . . . 1.0 113.018 169.001 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.9 t80 -73.14 -47.8 40.98 Favored 'General case' 0 C--N 1.341 0.227 0 CA-C-N 118.819 1.31 . . . . 1.0 112.451 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -43.84 -51.78 1.42 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 C-N-CA 124.76 1.224 . . . . 1.0 110.13 169.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -77.03 -0.93 26.39 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.265 1.426 . . . . 1.0 112.033 -177.548 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -81.17 -0.43 40.31 Favored 'General case' 0 C--N 1.343 0.286 0 O-C-N 120.945 -1.097 . . . . 1.0 111.662 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.41 36.42 20.45 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.256 -1.302 . . . . 1.0 110.195 -160.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -35.44 -39.14 0.12 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 125.539 1.536 . . . . 1.0 113.926 171.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -52.46 -32.33 39.11 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.563 0.949 . . . . 1.0 113.563 178.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.28 -12.96 66.86 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 119.169 -0.795 . . . . 1.0 113.236 176.033 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.5 mpt? -102.28 -9.57 20.27 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.873 1.669 . . . . 1.0 111.976 171.665 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 53.4 mt -73.64 -49.74 33.93 Favored 'Isoleucine or valine' 0 C--N 1.341 0.218 0 N-CA-C 107.348 -1.353 . . . . 1.0 107.348 173.329 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.8 t0 -64.91 150.23 48.19 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 164.336 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.357 0 C-N-CA 126.254 1.883 . . . . 1.0 114.424 -175.65 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.167 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.4 tp -48.48 -43.75 35.1 Favored 'General case' 0 CA--C 1.514 -0.406 0 C-N-CA 125.411 1.485 . . . . 1.0 113.421 -176.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -55.09 -34.17 63.41 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.46 0.648 . . . . 1.0 112.077 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.35 -31.02 73.64 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 124.341 0.972 . . . . 1.0 112.083 173.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.98 -36.11 62.04 Favored 'General case' 0 N--CA 1.456 -0.148 0 CA-C-N 118.998 1.399 . . . . 1.0 111.684 172.334 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 mt -59.37 -39.5 79.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-N 119.157 0.889 . . . . 1.0 109.757 167.351 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.24 -41.25 94.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 119.379 0.99 . . . . 1.0 109.53 175.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.15 -44.09 51.1 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.978 -0.901 . . . . 1.0 112.529 168.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -65.69 -51.58 58.26 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.79 1.295 . . . . 1.0 110.807 174.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.6 mt -47.89 -30.74 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 125.405 1.482 . . . . 1.0 112.502 171.172 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -91.38 -9.36 45.07 Favored 'General case' 0 CA--C 1.545 0.774 0 CA-C-O 117.723 -1.132 . . . . 1.0 113.602 178.537 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -145.49 -15.86 0.49 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 116.149 1.907 . . . . 1.0 116.149 -166.204 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.1 2.44 0.52 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 125.385 1.469 . . . . 1.0 113.487 -174.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.6 t90 -39.8 -41.34 1.11 Allowed 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 127.311 2.244 . . . . 1.0 113.727 -174.082 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -52.19 -31.27 31.0 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.845 1.258 . . . . 1.0 112.224 -169.244 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.77 -8.46 63.79 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-O 118.755 -1.025 . . . . 1.0 114.852 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.5 -12.5 17.76 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 126.162 1.785 . . . . 1.0 112.928 164.311 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.5 mt -79.24 -55.59 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.019 -1.845 . . . . 1.0 106.019 173.66 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -66.64 155.71 37.17 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 108.381 -0.97 . . . . 1.0 108.381 158.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 1.516 0 O-C-N 121.638 -0.664 . . . . 1.0 113.717 -166.943 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -67.26 173.21 4.05 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.844 0 C-N-CA 126.096 1.808 . . . . 1.0 109.95 -175.922 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -67.26 173.21 4.05 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.844 0 C-N-CA 126.096 1.808 . . . . 1.0 109.95 -175.922 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.217 0 N-CA-C 110.196 -1.162 . . . . 1.0 110.196 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.4 tp -45.83 -43.74 13.66 Favored 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 126.283 1.833 . . . . 1.0 113.469 -176.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -50.74 -35.05 29.53 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.54 0.736 . . . . 1.0 112.924 178.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.19 87.46 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.027 0.822 . . . . 1.0 112.122 173.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.89 -39.85 72.56 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.478 1.139 . . . . 1.0 111.349 173.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -56.72 -40.23 68.72 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-O 118.224 -0.893 . . . . 1.0 109.914 167.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.78 -31.85 72.75 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 120.136 1.335 . . . . 1.0 110.796 179.155 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.25 -55.3 31.11 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.915 -0.874 . . . . 1.0 110.915 164.503 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -55.85 -43.06 76.73 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 118.043 0.921 . . . . 1.0 111.977 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.8 mt -50.47 -26.65 3.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 125.431 1.493 . . . . 1.0 112.564 173.677 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -109.69 5.33 22.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.564 1.146 . . . . 1.0 112.164 178.316 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -138.06 -15.72 1.3 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 114.532 1.308 . . . . 1.0 114.532 -169.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -158.28 0.34 0.09 OUTLIER Glycine 0 CA--C 1.529 0.957 0 C-N-CA 125.146 1.355 . . . . 1.0 113.845 -174.13 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.1 t90 -44.79 -38.63 4.64 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 119.016 1.408 . . . . 1.0 113.074 176.454 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -57.05 -30.96 64.69 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 118.998 0.817 . . . . 1.0 112.145 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.18 -23.24 77.38 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 121.31 -0.869 . . . . 1.0 112.757 173.591 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 6.5 ptt? -92.67 -16.34 25.66 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.947 1.374 . . . . 1.0 112.5 173.752 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.7 mt -64.2 -56.71 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 106.562 -1.644 . . . . 1.0 106.562 160.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -54.95 -44.94 74.79 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.065 0.946 . . . . 1.0 111.08 176.255 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.358 0 CA-C-O 118.338 -1.257 . . . . 1.0 115.107 173.837 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.201 0 N-CA-C 110.195 -1.162 . . . . 1.0 110.195 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -46.39 -43.61 16.39 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 126.123 1.769 . . . . 1.0 113.635 -176.376 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.9 -34.16 53.67 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.655 0.782 . . . . 1.0 112.684 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.15 -35.49 83.41 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 124.032 0.825 . . . . 1.0 111.959 172.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.77 -31.68 68.55 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 118.561 1.18 . . . . 1.0 111.825 173.69 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -59.77 -42.46 88.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 119.461 1.028 . . . . 1.0 109.578 167.446 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.59 -31.0 71.42 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 119.568 1.076 . . . . 1.0 110.738 177.53 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -56.1 25.81 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 111.073 -0.811 . . . . 1.0 111.073 164.051 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -58.25 -39.45 79.19 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.392 1.096 . . . . 1.0 112.396 -179.509 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.1 mt -51.2 -24.21 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 125.546 1.539 . . . . 1.0 112.862 170.03 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -109.96 0.2 18.46 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.719 1.145 . . . . 1.0 112.06 173.091 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -145.17 66.54 1.24 Allowed 'General case' 0 CA--C 1.535 0.372 0 O-C-N 120.297 -1.502 . . . . 1.0 108.709 -165.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 108.04 2.05 33.92 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 118.661 -1.077 . . . . 1.0 114.36 173.404 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -37.72 -43.97 0.68 Allowed 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 127.195 2.198 . . . . 1.0 113.662 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.33 -38.68 19.73 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.659 1.584 . . . . 1.0 111.951 -174.075 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -63.68 -22.04 65.69 Favored Glycine 0 CA--C 1.534 1.239 0 CA-C-O 119.235 -0.758 . . . . 1.0 113.543 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 mmt -102.18 -9.39 20.52 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.94 1.696 . . . . 1.0 113.042 172.61 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.7 mt -68.99 -48.37 70.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 106.646 -1.612 . . . . 1.0 106.646 162.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -63.77 -62.65 1.51 Allowed 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.79 1.236 . . . . 1.0 110.472 169.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.115 0 C-N-CA 125.368 1.461 . . . . 1.0 114.766 177.083 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.163 0 N-CA-C 110.025 -1.23 . . . . 1.0 110.025 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -48.16 -43.67 31.68 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 125.588 1.555 . . . . 1.0 113.387 -177.087 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -52.16 -35.84 49.88 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.761 0.652 . . . . 1.0 112.761 178.207 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.83 -32.4 81.02 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 124.304 0.954 . . . . 1.0 112.103 174.067 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -38.91 58.06 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 118.783 1.292 . . . . 1.0 111.635 174.188 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.17 -39.45 73.25 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 CA-C-N 118.772 0.714 . . . . 1.0 109.861 167.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.74 -38.31 86.37 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 119.323 0.965 . . . . 1.0 109.677 176.163 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.13 -50.63 27.68 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 123.897 0.761 . . . . 1.0 111.747 165.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -62.46 -48.18 80.77 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.82 1.31 . . . . 1.0 111.211 175.781 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mt -49.83 -37.48 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-N 119.254 0.934 . . . . 1.0 111.942 172.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.9 mm-40 -87.29 -4.52 59.07 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.383 -0.823 . . . . 1.0 112.825 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -140.19 -15.93 0.97 Allowed 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 120.875 1.67 . . . . 1.0 114.656 -166.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.85 3.56 0.42 Allowed Glycine 0 CA--C 1.528 0.857 0 C-N-CA 126.298 1.904 . . . . 1.0 113.136 -172.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -46.0 -33.87 3.65 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 119.213 1.506 . . . . 1.0 113.454 174.092 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -55.91 -32.99 64.26 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 119.565 1.075 . . . . 1.0 111.538 177.01 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.56 -7.75 83.35 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.283 1.42 . . . . 1.0 114.151 174.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.2 ptm -102.63 -8.46 20.92 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.308 1.554 . . . . 1.0 113.189 163.408 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mt -72.42 -56.68 9.15 Favored 'Isoleucine or valine' 0 C--N 1.344 0.354 0 N-CA-C 106.029 -1.841 . . . . 1.0 106.029 161.68 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -60.16 151.63 26.55 Favored 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 109.16 -0.681 . . . . 1.0 109.16 165.745 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.534 0 C-N-CA 124.899 1.238 . . . . 1.0 114.662 -168.661 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.174 0 N-CA-C 110.216 -1.154 . . . . 1.0 110.216 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.3 tp -45.85 -43.61 13.63 Favored 'General case' 0 CA--C 1.515 -0.377 0 C-N-CA 126.474 1.91 . . . . 1.0 113.591 -176.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -51.46 -35.16 38.64 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.535 0.734 . . . . 1.0 112.793 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.89 85.42 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.175 0.893 . . . . 1.0 112.056 173.686 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.12 -38.01 72.32 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 118.656 1.228 . . . . 1.0 111.293 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -57.84 -39.95 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 117.922 -1.037 . . . . 1.0 109.86 168.061 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.41 86.25 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 120.176 1.353 . . . . 1.0 110.175 177.167 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.4 -47.21 51.5 Favored Glycine 0 CA--C 1.533 1.17 0 CA-C-O 119.48 -0.622 . . . . 1.0 111.84 166.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -68.25 -43.46 77.8 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.388 1.094 . . . . 1.0 113.043 177.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -44.18 -52.81 1.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.693 1.197 . . . . 1.0 109.33 168.268 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -79.06 2.08 21.87 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.907 1.283 . . . . 1.0 112.582 -176.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -86.83 11.23 13.77 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.361 0.982 . . . . 1.0 110.154 171.647 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.92 38.37 23.34 Favored Glycine 0 C--N 1.338 0.685 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 -170.676 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.8 t90 -38.43 -44.8 0.96 Allowed 'General case' 0 C--N 1.349 0.586 0 C-N-CA 123.915 0.886 . . . . 1.0 112.703 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -60.66 -23.54 64.88 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 113.781 1.03 . . . . 1.0 113.781 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.35 -31.88 29.73 Favored Glycine 0 C--N 1.34 0.804 0 CA-C-N 118.857 0.753 . . . . 1.0 111.478 170.217 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 16.3 mmt -68.82 -11.98 61.03 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.519 1.128 . . . . 1.0 112.356 176.353 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mt -65.46 -29.07 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.23 1.012 . . . . 1.0 109.729 168.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.4 t0 30.91 75.54 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 129.206 3.002 . . . . 1.0 114.118 177.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.932 0 CA-C-N 115.328 -0.851 . . . . 1.0 112.607 177.215 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.154 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -45.12 -43.55 9.83 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.29 1.836 . . . . 1.0 113.637 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -50.93 -34.28 27.97 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.984 0.914 . . . . 1.0 113.018 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.9 -36.56 86.83 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 123.981 0.8 . . . . 1.0 112.17 172.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.69 -36.07 73.11 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-N 118.316 1.058 . . . . 1.0 111.593 173.033 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mt -57.96 -39.64 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 118.016 -0.992 . . . . 1.0 110.067 168.023 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.68 91.3 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 120.072 1.306 . . . . 1.0 110.275 176.634 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.32 -48.66 59.15 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.692 -0.563 . . . . 1.0 111.692 167.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -63.23 -46.87 84.9 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 118.248 1.024 . . . . 1.0 112.157 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.5 mt -45.09 -45.2 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 125.295 1.438 . . . . 1.0 110.999 170.293 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -79.95 -8.05 59.12 Favored 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 112.791 0.663 . . . . 1.0 112.791 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -89.78 33.49 0.85 Allowed 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 120.408 1.458 . . . . 1.0 109.872 -174.265 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.3 22.93 73.15 Favored Glycine 0 CA--C 1.531 1.044 0 CA-C-O 118.17 -1.35 . . . . 1.0 112.504 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -41.42 -40.29 1.71 Allowed 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.039 1.336 . . . . 1.0 113.693 -179.007 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -51.31 -37.46 47.7 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.428 0.691 . . . . 1.0 111.996 -178.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.77 -9.56 75.17 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.754 -1.026 . . . . 1.0 113.836 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.6 ppp? -98.91 -8.23 25.94 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.76 1.28 . . . . 1.0 111.674 174.286 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.6 mt -66.39 -50.09 70.31 Favored 'Isoleucine or valine' 0 C--N 1.345 0.375 0 N-CA-C 108.878 -0.786 . . . . 1.0 108.878 176.648 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.5 t0 35.17 54.69 0.77 Allowed 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 128.51 2.724 . . . . 1.0 113.831 177.127 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.744 0 N-CA-C 109.772 -1.331 . . . . 1.0 109.772 -176.318 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.132 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -47.24 -43.61 22.03 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 125.862 1.665 . . . . 1.0 113.371 -176.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -51.87 -35.22 44.2 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.306 0.643 . . . . 1.0 112.671 178.693 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -32.51 76.18 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.243 0.925 . . . . 1.0 112.329 173.755 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.64 -37.81 65.22 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 118.826 1.313 . . . . 1.0 111.482 172.744 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.1 mt -58.4 -39.43 74.59 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 CA-C-O 118.453 -0.784 . . . . 1.0 109.787 167.31 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -40.44 93.79 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.8 1.182 . . . . 1.0 109.659 176.17 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.8 -46.67 39.63 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 124.029 0.823 . . . . 1.0 112.255 167.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -65.52 -49.98 66.97 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.488 1.144 . . . . 1.0 111.483 175.418 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -48.66 -32.09 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 C-N-CA 125.098 1.359 . . . . 1.0 112.135 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -89.81 -8.26 52.48 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-O 117.718 -1.134 . . . . 1.0 113.338 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.25 -15.98 0.45 Allowed 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.315 1.968 . . . . 1.0 116.315 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -144.9 -1.11 0.85 Allowed Glycine 0 CA--C 1.53 0.999 0 C-N-CA 125.875 1.703 . . . . 1.0 113.388 -175.335 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.0 t90 -37.7 -41.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 127.461 2.304 . . . . 1.0 113.759 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tm-20 -49.27 -37.01 22.25 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.238 1.415 . . . . 1.0 112.371 -175.394 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.31 -17.62 70.51 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-O 119.348 -0.695 . . . . 1.0 113.783 178.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.6 mmt -102.51 -7.78 21.6 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.577 1.951 . . . . 1.0 112.808 169.145 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 57.1 mt -66.9 -50.73 62.24 Favored 'Isoleucine or valine' 0 C--N 1.342 0.267 0 N-CA-C 106.19 -1.782 . . . . 1.0 106.19 162.681 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -64.16 168.05 5.88 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.216 1.007 . . . . 1.0 110.95 167.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.265 0 C-N-CA 124.305 0.955 . . . . 1.0 112.363 -170.281 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.195 0 N-CA-C 110.11 -1.196 . . . . 1.0 110.11 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp -46.1 -43.5 14.85 Favored 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 126.197 1.799 . . . . 1.0 113.686 -176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -51.09 -35.76 36.79 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.818 0.673 . . . . 1.0 112.818 178.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.57 -33.54 81.49 Favored Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.165 0.888 . . . . 1.0 112.135 174.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.54 -36.11 63.12 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 118.681 1.241 . . . . 1.0 111.889 174.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -57.91 -42.54 82.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 118.497 -0.763 . . . . 1.0 109.549 166.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.98 -35.89 82.62 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 119.34 0.973 . . . . 1.0 109.96 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -47.36 -59.56 5.76 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 118.53 -1.15 . . . . 1.0 111.487 163.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -59.27 -44.19 92.44 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 118.668 1.234 . . . . 1.0 112.143 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.7 mt -50.11 -24.89 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 125.671 1.588 . . . . 1.0 112.813 172.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.89 -1.16 17.94 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-N 119.468 1.031 . . . . 1.0 112.552 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -151.84 72.2 1.01 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.442 1.497 . . . . 1.0 108.524 -166.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 115.91 -5.03 20.53 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.538 -1.145 . . . . 1.0 113.761 173.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t90 -39.16 -41.99 0.9 Allowed 'General case' 0 C--N 1.343 0.297 0 C-N-CA 126.502 1.921 . . . . 1.0 113.044 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -50.81 -34.57 28.19 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.887 1.275 . . . . 1.0 112.438 -175.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.06 -18.7 67.15 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.675 -0.641 . . . . 1.0 113.725 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.43 -9.44 20.27 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.75 1.62 . . . . 1.0 113.038 169.098 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.9 mt -71.65 -43.14 71.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 166.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 44.4 t0 . . . . . 0 CA--C 1.542 0.644 0 C-N-CA 124.952 1.301 . . . . 1.0 111.588 172.583 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.32 -1.112 . . . . 1.0 110.32 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.5 tp -44.86 -43.69 8.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 C-N-CA 126.185 1.794 . . . . 1.0 113.51 -176.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -47.04 -35.51 6.87 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.83 1.252 . . . . 1.0 113.499 178.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.7 -42.88 86.52 Favored Glycine 0 CA--C 1.53 0.992 0 C-N-CA 123.913 0.768 . . . . 1.0 111.968 173.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.54 -30.17 70.42 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 118.356 1.078 . . . . 1.0 112.091 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.6 mt -54.57 -40.98 52.55 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-O 117.932 -1.033 . . . . 1.0 110.395 172.117 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.98 -29.31 70.16 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 120.416 1.462 . . . . 1.0 111.986 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.81 -47.84 64.71 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.885 -0.886 . . . . 1.0 110.885 169.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -60.27 -45.5 93.09 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.899 0.85 . . . . 1.0 112.653 177.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.2 mt -40.39 -50.25 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 C-N-CA 125.918 1.687 . . . . 1.0 110.937 168.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 mm-40 -79.87 -3.98 50.3 Favored 'General case' 0 CA--C 1.539 0.525 0 N-CA-C 113.037 0.754 . . . . 1.0 113.037 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -98.92 21.34 11.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 120.0 1.273 . . . . 1.0 110.583 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 24.77 47.54 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 118.849 -0.973 . . . . 1.0 112.015 -176.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -37.34 -49.91 1.01 Allowed 'General case' 0 C--N 1.347 0.477 0 C-N-CA 124.18 0.992 . . . . 1.0 112.615 173.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -59.08 -25.1 63.49 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.42 0.896 . . . . 1.0 113.42 -171.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.36 -43.59 6.93 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.529 -1.029 . . . . 1.0 110.529 171.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 5.7 ttt -63.58 -7.53 7.41 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.261 1.824 . . . . 1.0 114.057 177.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 66.3 mt -55.0 -30.37 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 C-N-CA 124.563 1.145 . . . . 1.0 110.649 162.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.7 t0 . . . . . 0 CA--C 1.537 0.451 0 CA-C-O 121.749 0.785 . . . . 1.0 111.111 178.358 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 109.995 -1.242 . . . . 1.0 109.995 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.8 tp -47.73 -43.7 27.27 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 125.647 1.579 . . . . 1.0 113.173 -176.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.91 -34.51 55.46 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.551 0.74 . . . . 1.0 112.582 179.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.89 -34.4 82.28 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 124.223 0.916 . . . . 1.0 112.041 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.7 -34.12 66.93 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 118.639 1.22 . . . . 1.0 111.806 172.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -59.15 -40.99 82.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 CA-C-N 119.313 0.96 . . . . 1.0 109.774 167.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.86 -39.89 94.26 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 119.767 1.167 . . . . 1.0 109.828 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.29 -49.49 31.35 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 119.163 -0.798 . . . . 1.0 112.023 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.3 t80 -64.68 -47.76 77.23 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.437 1.118 . . . . 1.0 111.686 177.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -47.99 -34.5 4.48 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.746 1.219 . . . . 1.0 111.735 172.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -91.46 -3.5 56.54 Favored 'General case' 0 CA--C 1.542 0.652 0 CA-C-O 117.867 -1.064 . . . . 1.0 113.318 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -145.11 -15.9 0.51 Allowed 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 115.956 1.836 . . . . 1.0 115.956 -166.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.44 0.55 0.39 Allowed Glycine 0 CA--C 1.529 0.925 0 CA-C-O 118.027 -1.429 . . . . 1.0 113.575 -174.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.3 t90 -38.41 -42.71 0.76 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.445 1.898 . . . . 1.0 113.519 -177.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -49.7 -34.78 19.72 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.967 1.307 . . . . 1.0 112.42 -177.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.69 -16.66 70.22 Favored Glycine 0 CA--C 1.533 1.184 0 CA-C-O 119.377 -0.679 . . . . 1.0 113.993 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.7 mtp -102.2 -8.19 21.54 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.328 1.451 . . . . 1.0 112.499 168.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mt -74.1 -54.65 14.42 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 107.136 -1.431 . . . . 1.0 107.136 165.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.3 t70 . . . . . 0 CA--C 1.543 0.697 0 C-N-CA 125.502 1.521 . . . . 1.0 110.712 -173.831 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.125 0 N-CA-C 110.27 -1.132 . . . . 1.0 110.27 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -45.59 -43.74 12.38 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 126.484 1.914 . . . . 1.0 113.89 -176.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.23 -35.3 49.23 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.301 0.572 . . . . 1.0 112.481 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -32.74 79.74 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.298 0.951 . . . . 1.0 112.078 174.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.32 -37.4 63.6 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.89 1.345 . . . . 1.0 111.658 173.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -58.36 -40.94 80.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-O 118.647 -0.692 . . . . 1.0 109.635 167.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.85 -35.89 81.94 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.421 1.01 . . . . 1.0 109.984 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.32 -56.43 10.79 Favored Glycine 0 CA--C 1.531 1.032 0 CA-C-O 118.862 -0.965 . . . . 1.0 111.359 164.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -60.74 -41.49 95.48 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.524 1.162 . . . . 1.0 112.396 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -51.52 -25.09 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 125.313 1.445 . . . . 1.0 112.56 170.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -105.32 -0.08 26.56 Favored 'General case' 0 CA--C 1.545 0.783 0 CA-C-N 119.459 1.027 . . . . 1.0 112.776 174.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -149.99 71.67 1.09 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 125.261 1.424 . . . . 1.0 108.767 -165.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 5.24 47.85 Favored Glycine 0 CA--C 1.528 0.904 0 CA-C-O 118.608 -1.107 . . . . 1.0 114.165 171.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -37.63 -44.78 0.72 Allowed 'General case' 0 C--N 1.343 0.294 0 C-N-CA 127.118 2.167 . . . . 1.0 113.737 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -48.06 -35.65 11.58 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.279 1.832 . . . . 1.0 112.219 -170.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.98 -27.83 65.25 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.598 -0.689 . . . . 1.0 113.484 178.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -95.19 -18.58 20.78 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.275 1.83 . . . . 1.0 111.963 176.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.9 mt -67.79 -50.03 63.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 168.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 30.1 t70 . . . . . 0 CA--C 1.533 0.325 0 C-N-CA 125.675 1.59 . . . . 1.0 110.793 170.367 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 110.086 -1.206 . . . . 1.0 110.086 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.8 tp -46.53 -43.72 17.19 Favored 'General case' 0 CA--C 1.513 -0.466 0 C-N-CA 126.113 1.765 . . . . 1.0 113.388 -177.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -51.74 -34.67 40.24 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.787 0.662 . . . . 1.0 112.787 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.21 -35.84 90.95 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.114 0.864 . . . . 1.0 112.243 173.116 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.95 -40.23 72.13 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.486 1.143 . . . . 1.0 111.264 173.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -56.7 -38.79 59.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-O 118.425 -0.798 . . . . 1.0 110.083 168.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -68.82 -26.14 65.03 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 119.703 1.138 . . . . 1.0 111.705 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.53 -55.42 27.44 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.48 -1.048 . . . . 1.0 110.48 163.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -55.16 -38.33 68.14 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 123.957 0.903 . . . . 1.0 112.146 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 mt -49.29 -26.54 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 126.298 1.839 . . . . 1.0 112.57 172.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -112.26 -4.92 14.23 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 119.931 1.241 . . . . 1.0 112.029 175.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -150.07 66.5 0.97 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 125.488 1.515 . . . . 1.0 108.11 -163.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.73 -20.9 4.05 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.957 -0.913 . . . . 1.0 112.405 178.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.6 t90 -46.86 -42.86 18.04 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 124.441 1.097 . . . . 1.0 111.259 174.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -59.22 -26.96 65.31 Favored 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 123.889 0.876 . . . . 1.0 113.052 -177.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.54 -13.76 82.65 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 119.385 -0.675 . . . . 1.0 113.137 172.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.2 ttt -101.59 -19.91 15.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.189 1.796 . . . . 1.0 111.833 173.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.9 mt -65.67 -48.53 82.14 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 162.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.7 t0 . . . . . 0 N--CA 1.467 0.39 0 C-N-CA 126.298 1.839 . . . . 1.0 111.282 -174.03 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.104 0 N-CA-C 110.18 -1.168 . . . . 1.0 110.18 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -46.91 -43.77 19.19 Favored 'General case' 0 CA--C 1.515 -0.368 0 C-N-CA 126.115 1.766 . . . . 1.0 113.532 -176.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.54 -34.51 58.5 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 121.455 0.645 . . . . 1.0 112.431 179.314 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.74 -34.17 86.53 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.114 0.864 . . . . 1.0 112.006 173.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.01 -36.1 66.95 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 118.642 1.221 . . . . 1.0 111.692 173.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -58.09 -41.82 81.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 118.967 0.803 . . . . 1.0 109.628 166.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.54 -31.63 72.47 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.507 1.049 . . . . 1.0 110.61 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.97 -58.47 12.55 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 119.065 -0.853 . . . . 1.0 110.97 162.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -55.77 -42.66 75.84 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 118.67 1.235 . . . . 1.0 112.16 -178.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.1 mt -50.16 -23.97 1.84 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 C-N-CA 125.929 1.691 . . . . 1.0 113.236 171.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 -113.0 -1.81 14.39 Favored 'General case' 0 CA--C 1.543 0.711 0 CA-C-N 119.698 1.135 . . . . 1.0 111.914 173.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -146.95 65.9 1.16 Allowed 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.638 1.575 . . . . 1.0 108.335 -164.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 117.66 -3.42 17.57 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.394 -1.225 . . . . 1.0 114.069 175.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.8 t90 -38.56 -39.6 0.49 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 126.865 2.066 . . . . 1.0 113.166 176.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -50.36 -33.61 21.09 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.37 1.068 . . . . 1.0 112.419 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.93 -23.14 65.41 Favored Glycine 0 CA--C 1.534 1.25 0 O-C-N 121.353 -0.842 . . . . 1.0 113.594 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 23.8 mmt -102.0 -8.32 21.6 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.448 1.899 . . . . 1.0 112.478 172.497 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.8 mt -71.58 -23.97 23.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 N-CA-C 108.492 -0.929 . . . . 1.0 108.492 160.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t0 . . . . . 0 C--N 1.344 0.326 0 C-N-CA 128.169 2.588 . . . . 1.0 113.669 159.614 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.144 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.8 tp -48.43 -43.66 34.53 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 125.504 1.522 . . . . 1.0 113.273 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.11 -35.06 59.25 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.395 0.678 . . . . 1.0 112.376 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.31 -33.65 78.3 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 124.336 0.97 . . . . 1.0 112.156 173.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.59 -38.77 67.76 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 118.71 1.255 . . . . 1.0 111.48 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.77 -39.82 72.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 118.467 -0.778 . . . . 1.0 110.01 167.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.79 95.5 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.663 1.119 . . . . 1.0 109.683 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.33 -45.21 52.86 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.955 -0.914 . . . . 1.0 112.38 168.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 52.1 t80 -65.96 -50.71 63.4 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.755 1.278 . . . . 1.0 111.47 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mt -47.64 -31.74 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 C-N-CA 125.667 1.587 . . . . 1.0 112.347 170.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -91.02 -8.06 50.16 Favored 'General case' 0 CA--C 1.544 0.712 0 CA-C-O 117.696 -1.145 . . . . 1.0 113.628 178.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.04 -15.94 0.46 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 116.381 1.993 . . . . 1.0 116.381 -166.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.0 1.12 0.65 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 124.925 1.25 . . . . 1.0 113.32 -176.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.5 t90 -40.32 -43.14 1.68 Allowed 'General case' 0 C--N 1.343 0.302 0 C-N-CA 127.12 2.168 . . . . 1.0 113.809 -171.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -51.75 -33.62 35.7 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.802 1.241 . . . . 1.0 112.177 -169.447 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.99 -13.92 62.57 Favored Glycine 0 CA--C 1.537 1.451 0 CA-C-O 118.988 -0.895 . . . . 1.0 114.389 178.143 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 27.8 ttt -102.47 -13.35 17.28 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.284 1.834 . . . . 1.0 111.928 170.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.9 mt -75.34 -48.31 31.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 N-CA-C 107.254 -1.388 . . . . 1.0 107.254 170.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 . . . . . 0 CA--C 1.537 0.464 0 N-CA-C 109.554 -0.536 . . . . 1.0 109.554 162.746 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.143 0 N-CA-C 110.186 -1.166 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.3 tp -46.6 -43.76 17.6 Favored 'General case' 0 CA--C 1.515 -0.399 0 C-N-CA 126.231 1.812 . . . . 1.0 113.507 -176.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -53.48 -34.17 57.04 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 121.494 0.664 . . . . 1.0 112.462 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.43 -34.59 85.2 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.241 0.925 . . . . 1.0 112.046 173.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.13 -37.36 69.47 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 118.653 1.227 . . . . 1.0 111.538 173.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.21 -41.4 77.9 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-O 118.358 -0.83 . . . . 1.0 109.796 167.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.75 -33.7 76.48 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 119.832 1.196 . . . . 1.0 110.733 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.01 -54.65 30.15 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 118.927 -0.929 . . . . 1.0 111.416 164.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -59.8 -42.59 93.74 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.31 1.055 . . . . 1.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -50.27 -24.17 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 C-N-CA 125.856 1.663 . . . . 1.0 112.898 171.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -108.69 -1.67 19.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.58 1.152 . . . . 1.0 112.229 175.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -155.48 71.79 0.78 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.684 1.594 . . . . 1.0 108.709 -165.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 120.69 -9.49 10.64 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-O 118.949 -0.917 . . . . 1.0 113.531 174.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -37.13 -44.4 0.55 Allowed 'General case' 0 C--N 1.343 0.301 0 C-N-CA 126.88 2.072 . . . . 1.0 112.641 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.4 pm0 -53.75 -29.13 38.41 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 124.882 1.273 . . . . 1.0 112.68 -175.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.1 -15.51 74.45 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 118.932 0.787 . . . . 1.0 113.811 175.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.5 mmt -102.25 -8.08 21.57 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.215 1.806 . . . . 1.0 112.201 169.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.0 mt -77.5 -43.91 30.0 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.328 -1.36 . . . . 1.0 107.328 164.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 43.3 t0 . . . . . 0 CA--C 1.539 0.52 0 C-N-CA 123.645 0.778 . . . . 1.0 110.473 167.03 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp -46.38 -43.44 16.23 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.245 1.818 . . . . 1.0 113.586 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -51.38 -35.43 38.77 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.527 0.731 . . . . 1.0 112.836 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.65 -36.92 92.02 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 124.042 0.83 . . . . 1.0 111.713 173.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.03 -34.24 71.09 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 118.525 1.163 . . . . 1.0 111.872 174.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.2 mt -58.94 -42.06 84.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 119.306 0.957 . . . . 1.0 109.747 167.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.55 73.91 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.622 1.101 . . . . 1.0 110.505 177.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.16 -55.14 27.8 Favored Glycine 0 CA--C 1.532 1.15 0 CA-C-O 119.197 -0.779 . . . . 1.0 111.336 164.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -60.56 -39.75 89.11 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.93 1.292 . . . . 1.0 112.474 -179.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.4 mt -50.49 -24.04 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 125.694 1.598 . . . . 1.0 112.764 169.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.36 0.13 19.31 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.27 1.028 . . . . 1.0 112.369 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -150.51 70.83 1.03 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.693 1.597 . . . . 1.0 108.862 -166.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 107.19 2.89 35.94 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.67 -1.072 . . . . 1.0 114.202 172.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -35.9 -43.43 0.31 Allowed 'General case' 0 C--N 1.343 0.311 0 C-N-CA 127.966 2.506 . . . . 1.0 113.531 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -49.77 -33.64 16.99 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.422 1.489 . . . . 1.0 112.15 -174.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.29 -18.21 64.91 Favored Glycine 0 CA--C 1.537 1.453 0 CA-C-O 119.18 -0.789 . . . . 1.0 114.149 177.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.6 ttt -102.36 -10.69 19.25 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.251 1.82 . . . . 1.0 112.052 171.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mt -75.13 -40.67 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 167.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 . . . . . 0 CA--C 1.538 0.517 0 C-N-CA 123.783 0.833 . . . . 1.0 110.807 167.579 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.14 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -45.27 -43.48 10.57 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.431 1.892 . . . . 1.0 113.608 -176.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -50.4 -34.22 23.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.12 0.968 . . . . 1.0 112.951 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.93 -37.15 87.69 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.156 0.884 . . . . 1.0 112.213 173.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.13 -32.17 71.36 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.424 1.112 . . . . 1.0 111.527 173.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -58.08 -40.01 75.15 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 CA-C-O 118.072 -0.966 . . . . 1.0 109.907 170.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.71 -25.99 67.55 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 120.299 1.409 . . . . 1.0 111.82 176.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.79 -54.21 35.33 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.795 -0.922 . . . . 1.0 110.795 165.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -58.27 -34.11 70.15 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.604 1.162 . . . . 1.0 112.914 177.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.418 ' HA ' ' HB2' ' A' ' 14' ' ' TRP . 1.2 mt -53.1 -28.73 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.802 1.241 . . . . 1.0 111.726 172.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -102.6 -0.17 32.4 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.164 0.986 . . . . 1.0 111.912 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 -151.81 66.54 0.86 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.305 1.442 . . . . 1.0 108.857 -163.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.23 -2.37 14.3 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.247 -1.307 . . . . 1.0 114.455 176.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.418 ' HB2' ' HA ' ' A' ' 10' ' ' ILE . 2.6 t90 -45.15 -34.23 2.6 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.199 1.4 . . . . 1.0 114.169 174.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.0 tm-20 -54.38 -35.58 62.98 Favored 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 118.621 0.646 . . . . 1.0 111.197 175.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.23 -8.05 82.97 Favored Glycine 0 CA--C 1.531 1.091 0 C-N-CA 125.16 1.362 . . . . 1.0 113.959 176.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 10.1 ptm -102.21 -10.26 19.73 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 119.284 1.542 . . . . 1.0 112.541 164.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -75.57 -43.46 41.53 Favored 'Isoleucine or valine' 0 C--N 1.341 0.216 0 N-CA-C 107.073 -1.454 . . . . 1.0 107.073 163.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.0 t0 . . . . . 0 CA--C 1.537 0.446 0 C-N-CA 119.443 -0.903 . . . . 1.0 108.925 160.441 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.129 0 N-CA-C 110.062 -1.215 . . . . 1.0 110.062 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -47.86 -43.68 28.59 Favored 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 125.517 1.527 . . . . 1.0 113.401 -176.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -51.9 -35.42 45.33 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.775 0.657 . . . . 1.0 112.775 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.78 -34.64 87.92 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.022 0.82 . . . . 1.0 112.101 173.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.99 -36.8 67.13 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 118.477 1.139 . . . . 1.0 111.612 173.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.22 -39.76 74.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-O 118.237 -0.887 . . . . 1.0 109.7 167.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.24 -41.01 97.18 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 119.748 1.158 . . . . 1.0 109.766 175.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.08 -39.22 49.21 Favored Glycine 0 CA--C 1.535 1.32 0 CA-C-O 118.961 -0.911 . . . . 1.0 113.018 169.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.9 t80 -73.14 -47.8 40.98 Favored 'General case' 0 C--N 1.341 0.227 0 CA-C-N 118.819 1.31 . . . . 1.0 112.451 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -43.84 -51.78 1.42 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 C-N-CA 124.76 1.224 . . . . 1.0 110.13 169.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -77.03 -0.93 26.39 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.265 1.426 . . . . 1.0 112.033 -177.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -81.17 -0.43 40.31 Favored 'General case' 0 C--N 1.343 0.286 0 O-C-N 120.945 -1.097 . . . . 1.0 111.662 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.41 36.42 20.45 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.256 -1.302 . . . . 1.0 110.195 -160.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -35.44 -39.14 0.12 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 125.539 1.536 . . . . 1.0 113.926 171.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -52.46 -32.33 39.11 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.563 0.949 . . . . 1.0 113.563 178.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.28 -12.96 66.86 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 119.169 -0.795 . . . . 1.0 113.236 176.033 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.5 mpt? -102.28 -9.57 20.27 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.873 1.669 . . . . 1.0 111.976 171.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 53.4 mt -73.64 -49.74 33.93 Favored 'Isoleucine or valine' 0 C--N 1.341 0.218 0 N-CA-C 107.348 -1.353 . . . . 1.0 107.348 173.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.8 t0 . . . . . 0 CA--C 1.534 0.356 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 164.336 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.167 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.4 tp -48.48 -43.75 35.1 Favored 'General case' 0 CA--C 1.514 -0.406 0 C-N-CA 125.411 1.485 . . . . 1.0 113.421 -176.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -55.09 -34.17 63.41 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.46 0.648 . . . . 1.0 112.077 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.35 -31.02 73.64 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 124.341 0.972 . . . . 1.0 112.083 173.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.98 -36.11 62.04 Favored 'General case' 0 N--CA 1.456 -0.148 0 CA-C-N 118.998 1.399 . . . . 1.0 111.684 172.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 mt -59.37 -39.5 79.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-N 119.157 0.889 . . . . 1.0 109.757 167.351 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.24 -41.25 94.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 119.379 0.99 . . . . 1.0 109.53 175.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.15 -44.09 51.1 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.978 -0.901 . . . . 1.0 112.529 168.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -65.69 -51.58 58.26 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.79 1.295 . . . . 1.0 110.807 174.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.6 mt -47.89 -30.74 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 125.405 1.482 . . . . 1.0 112.502 171.172 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -91.38 -9.36 45.07 Favored 'General case' 0 CA--C 1.545 0.774 0 CA-C-O 117.723 -1.132 . . . . 1.0 113.602 178.537 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -145.49 -15.86 0.49 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 116.149 1.907 . . . . 1.0 116.149 -166.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.1 2.44 0.52 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 125.385 1.469 . . . . 1.0 113.487 -174.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.6 t90 -39.8 -41.34 1.11 Allowed 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 127.311 2.244 . . . . 1.0 113.727 -174.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -52.19 -31.27 31.0 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.845 1.258 . . . . 1.0 112.224 -169.244 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.77 -8.46 63.79 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-O 118.755 -1.025 . . . . 1.0 114.852 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.5 -12.5 17.76 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 126.162 1.785 . . . . 1.0 112.928 164.311 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.5 mt -79.24 -55.59 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.019 -1.845 . . . . 1.0 106.019 173.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.9 t0 . . . . . 0 CA--C 1.534 0.339 0 N-CA-C 108.381 -0.97 . . . . 1.0 108.381 158.798 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 . . . . . 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 . . . . . 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.217 0 N-CA-C 110.196 -1.162 . . . . 1.0 110.196 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.4 tp -45.83 -43.74 13.66 Favored 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 126.283 1.833 . . . . 1.0 113.469 -176.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -50.74 -35.05 29.53 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.54 0.736 . . . . 1.0 112.924 178.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.19 87.46 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.027 0.822 . . . . 1.0 112.122 173.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.89 -39.85 72.56 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.478 1.139 . . . . 1.0 111.349 173.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -56.72 -40.23 68.72 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-O 118.224 -0.893 . . . . 1.0 109.914 167.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.78 -31.85 72.75 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 120.136 1.335 . . . . 1.0 110.796 179.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.25 -55.3 31.11 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.915 -0.874 . . . . 1.0 110.915 164.503 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -55.85 -43.06 76.73 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 118.043 0.921 . . . . 1.0 111.977 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.8 mt -50.47 -26.65 3.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 125.431 1.493 . . . . 1.0 112.564 173.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -109.69 5.33 22.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.564 1.146 . . . . 1.0 112.164 178.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -138.06 -15.72 1.3 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 114.532 1.308 . . . . 1.0 114.532 -169.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -158.28 0.34 0.09 OUTLIER Glycine 0 CA--C 1.529 0.957 0 C-N-CA 125.146 1.355 . . . . 1.0 113.845 -174.13 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.1 t90 -44.79 -38.63 4.64 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 119.016 1.408 . . . . 1.0 113.074 176.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -57.05 -30.96 64.69 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 118.998 0.817 . . . . 1.0 112.145 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.18 -23.24 77.38 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 121.31 -0.869 . . . . 1.0 112.757 173.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 6.5 ptt? -92.67 -16.34 25.66 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.947 1.374 . . . . 1.0 112.5 173.752 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.7 mt -64.2 -56.71 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 106.562 -1.644 . . . . 1.0 106.562 160.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.2 t70 . . . . . 0 CA--C 1.534 0.351 0 C-N-CA 124.065 0.946 . . . . 1.0 111.08 176.255 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.201 0 N-CA-C 110.195 -1.162 . . . . 1.0 110.195 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -46.39 -43.61 16.39 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 126.123 1.769 . . . . 1.0 113.635 -176.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.9 -34.16 53.67 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.655 0.782 . . . . 1.0 112.684 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.15 -35.49 83.41 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 124.032 0.825 . . . . 1.0 111.959 172.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.77 -31.68 68.55 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 118.561 1.18 . . . . 1.0 111.825 173.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -59.77 -42.46 88.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 119.461 1.028 . . . . 1.0 109.578 167.446 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.59 -31.0 71.42 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 119.568 1.076 . . . . 1.0 110.738 177.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -56.1 25.81 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 111.073 -0.811 . . . . 1.0 111.073 164.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -58.25 -39.45 79.19 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.392 1.096 . . . . 1.0 112.396 -179.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.1 mt -51.2 -24.21 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 125.546 1.539 . . . . 1.0 112.862 170.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -109.96 0.2 18.46 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.719 1.145 . . . . 1.0 112.06 173.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -145.17 66.54 1.24 Allowed 'General case' 0 CA--C 1.535 0.372 0 O-C-N 120.297 -1.502 . . . . 1.0 108.709 -165.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 108.04 2.05 33.92 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 118.661 -1.077 . . . . 1.0 114.36 173.404 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -37.72 -43.97 0.68 Allowed 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 127.195 2.198 . . . . 1.0 113.662 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.33 -38.68 19.73 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.659 1.584 . . . . 1.0 111.951 -174.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -63.68 -22.04 65.69 Favored Glycine 0 CA--C 1.534 1.239 0 CA-C-O 119.235 -0.758 . . . . 1.0 113.543 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 mmt -102.18 -9.39 20.52 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.94 1.696 . . . . 1.0 113.042 172.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.7 mt -68.99 -48.37 70.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 106.646 -1.612 . . . . 1.0 106.646 162.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 8.3 t70 . . . . . 0 CA--C 1.534 0.346 0 C-N-CA 124.79 1.236 . . . . 1.0 110.472 169.552 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.163 0 N-CA-C 110.025 -1.23 . . . . 1.0 110.025 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -48.16 -43.67 31.68 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 125.588 1.555 . . . . 1.0 113.387 -177.087 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -52.16 -35.84 49.88 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.761 0.652 . . . . 1.0 112.761 178.207 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.83 -32.4 81.02 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 124.304 0.954 . . . . 1.0 112.103 174.067 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -38.91 58.06 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 118.783 1.292 . . . . 1.0 111.635 174.188 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.17 -39.45 73.25 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 CA-C-N 118.772 0.714 . . . . 1.0 109.861 167.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.74 -38.31 86.37 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 119.323 0.965 . . . . 1.0 109.677 176.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.13 -50.63 27.68 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 123.897 0.761 . . . . 1.0 111.747 165.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -62.46 -48.18 80.77 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.82 1.31 . . . . 1.0 111.211 175.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mt -49.83 -37.48 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-N 119.254 0.934 . . . . 1.0 111.942 172.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.9 mm-40 -87.29 -4.52 59.07 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.383 -0.823 . . . . 1.0 112.825 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -140.19 -15.93 0.97 Allowed 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 120.875 1.67 . . . . 1.0 114.656 -166.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.85 3.56 0.42 Allowed Glycine 0 CA--C 1.528 0.857 0 C-N-CA 126.298 1.904 . . . . 1.0 113.136 -172.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -46.0 -33.87 3.65 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 119.213 1.506 . . . . 1.0 113.454 174.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -55.91 -32.99 64.26 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 119.565 1.075 . . . . 1.0 111.538 177.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.56 -7.75 83.35 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.283 1.42 . . . . 1.0 114.151 174.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.2 ptm -102.63 -8.46 20.92 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.308 1.554 . . . . 1.0 113.189 163.408 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mt -72.42 -56.68 9.15 Favored 'Isoleucine or valine' 0 C--N 1.344 0.354 0 N-CA-C 106.029 -1.841 . . . . 1.0 106.029 161.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 . . . . . 0 CA--C 1.535 0.384 0 N-CA-C 109.16 -0.681 . . . . 1.0 109.16 165.745 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.174 0 N-CA-C 110.216 -1.154 . . . . 1.0 110.216 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.3 tp -45.85 -43.61 13.63 Favored 'General case' 0 CA--C 1.515 -0.377 0 C-N-CA 126.474 1.91 . . . . 1.0 113.591 -176.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -51.46 -35.16 38.64 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.535 0.734 . . . . 1.0 112.793 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.89 85.42 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.175 0.893 . . . . 1.0 112.056 173.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.12 -38.01 72.32 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 118.656 1.228 . . . . 1.0 111.293 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -57.84 -39.95 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 117.922 -1.037 . . . . 1.0 109.86 168.061 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.41 86.25 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 120.176 1.353 . . . . 1.0 110.175 177.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.4 -47.21 51.5 Favored Glycine 0 CA--C 1.533 1.17 0 CA-C-O 119.48 -0.622 . . . . 1.0 111.84 166.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -68.25 -43.46 77.8 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.388 1.094 . . . . 1.0 113.043 177.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -44.18 -52.81 1.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.693 1.197 . . . . 1.0 109.33 168.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -79.06 2.08 21.87 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.907 1.283 . . . . 1.0 112.582 -176.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -86.83 11.23 13.77 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.361 0.982 . . . . 1.0 110.154 171.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.92 38.37 23.34 Favored Glycine 0 C--N 1.338 0.685 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 -170.676 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.8 t90 -38.43 -44.8 0.96 Allowed 'General case' 0 C--N 1.349 0.586 0 C-N-CA 123.915 0.886 . . . . 1.0 112.703 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -60.66 -23.54 64.88 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 113.781 1.03 . . . . 1.0 113.781 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.35 -31.88 29.73 Favored Glycine 0 C--N 1.34 0.804 0 CA-C-N 118.857 0.753 . . . . 1.0 111.478 170.217 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 16.3 mmt -68.82 -11.98 61.03 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.519 1.128 . . . . 1.0 112.356 176.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mt -65.46 -29.07 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.23 1.012 . . . . 1.0 109.729 168.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.4 t0 . . . . . 0 CA--C 1.535 0.393 0 C-N-CA 129.206 3.002 . . . . 1.0 114.118 177.724 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.154 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -45.12 -43.55 9.83 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.29 1.836 . . . . 1.0 113.637 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -50.93 -34.28 27.97 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.984 0.914 . . . . 1.0 113.018 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.9 -36.56 86.83 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 123.981 0.8 . . . . 1.0 112.17 172.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.69 -36.07 73.11 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-N 118.316 1.058 . . . . 1.0 111.593 173.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mt -57.96 -39.64 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 118.016 -0.992 . . . . 1.0 110.067 168.023 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.68 91.3 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 120.072 1.306 . . . . 1.0 110.275 176.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.32 -48.66 59.15 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.692 -0.563 . . . . 1.0 111.692 167.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -63.23 -46.87 84.9 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 118.248 1.024 . . . . 1.0 112.157 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.5 mt -45.09 -45.2 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 125.295 1.438 . . . . 1.0 110.999 170.293 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -79.95 -8.05 59.12 Favored 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 112.791 0.663 . . . . 1.0 112.791 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -89.78 33.49 0.85 Allowed 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 120.408 1.458 . . . . 1.0 109.872 -174.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.3 22.93 73.15 Favored Glycine 0 CA--C 1.531 1.044 0 CA-C-O 118.17 -1.35 . . . . 1.0 112.504 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -41.42 -40.29 1.71 Allowed 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.039 1.336 . . . . 1.0 113.693 -179.007 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -51.31 -37.46 47.7 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.428 0.691 . . . . 1.0 111.996 -178.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.77 -9.56 75.17 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.754 -1.026 . . . . 1.0 113.836 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.6 ppp? -98.91 -8.23 25.94 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.76 1.28 . . . . 1.0 111.674 174.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.6 mt -66.39 -50.09 70.31 Favored 'Isoleucine or valine' 0 C--N 1.345 0.375 0 N-CA-C 108.878 -0.786 . . . . 1.0 108.878 176.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.5 t0 . . . . . 0 CA--C 1.54 0.58 0 C-N-CA 128.51 2.724 . . . . 1.0 113.831 177.127 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.132 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -47.24 -43.61 22.03 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 125.862 1.665 . . . . 1.0 113.371 -176.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -51.87 -35.22 44.2 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.306 0.643 . . . . 1.0 112.671 178.693 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -32.51 76.18 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.243 0.925 . . . . 1.0 112.329 173.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.64 -37.81 65.22 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 118.826 1.313 . . . . 1.0 111.482 172.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.1 mt -58.4 -39.43 74.59 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 CA-C-O 118.453 -0.784 . . . . 1.0 109.787 167.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -40.44 93.79 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.8 1.182 . . . . 1.0 109.659 176.17 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.8 -46.67 39.63 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 124.029 0.823 . . . . 1.0 112.255 167.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -65.52 -49.98 66.97 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.488 1.144 . . . . 1.0 111.483 175.418 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -48.66 -32.09 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 C-N-CA 125.098 1.359 . . . . 1.0 112.135 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -89.81 -8.26 52.48 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-O 117.718 -1.134 . . . . 1.0 113.338 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.25 -15.98 0.45 Allowed 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.315 1.968 . . . . 1.0 116.315 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -144.9 -1.11 0.85 Allowed Glycine 0 CA--C 1.53 0.999 0 C-N-CA 125.875 1.703 . . . . 1.0 113.388 -175.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.0 t90 -37.7 -41.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 127.461 2.304 . . . . 1.0 113.759 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tm-20 -49.27 -37.01 22.25 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.238 1.415 . . . . 1.0 112.371 -175.394 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.31 -17.62 70.51 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-O 119.348 -0.695 . . . . 1.0 113.783 178.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.6 mmt -102.51 -7.78 21.6 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.577 1.951 . . . . 1.0 112.808 169.145 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 57.1 mt -66.9 -50.73 62.24 Favored 'Isoleucine or valine' 0 C--N 1.342 0.267 0 N-CA-C 106.19 -1.782 . . . . 1.0 106.19 162.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.9 t0 . . . . . 0 CA--C 1.542 0.636 0 C-N-CA 124.216 1.007 . . . . 1.0 110.95 167.764 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.195 0 N-CA-C 110.11 -1.196 . . . . 1.0 110.11 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp -46.1 -43.5 14.85 Favored 'General case' 0 CA--C 1.513 -0.443 0 C-N-CA 126.197 1.799 . . . . 1.0 113.686 -176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -51.09 -35.76 36.79 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.818 0.673 . . . . 1.0 112.818 178.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.57 -33.54 81.49 Favored Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.165 0.888 . . . . 1.0 112.135 174.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.54 -36.11 63.12 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 118.681 1.241 . . . . 1.0 111.889 174.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -57.91 -42.54 82.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 118.497 -0.763 . . . . 1.0 109.549 166.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.98 -35.89 82.62 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 119.34 0.973 . . . . 1.0 109.96 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -47.36 -59.56 5.76 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 118.53 -1.15 . . . . 1.0 111.487 163.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -59.27 -44.19 92.44 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 118.668 1.234 . . . . 1.0 112.143 -178.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.7 mt -50.11 -24.89 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 125.671 1.588 . . . . 1.0 112.813 172.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.89 -1.16 17.94 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-N 119.468 1.031 . . . . 1.0 112.552 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -151.84 72.2 1.01 Allowed 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 125.442 1.497 . . . . 1.0 108.524 -166.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 115.91 -5.03 20.53 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.538 -1.145 . . . . 1.0 113.761 173.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.0 t90 -39.16 -41.99 0.9 Allowed 'General case' 0 C--N 1.343 0.297 0 C-N-CA 126.502 1.921 . . . . 1.0 113.044 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -50.81 -34.57 28.19 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.887 1.275 . . . . 1.0 112.438 -175.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.06 -18.7 67.15 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.675 -0.641 . . . . 1.0 113.725 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.43 -9.44 20.27 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.75 1.62 . . . . 1.0 113.038 169.098 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 38.9 mt -71.65 -43.14 71.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 107.704 -1.221 . . . . 1.0 107.704 166.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -58.08 167.36 1.28 Allowed 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.952 1.301 . . . . 1.0 111.588 172.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.958 0 C-N-CA 125.575 1.56 . . . . 1.0 111.432 -173.707 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.32 -1.112 . . . . 1.0 110.32 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.5 tp -44.86 -43.69 8.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 C-N-CA 126.185 1.794 . . . . 1.0 113.51 -176.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -47.04 -35.51 6.87 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.83 1.252 . . . . 1.0 113.499 178.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.7 -42.88 86.52 Favored Glycine 0 CA--C 1.53 0.992 0 C-N-CA 123.913 0.768 . . . . 1.0 111.968 173.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.54 -30.17 70.42 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 118.356 1.078 . . . . 1.0 112.091 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.6 mt -54.57 -40.98 52.55 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-O 117.932 -1.033 . . . . 1.0 110.395 172.117 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -61.98 -29.31 70.16 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 120.416 1.462 . . . . 1.0 111.986 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.81 -47.84 64.71 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.885 -0.886 . . . . 1.0 110.885 169.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -60.27 -45.5 93.09 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.899 0.85 . . . . 1.0 112.653 177.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.2 mt -40.39 -50.25 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 C-N-CA 125.918 1.687 . . . . 1.0 110.937 168.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 mm-40 -79.87 -3.98 50.3 Favored 'General case' 0 CA--C 1.539 0.525 0 N-CA-C 113.037 0.754 . . . . 1.0 113.037 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 71.8 m-20 -98.92 21.34 11.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 120.0 1.273 . . . . 1.0 110.583 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 24.77 47.54 Favored Glycine 0 CA--C 1.528 0.863 0 CA-C-O 118.849 -0.973 . . . . 1.0 112.015 -176.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -37.34 -49.91 1.01 Allowed 'General case' 0 C--N 1.347 0.477 0 C-N-CA 124.18 0.992 . . . . 1.0 112.615 173.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -59.08 -25.1 63.49 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.42 0.896 . . . . 1.0 113.42 -171.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.36 -43.59 6.93 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.529 -1.029 . . . . 1.0 110.529 171.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 5.7 ttt -63.58 -7.53 7.41 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 126.261 1.824 . . . . 1.0 114.057 177.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 66.3 mt -55.0 -30.37 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 C-N-CA 124.563 1.145 . . . . 1.0 110.649 162.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -58.54 150.69 22.2 Favored 'General case' 0 CA--C 1.537 0.451 0 CA-C-O 121.749 0.785 . . . . 1.0 111.111 178.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.327 0 CA-C-O 118.66 -1.078 . . . . 1.0 112.379 -163.668 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 109.995 -1.242 . . . . 1.0 109.995 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.8 tp -47.73 -43.7 27.27 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 125.647 1.579 . . . . 1.0 113.173 -176.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.91 -34.51 55.46 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.551 0.74 . . . . 1.0 112.582 179.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.89 -34.4 82.28 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 124.223 0.916 . . . . 1.0 112.041 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.7 -34.12 66.93 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 118.639 1.22 . . . . 1.0 111.806 172.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -59.15 -40.99 82.32 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 CA-C-N 119.313 0.96 . . . . 1.0 109.774 167.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.86 -39.89 94.26 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 119.767 1.167 . . . . 1.0 109.828 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.29 -49.49 31.35 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 119.163 -0.798 . . . . 1.0 112.023 167.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.3 t80 -64.68 -47.76 77.23 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.437 1.118 . . . . 1.0 111.686 177.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -47.99 -34.5 4.48 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 C-N-CA 124.746 1.219 . . . . 1.0 111.735 172.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -91.46 -3.5 56.54 Favored 'General case' 0 CA--C 1.542 0.652 0 CA-C-O 117.867 -1.064 . . . . 1.0 113.318 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -145.11 -15.9 0.51 Allowed 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 115.956 1.836 . . . . 1.0 115.956 -166.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.44 0.55 0.39 Allowed Glycine 0 CA--C 1.529 0.925 0 CA-C-O 118.027 -1.429 . . . . 1.0 113.575 -174.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.3 t90 -38.41 -42.71 0.76 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 126.445 1.898 . . . . 1.0 113.519 -177.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -49.7 -34.78 19.72 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.967 1.307 . . . . 1.0 112.42 -177.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.69 -16.66 70.22 Favored Glycine 0 CA--C 1.533 1.184 0 CA-C-O 119.377 -0.679 . . . . 1.0 113.993 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.7 mtp -102.2 -8.19 21.54 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.328 1.451 . . . . 1.0 112.499 168.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mt -74.1 -54.65 14.42 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 N-CA-C 107.136 -1.431 . . . . 1.0 107.136 165.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.3 t70 43.2 -105.95 0.08 Allowed 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 125.502 1.521 . . . . 1.0 110.712 -173.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.135 0 CA-C-O 118.031 -1.427 . . . . 1.0 115.11 -178.721 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.125 0 N-CA-C 110.27 -1.132 . . . . 1.0 110.27 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -45.59 -43.74 12.38 Favored 'General case' 0 CA--C 1.513 -0.447 0 C-N-CA 126.484 1.914 . . . . 1.0 113.89 -176.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.23 -35.3 49.23 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.301 0.572 . . . . 1.0 112.481 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -32.74 79.74 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.298 0.951 . . . . 1.0 112.078 174.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.32 -37.4 63.6 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 118.89 1.345 . . . . 1.0 111.658 173.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -58.36 -40.94 80.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 CA-C-O 118.647 -0.692 . . . . 1.0 109.635 167.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.85 -35.89 81.94 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.421 1.01 . . . . 1.0 109.984 177.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.32 -56.43 10.79 Favored Glycine 0 CA--C 1.531 1.032 0 CA-C-O 118.862 -0.965 . . . . 1.0 111.359 164.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -60.74 -41.49 95.48 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 118.524 1.162 . . . . 1.0 112.396 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -51.52 -25.09 4.58 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 125.313 1.445 . . . . 1.0 112.56 170.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -105.32 -0.08 26.56 Favored 'General case' 0 CA--C 1.545 0.783 0 CA-C-N 119.459 1.027 . . . . 1.0 112.776 174.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -149.99 71.67 1.09 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 125.261 1.424 . . . . 1.0 108.767 -165.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 5.24 47.85 Favored Glycine 0 CA--C 1.528 0.904 0 CA-C-O 118.608 -1.107 . . . . 1.0 114.165 171.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -37.63 -44.78 0.72 Allowed 'General case' 0 C--N 1.343 0.294 0 C-N-CA 127.118 2.167 . . . . 1.0 113.737 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -48.06 -35.65 11.58 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.279 1.832 . . . . 1.0 112.219 -170.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.98 -27.83 65.25 Favored Glycine 0 CA--C 1.535 1.308 0 O-C-N 121.598 -0.689 . . . . 1.0 113.484 178.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -95.19 -18.58 20.78 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.275 1.83 . . . . 1.0 111.963 176.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 23.9 mt -67.79 -50.03 63.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 168.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -61.14 -56.07 25.0 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 125.675 1.59 . . . . 1.0 110.793 170.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.016 0 C-N-CA 124.953 1.263 . . . . 1.0 112.251 175.863 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 110.086 -1.206 . . . . 1.0 110.086 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.8 tp -46.53 -43.72 17.19 Favored 'General case' 0 CA--C 1.513 -0.466 0 C-N-CA 126.113 1.765 . . . . 1.0 113.388 -177.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -51.74 -34.67 40.24 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.787 0.662 . . . . 1.0 112.787 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.21 -35.84 90.95 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.114 0.864 . . . . 1.0 112.243 173.116 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.95 -40.23 72.13 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.486 1.143 . . . . 1.0 111.264 173.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -56.7 -38.79 59.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-O 118.425 -0.798 . . . . 1.0 110.083 168.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -68.82 -26.14 65.03 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 119.703 1.138 . . . . 1.0 111.705 178.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.53 -55.42 27.44 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.48 -1.048 . . . . 1.0 110.48 163.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -55.16 -38.33 68.14 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 123.957 0.903 . . . . 1.0 112.146 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 mt -49.29 -26.54 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 126.298 1.839 . . . . 1.0 112.57 172.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -112.26 -4.92 14.23 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 119.931 1.241 . . . . 1.0 112.029 175.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -150.07 66.5 0.97 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 125.488 1.515 . . . . 1.0 108.11 -163.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.73 -20.9 4.05 Favored Glycine 0 CA--C 1.525 0.67 0 CA-C-O 118.957 -0.913 . . . . 1.0 112.405 178.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 14.6 t90 -46.86 -42.86 18.04 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 124.441 1.097 . . . . 1.0 111.259 174.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.2 pm0 -59.22 -26.96 65.31 Favored 'General case' 0 N--CA 1.446 -0.638 0 C-N-CA 123.889 0.876 . . . . 1.0 113.052 -177.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.54 -13.76 82.65 Favored Glycine 0 CA--C 1.533 1.166 0 CA-C-O 119.385 -0.675 . . . . 1.0 113.137 172.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.2 ttt -101.59 -19.91 15.26 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.189 1.796 . . . . 1.0 111.833 173.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 44.9 mt -65.67 -48.53 82.14 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 107.756 -1.201 . . . . 1.0 107.756 162.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.7 t0 45.08 57.19 4.88 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 126.298 1.839 . . . . 1.0 111.282 -174.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.099 0 C-N-CA 124.559 1.076 . . . . 1.0 112.841 -176.105 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.104 0 N-CA-C 110.18 -1.168 . . . . 1.0 110.18 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -46.91 -43.77 19.19 Favored 'General case' 0 CA--C 1.515 -0.368 0 C-N-CA 126.115 1.766 . . . . 1.0 113.532 -176.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.54 -34.51 58.5 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-O 121.455 0.645 . . . . 1.0 112.431 179.314 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.74 -34.17 86.53 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.114 0.864 . . . . 1.0 112.006 173.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.01 -36.1 66.95 Favored 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 118.642 1.221 . . . . 1.0 111.692 173.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -58.09 -41.82 81.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 118.967 0.803 . . . . 1.0 109.628 166.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.54 -31.63 72.47 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.507 1.049 . . . . 1.0 110.61 178.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.97 -58.47 12.55 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-O 119.065 -0.853 . . . . 1.0 110.97 162.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -55.77 -42.66 75.84 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 118.67 1.235 . . . . 1.0 112.16 -178.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.1 mt -50.16 -23.97 1.84 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 C-N-CA 125.929 1.691 . . . . 1.0 113.236 171.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 mm-40 -113.0 -1.81 14.39 Favored 'General case' 0 CA--C 1.543 0.711 0 CA-C-N 119.698 1.135 . . . . 1.0 111.914 173.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -146.95 65.9 1.16 Allowed 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.638 1.575 . . . . 1.0 108.335 -164.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 117.66 -3.42 17.57 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.394 -1.225 . . . . 1.0 114.069 175.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.8 t90 -38.56 -39.6 0.49 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 126.865 2.066 . . . . 1.0 113.166 176.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -50.36 -33.61 21.09 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.37 1.068 . . . . 1.0 112.419 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.93 -23.14 65.41 Favored Glycine 0 CA--C 1.534 1.25 0 O-C-N 121.353 -0.842 . . . . 1.0 113.594 175.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 23.8 mmt -102.0 -8.32 21.6 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.448 1.899 . . . . 1.0 112.478 172.497 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.8 mt -71.58 -23.97 23.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 N-CA-C 108.492 -0.929 . . . . 1.0 108.492 160.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t0 50.16 88.12 0.03 OUTLIER 'General case' 0 C--N 1.344 0.326 0 C-N-CA 128.169 2.588 . . . . 1.0 113.669 159.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.96 0 C-N-CA 124.698 1.142 . . . . 1.0 112.493 178.668 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.144 0 N-CA-C 109.988 -1.245 . . . . 1.0 109.988 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.8 tp -48.43 -43.66 34.53 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 125.504 1.522 . . . . 1.0 113.273 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -53.11 -35.06 59.25 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 123.395 0.678 . . . . 1.0 112.376 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.31 -33.65 78.3 Favored Glycine 0 CA--C 1.53 1.009 0 C-N-CA 124.336 0.97 . . . . 1.0 112.156 173.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.59 -38.77 67.76 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 118.71 1.255 . . . . 1.0 111.48 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.77 -39.82 72.65 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 118.467 -0.778 . . . . 1.0 110.01 167.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.79 95.5 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.663 1.119 . . . . 1.0 109.683 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.33 -45.21 52.86 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-O 118.955 -0.914 . . . . 1.0 112.38 168.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 52.1 t80 -65.96 -50.71 63.4 Favored 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.755 1.278 . . . . 1.0 111.47 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mt -47.64 -31.74 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 C-N-CA 125.667 1.587 . . . . 1.0 112.347 170.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -91.02 -8.06 50.16 Favored 'General case' 0 CA--C 1.544 0.712 0 CA-C-O 117.696 -1.145 . . . . 1.0 113.628 178.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.04 -15.94 0.46 Allowed 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 116.381 1.993 . . . . 1.0 116.381 -166.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -148.0 1.12 0.65 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 124.925 1.25 . . . . 1.0 113.32 -176.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.5 t90 -40.32 -43.14 1.68 Allowed 'General case' 0 C--N 1.343 0.302 0 C-N-CA 127.12 2.168 . . . . 1.0 113.809 -171.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -51.75 -33.62 35.7 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.802 1.241 . . . . 1.0 112.177 -169.447 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -66.99 -13.92 62.57 Favored Glycine 0 CA--C 1.537 1.451 0 CA-C-O 118.988 -0.895 . . . . 1.0 114.389 178.143 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 27.8 ttt -102.47 -13.35 17.28 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.284 1.834 . . . . 1.0 111.928 170.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.9 mt -75.34 -48.31 31.7 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 N-CA-C 107.254 -1.388 . . . . 1.0 107.254 170.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -65.39 157.75 28.48 Favored 'General case' 0 CA--C 1.537 0.464 0 N-CA-C 109.554 -0.536 . . . . 1.0 109.554 162.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.011 0 C-N-CA 125.272 1.415 . . . . 1.0 111.799 -173.68 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.143 0 N-CA-C 110.186 -1.166 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.3 tp -46.6 -43.76 17.6 Favored 'General case' 0 CA--C 1.515 -0.399 0 C-N-CA 126.231 1.812 . . . . 1.0 113.507 -176.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -53.48 -34.17 57.04 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-O 121.494 0.664 . . . . 1.0 112.462 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.43 -34.59 85.2 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.241 0.925 . . . . 1.0 112.046 173.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.13 -37.36 69.47 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 118.653 1.227 . . . . 1.0 111.538 173.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -57.21 -41.4 77.9 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 CA-C-O 118.358 -0.83 . . . . 1.0 109.796 167.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.75 -33.7 76.48 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 119.832 1.196 . . . . 1.0 110.733 178.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.01 -54.65 30.15 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 118.927 -0.929 . . . . 1.0 111.416 164.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -59.8 -42.59 93.74 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 118.31 1.055 . . . . 1.0 112.142 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mt -50.27 -24.17 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 C-N-CA 125.856 1.663 . . . . 1.0 112.898 171.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -108.69 -1.67 19.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.58 1.152 . . . . 1.0 112.229 175.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -155.48 71.79 0.78 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.684 1.594 . . . . 1.0 108.709 -165.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 120.69 -9.49 10.64 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-O 118.949 -0.917 . . . . 1.0 113.531 174.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -37.13 -44.4 0.55 Allowed 'General case' 0 C--N 1.343 0.301 0 C-N-CA 126.88 2.072 . . . . 1.0 112.641 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.4 pm0 -53.75 -29.13 38.41 Favored 'General case' 0 N--CA 1.443 -0.777 0 C-N-CA 124.882 1.273 . . . . 1.0 112.68 -175.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.1 -15.51 74.45 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 118.932 0.787 . . . . 1.0 113.811 175.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.5 mmt -102.25 -8.08 21.57 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.215 1.806 . . . . 1.0 112.201 169.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 32.0 mt -77.5 -43.91 30.0 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.328 -1.36 . . . . 1.0 107.328 164.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -57.08 157.66 5.75 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 123.645 0.778 . . . . 1.0 110.473 167.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.361 0 C-N-CA 124.58 1.086 . . . . 1.0 112.213 -162.456 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.157 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp -46.38 -43.44 16.23 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.245 1.818 . . . . 1.0 113.586 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -51.38 -35.43 38.77 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.527 0.731 . . . . 1.0 112.836 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.65 -36.92 92.02 Favored Glycine 0 CA--C 1.529 0.916 0 C-N-CA 124.042 0.83 . . . . 1.0 111.713 173.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.03 -34.24 71.09 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 118.525 1.163 . . . . 1.0 111.872 174.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.2 mt -58.94 -42.06 84.9 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 119.306 0.957 . . . . 1.0 109.747 167.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.55 73.91 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.622 1.101 . . . . 1.0 110.505 177.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.16 -55.14 27.8 Favored Glycine 0 CA--C 1.532 1.15 0 CA-C-O 119.197 -0.779 . . . . 1.0 111.336 164.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -60.56 -39.75 89.11 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.93 1.292 . . . . 1.0 112.474 -179.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.4 mt -50.49 -24.04 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 125.694 1.598 . . . . 1.0 112.764 169.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -109.36 0.13 19.31 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 124.27 1.028 . . . . 1.0 112.369 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -150.51 70.83 1.03 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 125.693 1.597 . . . . 1.0 108.862 -166.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 107.19 2.89 35.94 Favored Glycine 0 CA--C 1.529 0.939 0 CA-C-O 118.67 -1.072 . . . . 1.0 114.202 172.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.8 t90 -35.9 -43.43 0.31 Allowed 'General case' 0 C--N 1.343 0.311 0 C-N-CA 127.966 2.506 . . . . 1.0 113.531 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -49.77 -33.64 16.99 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.422 1.489 . . . . 1.0 112.15 -174.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.29 -18.21 64.91 Favored Glycine 0 CA--C 1.537 1.453 0 CA-C-O 119.18 -0.789 . . . . 1.0 114.149 177.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.6 ttt -102.36 -10.69 19.25 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.251 1.82 . . . . 1.0 112.052 171.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.9 mt -75.13 -40.67 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 167.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -58.86 160.06 6.25 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 123.783 0.833 . . . . 1.0 110.807 167.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.157 0 C-N-CA 124.684 1.135 . . . . 1.0 111.272 -164.669 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.14 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -45.27 -43.48 10.57 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 126.431 1.892 . . . . 1.0 113.608 -176.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -50.4 -34.22 23.54 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.12 0.968 . . . . 1.0 112.951 178.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.93 -37.15 87.69 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.156 0.884 . . . . 1.0 112.213 173.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.13 -32.17 71.36 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.424 1.112 . . . . 1.0 111.527 173.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.4 mt -58.08 -40.01 75.15 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 CA-C-O 118.072 -0.966 . . . . 1.0 109.907 170.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.71 -25.99 67.55 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 120.299 1.409 . . . . 1.0 111.82 176.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.79 -54.21 35.33 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.795 -0.922 . . . . 1.0 110.795 165.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -58.27 -34.11 70.15 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 124.604 1.162 . . . . 1.0 112.914 177.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.418 ' HA ' ' HB2' ' A' ' 14' ' ' TRP . 1.2 mt -53.1 -28.73 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.802 1.241 . . . . 1.0 111.726 172.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -102.6 -0.17 32.4 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 124.164 0.986 . . . . 1.0 111.912 175.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 -151.81 66.54 0.86 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.305 1.442 . . . . 1.0 108.857 -163.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.23 -2.37 14.3 Favored Glycine 0 CA--C 1.527 0.814 0 CA-C-O 118.247 -1.307 . . . . 1.0 114.455 176.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.418 ' HB2' ' HA ' ' A' ' 10' ' ' ILE . 2.6 t90 -45.15 -34.23 2.6 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.199 1.4 . . . . 1.0 114.169 174.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.0 tm-20 -54.38 -35.58 62.98 Favored 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 118.621 0.646 . . . . 1.0 111.197 175.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.23 -8.05 82.97 Favored Glycine 0 CA--C 1.531 1.091 0 C-N-CA 125.16 1.362 . . . . 1.0 113.959 176.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 10.1 ptm -102.21 -10.26 19.73 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 119.284 1.542 . . . . 1.0 112.541 164.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.9 mt -75.57 -43.46 41.53 Favored 'Isoleucine or valine' 0 C--N 1.341 0.216 0 N-CA-C 107.073 -1.454 . . . . 1.0 107.073 163.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -55.46 138.87 45.34 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 119.443 -0.903 . . . . 1.0 108.925 160.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 1.669 0 C-N-CA 126.217 1.865 . . . . 1.0 116.798 -173.856 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.129 0 N-CA-C 110.062 -1.215 . . . . 1.0 110.062 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.7 tp -47.86 -43.68 28.59 Favored 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 125.517 1.527 . . . . 1.0 113.401 -176.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -51.9 -35.42 45.33 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.775 0.657 . . . . 1.0 112.775 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.78 -34.64 87.92 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.022 0.82 . . . . 1.0 112.101 173.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.99 -36.8 67.13 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 118.477 1.139 . . . . 1.0 111.612 173.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.22 -39.76 74.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-O 118.237 -0.887 . . . . 1.0 109.7 167.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.24 -41.01 97.18 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 119.748 1.158 . . . . 1.0 109.766 175.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.08 -39.22 49.21 Favored Glycine 0 CA--C 1.535 1.32 0 CA-C-O 118.961 -0.911 . . . . 1.0 113.018 169.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.9 t80 -73.14 -47.8 40.98 Favored 'General case' 0 C--N 1.341 0.227 0 CA-C-N 118.819 1.31 . . . . 1.0 112.451 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -43.84 -51.78 1.42 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 C-N-CA 124.76 1.224 . . . . 1.0 110.13 169.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -77.03 -0.93 26.39 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 125.265 1.426 . . . . 1.0 112.033 -177.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -81.17 -0.43 40.31 Favored 'General case' 0 C--N 1.343 0.286 0 O-C-N 120.945 -1.097 . . . . 1.0 111.662 179.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 81.41 36.42 20.45 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 118.256 -1.302 . . . . 1.0 110.195 -160.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 4.4 t90 -35.44 -39.14 0.12 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 125.539 1.536 . . . . 1.0 113.926 171.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -52.46 -32.33 39.11 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.563 0.949 . . . . 1.0 113.563 178.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.28 -12.96 66.86 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 119.169 -0.795 . . . . 1.0 113.236 176.033 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.5 mpt? -102.28 -9.57 20.27 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.873 1.669 . . . . 1.0 111.976 171.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 53.4 mt -73.64 -49.74 33.93 Favored 'Isoleucine or valine' 0 C--N 1.341 0.218 0 N-CA-C 107.348 -1.353 . . . . 1.0 107.348 173.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.8 t0 -64.91 150.23 48.19 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 109.04 -0.726 . . . . 1.0 109.04 164.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.357 0 C-N-CA 126.254 1.883 . . . . 1.0 114.424 -175.65 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.167 0 N-CA-C 110.004 -1.238 . . . . 1.0 110.004 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.4 tp -48.48 -43.75 35.1 Favored 'General case' 0 CA--C 1.514 -0.406 0 C-N-CA 125.411 1.485 . . . . 1.0 113.421 -176.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -55.09 -34.17 63.41 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.46 0.648 . . . . 1.0 112.077 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.35 -31.02 73.64 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 124.341 0.972 . . . . 1.0 112.083 173.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.98 -36.11 62.04 Favored 'General case' 0 N--CA 1.456 -0.148 0 CA-C-N 118.998 1.399 . . . . 1.0 111.684 172.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.7 mt -59.37 -39.5 79.18 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 CA-C-N 119.157 0.889 . . . . 1.0 109.757 167.351 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.24 -41.25 94.54 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 119.379 0.99 . . . . 1.0 109.53 175.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.15 -44.09 51.1 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.978 -0.901 . . . . 1.0 112.529 168.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -65.69 -51.58 58.26 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.79 1.295 . . . . 1.0 110.807 174.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.6 mt -47.89 -30.74 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 125.405 1.482 . . . . 1.0 112.502 171.172 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -91.38 -9.36 45.07 Favored 'General case' 0 CA--C 1.545 0.774 0 CA-C-O 117.723 -1.132 . . . . 1.0 113.602 178.537 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -145.49 -15.86 0.49 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 116.149 1.907 . . . . 1.0 116.149 -166.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.1 2.44 0.52 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 125.385 1.469 . . . . 1.0 113.487 -174.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.6 t90 -39.8 -41.34 1.11 Allowed 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 127.311 2.244 . . . . 1.0 113.727 -174.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -52.19 -31.27 31.0 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.845 1.258 . . . . 1.0 112.224 -169.244 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.77 -8.46 63.79 Favored Glycine 0 CA--C 1.537 1.421 0 CA-C-O 118.755 -1.025 . . . . 1.0 114.852 177.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.5 -12.5 17.76 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 126.162 1.785 . . . . 1.0 112.928 164.311 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.5 mt -79.24 -55.59 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.019 -1.845 . . . . 1.0 106.019 173.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -66.64 155.71 37.17 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 108.381 -0.97 . . . . 1.0 108.381 158.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 1.516 0 O-C-N 121.638 -0.664 . . . . 1.0 113.717 -166.943 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -67.26 173.21 4.05 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.844 0 C-N-CA 126.096 1.808 . . . . 1.0 109.95 -175.922 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.12 0 N-CA-C 110.028 -1.229 . . . . 1.0 110.028 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.4 tp -47.17 -43.75 21.4 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 125.944 1.698 . . . . 1.0 113.635 -176.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -52.91 -35.2 57.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.419 0.628 . . . . 1.0 112.459 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.07 -32.39 76.68 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.328 0.966 . . . . 1.0 112.229 173.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.06 -37.85 64.14 Favored 'General case' 0 N--CA 1.456 -0.162 0 CA-C-N 118.877 1.338 . . . . 1.0 111.623 173.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.9 mt -57.86 -41.32 79.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-O 118.64 -0.695 . . . . 1.0 109.73 166.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.44 -35.42 80.88 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 119.286 0.948 . . . . 1.0 110.134 178.083 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.05 -59.32 6.98 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.283 0.944 . . . . 1.0 111.117 163.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 50.9 t80 -57.61 -43.33 84.66 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 118.902 1.351 . . . . 1.0 112.182 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.7 mt -51.19 -25.0 3.58 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.451 1.5 . . . . 1.0 112.868 171.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -108.83 -0.45 19.84 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 119.78 1.173 . . . . 1.0 112.254 174.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -145.37 67.49 1.23 Allowed 'General case' 0 CA--C 1.531 0.243 0 O-C-N 120.267 -1.521 . . . . 1.0 108.357 -164.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 106.19 3.96 38.46 Favored Glycine 0 CA--C 1.529 0.945 0 CA-C-O 118.47 -1.183 . . . . 1.0 114.014 172.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -40.91 -40.93 1.5 Allowed 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 125.725 1.61 . . . . 1.0 113.54 178.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -48.56 -38.36 20.33 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.329 1.452 . . . . 1.0 113.096 -168.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.06 -17.81 68.25 Favored Glycine 0 CA--C 1.537 1.43 0 CA-C-N 118.912 0.778 . . . . 1.0 113.987 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.56 -8.14 21.25 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 126.828 2.051 . . . . 1.0 113.163 169.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 36.1 mt -73.46 -43.96 54.83 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 107.02 -1.474 . . . . 1.0 107.02 162.137 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -67.26 173.21 4.05 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 125.97 1.708 . . . . 1.0 111.351 166.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.844 0 C-N-CA 126.096 1.808 . . . . 1.0 109.95 -175.922 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.217 0 N-CA-C 110.196 -1.162 . . . . 1.0 110.196 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.4 tp -45.83 -43.74 13.66 Favored 'General case' 0 C--O 1.221 -0.44 0 C-N-CA 126.283 1.833 . . . . 1.0 113.469 -176.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -50.74 -35.05 29.53 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.54 0.736 . . . . 1.0 112.924 178.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.19 87.46 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.027 0.822 . . . . 1.0 112.122 173.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.89 -39.85 72.56 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.478 1.139 . . . . 1.0 111.349 173.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.0 mt -56.72 -40.23 68.72 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-O 118.224 -0.893 . . . . 1.0 109.914 167.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.78 -31.85 72.75 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 120.136 1.335 . . . . 1.0 110.796 179.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.25 -55.3 31.11 Favored Glycine 0 CA--C 1.531 1.068 0 N-CA-C 110.915 -0.874 . . . . 1.0 110.915 164.503 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.5 t80 -55.85 -43.06 76.73 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-N 118.043 0.921 . . . . 1.0 111.977 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.8 mt -50.47 -26.65 3.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 125.431 1.493 . . . . 1.0 112.564 173.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -109.69 5.33 22.79 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.564 1.146 . . . . 1.0 112.164 178.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -138.06 -15.72 1.3 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 114.532 1.308 . . . . 1.0 114.532 -169.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -158.28 0.34 0.09 OUTLIER Glycine 0 CA--C 1.529 0.957 0 C-N-CA 125.146 1.355 . . . . 1.0 113.845 -174.13 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 9.1 t90 -44.79 -38.63 4.64 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 119.016 1.408 . . . . 1.0 113.074 176.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -57.05 -30.96 64.69 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 118.998 0.817 . . . . 1.0 112.145 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.18 -23.24 77.38 Favored Glycine 0 CA--C 1.531 1.035 0 O-C-N 121.31 -0.869 . . . . 1.0 112.757 173.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 6.5 ptt? -92.67 -16.34 25.66 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.947 1.374 . . . . 1.0 112.5 173.752 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.7 mt -64.2 -56.71 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 106.562 -1.644 . . . . 1.0 106.562 160.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -54.95 -44.94 74.79 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.065 0.946 . . . . 1.0 111.08 176.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.358 0 CA-C-O 118.338 -1.257 . . . . 1.0 115.107 173.837 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.201 0 N-CA-C 110.195 -1.162 . . . . 1.0 110.195 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 tp -46.39 -43.61 16.39 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 126.123 1.769 . . . . 1.0 113.635 -176.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -52.9 -34.16 53.67 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.655 0.782 . . . . 1.0 112.684 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.15 -35.49 83.41 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 124.032 0.825 . . . . 1.0 111.959 172.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.77 -31.68 68.55 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 118.561 1.18 . . . . 1.0 111.825 173.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 mt -59.77 -42.46 88.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 CA-C-N 119.461 1.028 . . . . 1.0 109.578 167.446 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.59 -31.0 71.42 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 119.568 1.076 . . . . 1.0 110.738 177.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -56.1 25.81 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 111.073 -0.811 . . . . 1.0 111.073 164.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -58.25 -39.45 79.19 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 118.392 1.096 . . . . 1.0 112.396 -179.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.1 mt -51.2 -24.21 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 125.546 1.539 . . . . 1.0 112.862 170.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 77.7 mm-40 -109.96 0.2 18.46 Favored 'General case' 0 CA--C 1.543 0.685 0 CA-C-N 119.719 1.145 . . . . 1.0 112.06 173.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -145.17 66.54 1.24 Allowed 'General case' 0 CA--C 1.535 0.372 0 O-C-N 120.297 -1.502 . . . . 1.0 108.709 -165.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 108.04 2.05 33.92 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-O 118.661 -1.077 . . . . 1.0 114.36 173.404 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -37.72 -43.97 0.68 Allowed 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 127.195 2.198 . . . . 1.0 113.662 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -48.33 -38.68 19.73 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.659 1.584 . . . . 1.0 111.951 -174.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -63.68 -22.04 65.69 Favored Glycine 0 CA--C 1.534 1.239 0 CA-C-O 119.235 -0.758 . . . . 1.0 113.543 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 mmt -102.18 -9.39 20.52 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.94 1.696 . . . . 1.0 113.042 172.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.7 mt -68.99 -48.37 70.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 106.646 -1.612 . . . . 1.0 106.646 162.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -63.77 -62.65 1.51 Allowed 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.79 1.236 . . . . 1.0 110.472 169.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.115 0 C-N-CA 125.368 1.461 . . . . 1.0 114.766 177.083 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.163 0 N-CA-C 110.025 -1.23 . . . . 1.0 110.025 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.6 tp -48.16 -43.67 31.68 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 125.588 1.555 . . . . 1.0 113.387 -177.087 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -52.16 -35.84 49.88 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.761 0.652 . . . . 1.0 112.761 178.207 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.83 -32.4 81.02 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 124.304 0.954 . . . . 1.0 112.103 174.067 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -38.91 58.06 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 118.783 1.292 . . . . 1.0 111.635 174.188 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.3 mt -58.17 -39.45 73.25 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 CA-C-N 118.772 0.714 . . . . 1.0 109.861 167.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.74 -38.31 86.37 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 119.323 0.965 . . . . 1.0 109.677 176.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.13 -50.63 27.68 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 123.897 0.761 . . . . 1.0 111.747 165.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.3 t80 -62.46 -48.18 80.77 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 118.82 1.31 . . . . 1.0 111.211 175.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mt -49.83 -37.48 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-N 119.254 0.934 . . . . 1.0 111.942 172.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.9 mm-40 -87.29 -4.52 59.07 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.383 -0.823 . . . . 1.0 112.825 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -140.19 -15.93 0.97 Allowed 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 120.875 1.67 . . . . 1.0 114.656 -166.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -151.85 3.56 0.42 Allowed Glycine 0 CA--C 1.528 0.857 0 C-N-CA 126.298 1.904 . . . . 1.0 113.136 -172.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 1.8 t90 -46.0 -33.87 3.65 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 119.213 1.506 . . . . 1.0 113.454 174.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -55.91 -32.99 64.26 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 119.565 1.075 . . . . 1.0 111.538 177.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.56 -7.75 83.35 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.283 1.42 . . . . 1.0 114.151 174.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.2 ptm -102.63 -8.46 20.92 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.308 1.554 . . . . 1.0 113.189 163.408 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.5 mt -72.42 -56.68 9.15 Favored 'Isoleucine or valine' 0 C--N 1.344 0.354 0 N-CA-C 106.029 -1.841 . . . . 1.0 106.029 161.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -60.16 151.63 26.55 Favored 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 109.16 -0.681 . . . . 1.0 109.16 165.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.534 0 C-N-CA 124.899 1.238 . . . . 1.0 114.662 -168.661 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.174 0 N-CA-C 110.216 -1.154 . . . . 1.0 110.216 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 16.3 tp -45.85 -43.61 13.63 Favored 'General case' 0 CA--C 1.515 -0.377 0 C-N-CA 126.474 1.91 . . . . 1.0 113.591 -176.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -51.46 -35.16 38.64 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.535 0.734 . . . . 1.0 112.793 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.89 85.42 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.175 0.893 . . . . 1.0 112.056 173.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.12 -38.01 72.32 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 118.656 1.228 . . . . 1.0 111.293 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.6 mt -57.84 -39.95 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 117.922 -1.037 . . . . 1.0 109.86 168.061 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.41 86.25 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 120.176 1.353 . . . . 1.0 110.175 177.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.4 -47.21 51.5 Favored Glycine 0 CA--C 1.533 1.17 0 CA-C-O 119.48 -0.622 . . . . 1.0 111.84 166.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -68.25 -43.46 77.8 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 118.388 1.094 . . . . 1.0 113.043 177.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.2 mt -44.18 -52.81 1.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.693 1.197 . . . . 1.0 109.33 168.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -79.06 2.08 21.87 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.907 1.283 . . . . 1.0 112.582 -176.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -86.83 11.23 13.77 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.361 0.982 . . . . 1.0 110.154 171.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 78.92 38.37 23.34 Favored Glycine 0 C--N 1.338 0.685 0 N-CA-C 109.771 -1.332 . . . . 1.0 109.771 -170.676 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 5.8 t90 -38.43 -44.8 0.96 Allowed 'General case' 0 C--N 1.349 0.586 0 C-N-CA 123.915 0.886 . . . . 1.0 112.703 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -60.66 -23.54 64.88 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 113.781 1.03 . . . . 1.0 113.781 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.35 -31.88 29.73 Favored Glycine 0 C--N 1.34 0.804 0 CA-C-N 118.857 0.753 . . . . 1.0 111.478 170.217 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 16.3 mmt -68.82 -11.98 61.03 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.519 1.128 . . . . 1.0 112.356 176.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mt -65.46 -29.07 46.01 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 124.23 1.012 . . . . 1.0 109.729 168.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.4 t0 30.91 75.54 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 129.206 3.002 . . . . 1.0 114.118 177.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.932 0 CA-C-N 115.328 -0.851 . . . . 1.0 112.607 177.215 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.154 0 N-CA-C 110.08 -1.208 . . . . 1.0 110.08 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -45.12 -43.55 9.83 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 126.29 1.836 . . . . 1.0 113.637 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -50.93 -34.28 27.97 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.984 0.914 . . . . 1.0 113.018 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.9 -36.56 86.83 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 123.981 0.8 . . . . 1.0 112.17 172.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.69 -36.07 73.11 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-N 118.316 1.058 . . . . 1.0 111.593 173.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mt -57.96 -39.64 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 CA-C-O 118.016 -0.992 . . . . 1.0 110.067 168.023 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.68 91.3 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 120.072 1.306 . . . . 1.0 110.275 176.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -53.32 -48.66 59.15 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.692 -0.563 . . . . 1.0 111.692 167.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -63.23 -46.87 84.9 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 118.248 1.024 . . . . 1.0 112.157 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.5 mt -45.09 -45.2 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 125.295 1.438 . . . . 1.0 110.999 170.293 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -79.95 -8.05 59.12 Favored 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 112.791 0.663 . . . . 1.0 112.791 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -89.78 33.49 0.85 Allowed 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 120.408 1.458 . . . . 1.0 109.872 -174.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.3 22.93 73.15 Favored Glycine 0 CA--C 1.531 1.044 0 CA-C-O 118.17 -1.35 . . . . 1.0 112.504 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -41.42 -40.29 1.71 Allowed 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 125.039 1.336 . . . . 1.0 113.693 -179.007 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -51.31 -37.46 47.7 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.428 0.691 . . . . 1.0 111.996 -178.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.77 -9.56 75.17 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.754 -1.026 . . . . 1.0 113.836 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.6 ppp? -98.91 -8.23 25.94 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 118.76 1.28 . . . . 1.0 111.674 174.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.6 mt -66.39 -50.09 70.31 Favored 'Isoleucine or valine' 0 C--N 1.345 0.375 0 N-CA-C 108.878 -0.786 . . . . 1.0 108.878 176.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.5 t0 35.17 54.69 0.77 Allowed 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 128.51 2.724 . . . . 1.0 113.831 177.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.744 0 N-CA-C 109.772 -1.331 . . . . 1.0 109.772 -176.318 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.132 0 N-CA-C 110.05 -1.22 . . . . 1.0 110.05 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.2 tp -47.24 -43.61 22.03 Favored 'General case' 0 CA--C 1.514 -0.42 0 C-N-CA 125.862 1.665 . . . . 1.0 113.371 -176.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -51.87 -35.22 44.2 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 123.306 0.643 . . . . 1.0 112.671 178.693 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -32.51 76.18 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.243 0.925 . . . . 1.0 112.329 173.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.64 -37.81 65.22 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 118.826 1.313 . . . . 1.0 111.482 172.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.1 mt -58.4 -39.43 74.59 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 CA-C-O 118.453 -0.784 . . . . 1.0 109.787 167.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -40.44 93.79 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 119.8 1.182 . . . . 1.0 109.659 176.17 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.8 -46.67 39.63 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 124.029 0.823 . . . . 1.0 112.255 167.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -65.52 -49.98 66.97 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.488 1.144 . . . . 1.0 111.483 175.418 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -48.66 -32.09 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 C-N-CA 125.098 1.359 . . . . 1.0 112.135 172.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -89.81 -8.26 52.48 Favored 'General case' 0 CA--C 1.543 0.697 0 CA-C-O 117.718 -1.134 . . . . 1.0 113.338 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -146.25 -15.98 0.45 Allowed 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 116.315 1.968 . . . . 1.0 116.315 -165.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -144.9 -1.11 0.85 Allowed Glycine 0 CA--C 1.53 0.999 0 C-N-CA 125.875 1.703 . . . . 1.0 113.388 -175.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.0 t90 -37.7 -41.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 127.461 2.304 . . . . 1.0 113.759 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.6 tm-20 -49.27 -37.01 22.25 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.238 1.415 . . . . 1.0 112.371 -175.394 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.31 -17.62 70.51 Favored Glycine 0 CA--C 1.535 1.317 0 CA-C-O 119.348 -0.695 . . . . 1.0 113.783 178.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.6 mmt -102.51 -7.78 21.6 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.577 1.951 . . . . 1.0 112.808 169.145 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 57.1 mt -66.9 -50.73 62.24 Favored 'Isoleucine or valine' 0 C--N 1.342 0.267 0 N-CA-C 106.19 -1.782 . . . . 1.0 106.19 162.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -64.16 168.05 5.88 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.216 1.007 . . . . 1.0 110.95 167.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.265 0 C-N-CA 124.305 0.955 . . . . 1.0 112.363 -170.281 . . . . . . . . 0 0 . 1 stop_ save_